Erythromycin derivative as well as preparation method and application thereof
By designing the combination of new erythromycin derivatives containing specific groups and quinolones, an antibacterial drug that is effective against a variety of drug-resistant strains has been formed, which has solved the problem of erythromycin antibiotics failing to drug-resistant strains and achieved more Strong antibacterial activity and simple preparation process.
Patent Information
- Application Number
- CN202310628481.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
The existing erythromycin antibiotics are ineffective against a variety of bacterial drug-resistant strains, resulting in the dilemma of the treatment of infections caused by erythromycin-resistant pathogenic microorganisms.
Develop a new erythromycin derivative with a structure containing specific groups such as oxygen atoms, secondary amines, methylenes, methmethyl and nitrogen atoms. By combining with quinolones, it forms a hybrid with stronger antibacterial activity. and improve its antibacterial activity through specific synthetic methods.
This novel erythromycin derivative is significantly better than the traditional clarithromycin, telimycin and azithromycin, and has excellent inhibitory effects on a variety of drug-resistant strains. It has a simple preparation method and has the prospect of industrial production.
Smart Images

Figure CN119060110A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of chemical synthesis and pharmacy, and in particular to an erythromycin derivative and a preparation method and application thereof. Background Art
[0002] Macrolide-lincosamide-streptogramin B (MLS B ) have the same ribosome binding site and have cross-resistance. Among them, erythromycin, a 14-membered macrolide antibiotic, is a very important therapeutic drug for upper and lower respiratory tract infections. It is clinically used in the treatment of upper and lower respiratory tract infections caused by pathogenic microorganisms, as well as skin and soft tissue infections. It has mild side effects and has provided a very efficient and safe medication route for humans, especially children, for half a century. Since the main antibacterial mechanism is that the hydroxyl group and tertiary amino group of the 5-position desaccharamine act on the bases A2058 / A2059 of the nascent peptide release channel of the 50S subunit of the ribosome in the form of hydrogen bonds, the mutation of the bacterial ribosome A2058 / A2059 bases or the expression of methylase by strains containing the erm gene leading to the methylation of N6 of A2058 will lead to a sharp decrease in the affinity of erythromycin drugs; in addition, strains containing the mef gene will be induced by erythromycins containing cladinose to express efflux pump proteins, resulting in the concentration of intracellular drug molecules being reduced to below the antibacterial level and becoming resistant. At present, more and more bacterial strains isolated clinically show drug resistance, such as Streptococcus pneumoniae (S.pneumoniae), Staphylococcus aureus (S.aureus) and Streptococcus pyogenes (S.pyogenes).
[0003] The second generation of erythromycins, clarithromycin and azithromycin, which appeared in the 1980s, have high resistance to (gastric) acid and good pharmacokinetic properties, but have no antibacterial activity against erythromycin-resistant bacteria. The main reason is that the 3-position clarithromycin sugar induces bacterial resistance, causing the key target A2058 to be modified or pumped out of the cell by an efflux pump.
[0004] As a third-generation erythromycin, telithromycin is the only erythromycin derivative approved for the treatment of community-acquired bacterial pneumonia infections. It has excellent antibacterial activity against inducible and efflux resistant bacteria. At the same time, it acts on the base pairs A752 and U2609 of the microbial ribosome, so it has good antibacterial activity against constitutively resistant Streptococcus pneumoniae and Streptococcus pyogenes, but has no activity against constitutively resistant Staphylococcus aureus and resistant mycoplasma. Ketolides such as solithromycin in Phase III clinical trials have the same antibacterial target as telithromycin. After telithromycin was launched, it was found to be hepatotoxic and its use was strictly restricted. Other clinical research compounds were questioned for their safety because they all had similar ketolide structures, resulting in telithromycin being the only one to be launched in the past 20 years.
[0005] Therefore, what needs to be solved is to find a macrolide antibiotic with a new structure to treat infections caused by pathogenic microorganisms resistant to erythromycin. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a compound as shown in the following formula I, its tautomers, stereoisomers, pharmaceutically acceptable salts or prodrugs:
[0007]
[0008] Where W is an oxygen atom O or NOC 1-12 alkyl; V is an oxygen atom O or a secondary amine NH, X is a methylene CH2, a secondary amine NH or an oxygen atom O; Y is a nitrogen atom N or a methine CH; n1 is an integer in the range of 1-10, n2 is an integer in the range of 0-6, m1 is 0, 1 or 2, m2 is 0, 1 or 2; Q is a methine CH, CRa or a nitrogen atom N, Ra is a halogen, C 1-12 Alkyl, haloC 1-12 Alkyl or C 1-12 Alkoxy;
[0009] R 1 is a hydrogen atom, an amino group, a halogen, or the following groups which are unsubstituted or optionally substituted by one, two or more Rb: 1-12 Alkyl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group, C 6-20 Aryl or 5-20 membered heteroaryl; Rb is selected from halogen, amino, C 1-12 Alkyl, halogenated C 1-12 Alkyl or C 1-12 Alkoxy;
[0010] R 2 is absent, a hydrogen atom, unsubstituted or optionally substituted by one, two or more Rb: 1-12Alkyl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group, C 6-20 Aryl or 5-20 membered heteroaryl; Rb is selected from halogen, C 1-12 Alkyl, halogenated C 1-12 Alkyl or C 1-12 Alkoxy; Z is CH, CRc, nitrogen atom N, or Z is C and R 2 The connected N is connected to form a ring, where the connecting part between Z and N is -OCH2-CH(CH3)-, then R 2 does not exist; Rc is halogen, nitrile, amino, C 1-12 Alkyl, haloC 1-12 Alkyl, C 1-12 Alkoxy or halogenated C 1-12 Alkoxy.
[0011] In some embodiments, W is an oxygen atom O or NOC 1-6 alkyl; V is an oxygen atom O or a secondary amine NH, X is a methylene CH2, a secondary amine NH or an oxygen atom O; Y is a nitrogen atom N or a methine CH; n1 is 1, 2, 3, 4, 5, 6 or 7, n2 is 0, 1, 2, 3, 4, 5 or 6, m1 is 0 or 1, m2 is 1 or 2; Q is a methine CH, CRa or a nitrogen atom N, Ra is a halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or C 1-6 Alkoxy;
[0012] R 1 is a hydrogen atom, a halogen, or the following groups which are unsubstituted or optionally substituted by one, two or more Rb: 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Rb is selected from halogen, C 1-6 Alkyl or C 1-6 Alkoxy;
[0013] R 2 is absent, a hydrogen atom, unsubstituted or optionally substituted by one, two or more Rb: 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Rb is selected from halogen, C 1-6 Alkyl or C 1-6 Alkoxy;
[0014] Z is CH, CRc, nitrogen atom N, or Z is C and R 2The connected N is connected to form a ring, where the connecting part between Z and N is -OCH2-CH(CH3)-, then R 2 does not exist; Rc is a halogen, C 1-6 Alkyl or C 1-6 Alkoxy.
[0015] In some preferred embodiments, W is an oxygen atom O or NOCH3; V is an oxygen atom O or a secondary amine NH, X is a methylene CH2, a secondary amine NH or an oxygen atom O; Y is a nitrogen atom N or a methine CH; n1 is 2, 3, 4, 5, 6 or 7, n2 is 0, 1 or 2, m1 is 0 or 1, and m2 is 1 or 2; Q is a methine CH, a fluorine-substituted carbon atom CF or a nitrogen atom N;
[0016] R 1 is a hydrogen atom, a methyl group or an ethyl group;
[0017] R 2 is absent, a hydrogen atom, a methyl group, an ethyl group, a cyclopropyl group, a fluoroethyl group, a fluorocyclopropyl group; Z is a methine group CH, a carbon atom CF substituted with fluorine, a nitrogen atom N, a carbon atom C-OCH3 substituted with methoxy, or when Z is C, the same as R 2 The connected N is connected to form a ring, where the connecting part between Z and N is -OCH2-CH(CH3)-, then R 2 Does not exist.
[0018] In some specific embodiments, the compound represented by formula I is selected from the following:
[0019]
[0020] The present invention also provides the use of the compound shown in the above formula I, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug in the preparation of antibacterial drugs.
[0021] According to an embodiment of the present invention, the pharmaceutically acceptable salt includes a salt formed by a tertiary amino group on 5'-desosamine or a nitrogen atom on a side chain heterocyclic ring and a pharmaceutically acceptable organic acid or inorganic acid. The prodrug is an ester formed by a carboxyl group of a quinolone moiety and RxOH, or an ester formed by a 2'-OH of desosamine and RxCOOH; wherein Rx is unsubstituted or optionally substituted by one, two or more Rb as follows: C 1-12 Alkyl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group, C 6-20 Aryl or 5-20 membered heteroaryl; Rb is selected from halogen, C 1-12 Alkyl or C 1-12 Alkoxy.
[0022] According to an embodiment of the present invention, the antibacterial drug is used to inhibit or kill at least one of the following pathogenic microorganisms: Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Mycoplasma or Chlamydia.
[0023] According to a specific embodiment of the present invention, the antibacterial drug is used to inhibit or kill at least one of the following bacterial species that are sensitive to erythromycin or have different types of resistance: sensitive Streptococcus pneumoniae, constitutively resistant Streptococcus pneumoniae, exudative resistant Streptococcus pneumoniae, sensitive Staphylococcus aureus, inducible resistant Staphylococcus aureus, constitutively resistant Staphylococcus aureus, sensitive Streptococcus pyogenes, exudative resistant Streptococcus pyogenes, inducible resistant Streptococcus pyogenes, constitutively resistant Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.
[0024] The present invention also provides a pharmaceutical composition comprising a compound of formula I, a tautomer, a stereoisomer, a pharmaceutically acceptable salt or a prodrug thereof, and optionally a pharmaceutically acceptable carrier.
[0025] According to an embodiment of the present invention, the pharmaceutical composition is used for preparing an antibacterial drug.
[0026] The present invention uses carbamate to derive the 3-position of clarithromycin. The present invention provides a novel macrolide-quinolone heterocompound for resisting drug-resistant bacteria, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug, and its structural characteristics are that a side chain of suitable length is introduced from the nitrogen atom in the 3-position carbamate functional group of clarithromycin, and its end is connected to quinolone through various piperazine, pyrrolidine, piperidine and other heterocycles, replacing the 3-O-cladinose of the original clarithromycin; at the same time, it is combined with other modifications such as 11,12-OH ring carbonation, or 11,12-OH ring carbamate, or 9-carbonyl oximation.
[0027] In the present application, a step-by-step introduction method can be used, that is, first construct a side chain containing a hydroxyl group, introduce a good leaving group such as mesylate or p-toluenesulfonate on the terminal hydroxyl group of the side chain, and then couple it with the nitrogen atom on the piperazine of the quinolone, or couple it with the terminal nitrogen atom of the side chain linked to different atomic lengths on piperazine, and finally remove the protecting group to obtain the target compound; or first introduce diamines of different lengths, and then react with diols of different carbon chain lengths, and then introduce a good leaving group such as mesylate or p-toluenesulfonate on the terminal hydroxyl group, and then couple it with the nitrogen atom on the piperazine of the quinolone, and finally remove the protecting group to obtain the target compound; furthermore, first introduce a side chain with a piperidine ring or a pyrrole ring at the end on 3-OH, and then couple the NH at the end of the side chain with the quinolone mother ring protected by borate, and remove the protecting group to obtain the target compound.
[0028] The present invention also provides a method for preparing the compound shown in the above formula I, comprising the following steps:
[0029]
[0030] Among them, W, V, X, Y, n1, n2, m1, m2, R 1 , R 2 , Z, Q have the definitions as described above;
[0031] R is Ac or Bz.
[0032] Beneficial Effects
[0033] The invention discloses an erythromycin derivative, which is proved to have excellent inhibitory effect on various pathogenic microorganisms such as Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, mycoplasma or Chlamydia, and the inhibitory effect is significantly better than that of clarithromycin, telithromycin, azithromycin and ciprofloxacin.
[0034] In addition, the preparation method of this series of compounds is simple, so it has certain prospects for industrial synthetic preparation.
[0035] Terms and Definitions
[0036] As used herein, the term "pharmaceutically acceptable carrier" refers to any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and agents for delaying absorption of pharmaceutically active substances, which are well known in the art. Any conventional media or agents, except those that are incompatible with the compound, are contemplated for use in the pharmaceutical composition. Supplementary compounds may also be added to the composition.
[0037] The present invention also includes prodrugs of the compounds of the present invention, that is, a compound that is administered in a certain structure that is not disclosed but is metabolized or converted into the compounds disclosed in the present invention in the human body, and exerts a pharmacological effect as a pharmacological component. For the present invention, various pharmaceutically acceptable acids can form salts on the nitrogen of the dimethylamino group of 5-O-desaccharamine or the nitrogen of the side chain piperazine in the general formula; the prodrug is esterified on the 3-carboxyl group of the quinolone, such as methyl ester, ethyl ester, isopropyl ester, or other (cyclic) alkyl esters containing heteroatoms, and the ester group is hydrolyzed in vivo to release the active group 3-carboxyl group. Conventional methods for preparing prodrugs are shown in "Design of Prodrugs" (H.Bundgaad, Elsevier, 1985). In a specific embodiment, the prodrug is the ethyl ester of the compound, for example, the prodrug of compound 69a is compound 69p.
[0038] In some compounds of the present application, the group definition CH is followed by (R) or (S), which means that the C at that location is a chiral carbon and can form an R or S configuration.
[0039] The NMR data of some compounds in the present application are marked with ax or eq, where ax represents an upright bond and eq represents an equatorial bond.
[0040] Partial Substituents The ligation site is indicated.
[0041] In this document, the term "halogen" means fluorine, chlorine, bromine and / or iodine. Correspondingly, the term "halo" refers to fluoro, chloro, bromo and / or iodo. Within the scope of this document, when an atom, residue, group or moiety is halogenated, the atom at the halogenated position may be monosubstituted, disubstituted or polysubstituted up to full substitution by halogen atoms, for example, "halo C 1-12 Alkyl" and "halogenated C 1-12 "Alkoxy".
[0042] The term "C 1-12 "Alkyl" is understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1 to 12 carbon atoms, preferably C 1-6 Alkyl. "C 1-6 “Alkyl” is understood as meaning preferably a linear or branched, saturated, monovalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl radical is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, etc. or their isomers. In particular, the radical has 1, 2 or 3 carbon atoms (“C 1-3 alkyl"), for example methyl, ethyl, n-propyl or isopropyl.
[0043] The term "C 3-20 "Cycloalkyl" should be understood to mean a saturated monovalent monocyclic, bicyclic hydrocarbon ring or polycyclic hydrocarbon ring (also called condensed hydrocarbon ring) having 3-20 carbon atoms. Bicyclic or polycyclic cycloalkyl groups include paracyclic cycloalkyl, bridged cycloalkyl and spirocyclic cycloalkyl; the paracyclic refers to a condensed ring structure formed by two or more cyclic structures sharing two adjacent ring atoms (i.e., sharing one bond). The bridged ring refers to a condensed ring structure formed by two or more cyclic structures sharing two non-adjacent ring atoms. The spirocyclic refers to a condensed ring structure formed by two or more cyclic structures sharing one ring atom. For example, the C 3-20 The cycloalkyl group may be C 3-8Monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or C 7-12 Cycloalkyl ring, such as decalin ring.
[0044] The term "3-20 membered heterocyclyl" means a saturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1-5 heteroatoms independently selected from N, O and S, preferably a "3-12 membered heterocyclyl". The term "3-12 membered heterocyclyl" means a saturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1-5, preferably 1-3 heteroatoms selected from N, O and S. The heterocyclyl may be connected to the rest of the molecule through any one of the carbon atoms or the nitrogen atom (if present). In particular, the heterocyclyl may include, but is not limited to, a 4-membered ring such as azetidinyl, oxetanyl; a 5-membered ring such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or a 6-membered ring such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or a 7-membered ring such as diazepanyl. Optionally, the heterocyclic group may be benzo-fused. The heterocyclic group may be bicyclic, for example, but not limited to, a 5,5-membered ring, such as a hexahydrocyclopenta[c]pyrrole-2(1H)-yl ring, or a 5,6-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazine-2(1H)-yl ring. The ring containing the nitrogen atom may be partially unsaturated, i.e., it may contain one or more double bonds, for example, but not limited to, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl, or it may be benzo-fused, for example, but not limited to, dihydroisoquinolinyl.
[0045] The term "C 6-20 "Aryl" is understood to mean a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring having 6 to 20 carbon atoms, preferably "C 6-14 The term "C 6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring ("C 6-14 or a ring having 9 carbon atoms ("C9 aryl"), for example indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 aryl), such as tetrahydronaphthyl, dihydronaphthyl or naphthyl, or a ring having 13 carbon atoms ("C 13 aryl), such as fluorenyl, or a ring having 14 carbon atoms ("C 14 "aryl"), for example anthracenyl.
[0046] The term "5-20 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5 to 20 ring atoms and containing 1 to 5 heteroatoms independently selected from N, O and S, for example "5-12 membered heteroaryl". The term "5-12 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and containing 1 to 5, preferably 1 to 3 heteroatoms each independently selected from N, O and S and, in addition, in each case may be benzo-fused. In particular, the heteroaryl group is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl and the like and benzo derivatives thereof, such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl and the like; or azinyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like.
[0047] Unless otherwise indicated, heterocyclyl, heteroaryl or heteroarylene includes all possible isomeric forms thereof, such as positional isomers thereof. Thus, for some illustrative non-limiting examples, pyridyl or pyridylene includes pyridine-2-yl, pyridine-2-yl, pyridine-3-yl, pyridine-3-yl, pyridine-4-yl and pyridine-4-yl; thienyl or thienylene includes thien-2-yl, thien-2-yl, thien-3-yl and thien-3-yl.
[0048] The above term “C 1-12 The definition of "alkyl" also applies to compounds containing "C 1-12 Other terms for "alkyl", such as the term "halo-C 1-12 Alkyl" or "C 1-12 Alkoxy" or "halogenated C 1-12 Alkoxy" and so on.
[0049] As used herein, "pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity.
[0050] Pharmaceutically acceptable salts include acid addition salts of compounds of the invention having nitrogen atoms in the chain or ring with sufficient basicity. In addition, basic nitrogen-containing groups can be quaternized with the following reagents: lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl sulfate, diethyl sulfate, dibutyl sulfate and diamyl sulfate; long chain halides, such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides such as benzyl and phenethyl bromides, etc. As examples, physiologically / pharmaceutically acceptable salts include, but are not limited to, hydrochlorides, sulfates, nitrates, bisulfates, hydrobromides, acetates, oxalates, citrates, methanesulfonates, formates or meglumine salts, etc. DETAILED DESCRIPTION
[0051] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0052] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0053] 1. Raw Materials Preparation
[0054] 1) 9-Methoxyoxime series starting materials The compounds shown below are known compounds. The synthesis method can be found in European Journal of Medicinal Chemistry 59 (2013) 54-63.
[0055]
[0056] 2) Preparation of clarithromycin series raw materials
[0057]
[0058] Reaction conditions and reagents: a. benzoic anhydride, DMAP (4-dimethylaminopyridine), THF, N,N-dimethylethylenediamine, room temperature; b. CDI (carbonyldiimidazole), NaHMDS, THF / DMF=1.5 / 1, room temperature; c. ammonia water, THF / DMF=1.5 / 1, potassium tert-butoxide, room temperature; d. 4M HCl solution, ethanol, 45°C.
[0059] Synthesis of compound 2
[0060] Clarithromycin (20.000g, 26.740mmol), DMAP (3.267g, 26.740mmol), benzoic anhydride (18.148g, 80.219mmol) were dissolved in 150mL of anhydrous tetrahydrofuran, triethylamine (11.12mL, 80.219mmol) was added, stirred at room temperature, and the reaction progress was monitored by TLC. After about 48h of complete reaction, N,N-dimethylethylenediamine (5.84mL, 53.480mmol) was added dropwise under ice bath, and after half an hour of reaction, the reaction solution was concentrated by rotary evaporation, 200mL of dichloromethane was added to the system, and the organic phase was washed with saturated ammonium chloride solution, saturated sodium bicarbonate, water, and saturated brine respectively. The organic phase was dried by rotary evaporation and recrystallized with anhydrous ethanol to obtain 22.440g (23.469mmol, 87.77%) of white crystals.
[0061] Synthesis of compound 3
[0062] Compound 2 (10.000 g, 10.458 mmol) and CDI (6.783 g, 41.832 mmol) were dispersed in a mixed solution of THF / DMF (42 mL / 15 mL), and 2 mol / L NaHMDS solution (8.37 mL, 16.733 mmol) was slowly added dropwise while stirring. After the addition was complete, the mixture was stirred at room temperature for about 2 h. After the reaction was completed, 100 mL of ethyl acetate was added, and then the mixture was washed with saturated sodium bicarbonate, water, and saturated brine, respectively. The organic phase was dried to obtain 10.660 g (10.327 mmol, 98.75%) of a white solid.
[0063] Synthesis of compound 4
[0064] Under ice bath, compound 3 (10.660g, 10.327mmol) was dispersed in a mixed solution of THF / DMF (42mL / 15mL), and 20mL of concentrated aqueous ammonia was added. Stirred under ice bath for 48h, transferred to room temperature for reaction for 48h. After the reaction was complete, 100mL of ethyl acetate was added, and then washed with saturated sodium bicarbonate, water, and saturated brine respectively, the organic phase was spin-dried and added with 60mL of THF, potassium tert-butoxide (1.158g, 10.327mmol), and reacted at room temperature for 30min. After the reaction was completed, 100mL of ethyl acetate was added, and then washed with saturated sodium bicarbonate, water, and saturated brine respectively, and the organic phase was spin-dried. The product was recrystallized from ethanol to obtain a white solid.
[0065] The white solid was dispersed in 40 mL of ethanol, and 40 mL of 4M hydrochloric acid solution was slowly added dropwise at 45°C. The reaction progress was monitored by TLC. After the reaction was complete, 20 mL of water was added, and the aqueous layer was washed with methyl tert-butyl ether and separated. The aqueous layer was adjusted to pH 9 with ammonia water, extracted with ethyl acetate, and the organic layer was washed with water and saturated brine, respectively. The organic phase was spin-dried to obtain 3.080 g (4.284 mmol, 41.48%) of a white solid. HRMS (ESI) (M+H) + m / z 719.4114, calculated value C 38 H 59 N2O 11 719.4223. 1 HNMR(CDCl3,400MHz)δ:8.11-8.03(m,2H,2H-Bz),7.60-7.52(m,1H,2H-Bz),7.48-7.42(m,2H,2H-Bz),5. 77(s,1H,11-NH),5.16(dd,J=2.3Hz,10.9Hz,1H,H-13),5.04(dd,J=7.6Hz,10.5Hz,1H,H-2′),4.76(d,J=7 .6Hz,1H,H-1′),3.73(d,J=2.6Hz,1H,H-5),3.71(s,1H,H-11),3.61-3.51(m,1H,H-5′),3.46(dd,J=6.6H z,10.6Hz,1H,H-3),2.95-2.89(m,1H,H-3′),2.97(s,3H,6-O-CH3),2.79(q,J=6.5Hz,1H,H-10),2.64-2.5 4(m,1H,H-2),2.52-2.42(m,1H,H-8),2.28(s,6H,-N(CH3)2),2.18(d,J=6.5Hz,1H,3-OH),1.94-1.83(m, 2H,H-4,H-14eq),1.94-1.81(m,1H,H-4′a),1.66-1.55(m,1H,H-7a),1.52-1.37(m,3H,H-7b,H-14eq,H-4′ a),1.32(s,3H,12-CH3),1.31-1.24(m,6H,6-CH3,5′-CH3),1.22(d,J=6.8Hz,3H,2-CH3),1.09(d,J=6.6H z,3H,10-CH3),1.05(d,J=7.1Hz,3H,8-CH3),0.81(t,J=7.4Hz,3H,15-CH3),0.71(d,J=7.4Hz,3H,4-CH3). 13C NMR(CDCl3,100MHz)δ:217.87,175.24,165.40,158.54,132.73,130.65,129.79,128.26,99.79,83.95,80.83,77.96,77.65,75.53,72.11,6 8.99,63.27,58.18,49.52,45.34,44.08,40.82,38.76,37.18,35.84, 32.00,22.08,21.15,19.27,18.13,15.34,13.82,13.28,10.22,7.81.
[0066]
[0067] Reaction conditions and reagents: a. phthalimide, triphenylphosphine, DIAD (diisopropyl azodicarboxylate), toluene, room temperature; b. 80% hydrazine hydrate, ethanol, 80°C.
[0068] Synthesis of compound 6
[0069] Compound 5 (1.000 g, 3.885 mmol), phthalimide (0.556 g, 3.885 mmol), and triphenylphosphine (1.121 g, 4.274 mmol) were dissolved in 30 mL of toluene, and DIAD (0.84 mL, 4.274 mmol) was added dropwise to the reaction system under an ice bath. After the addition was complete, the reaction system was moved to room temperature. TLC monitored the reaction progress, and after the reaction was completed, the reaction solution was dried and purified by column chromatography (petroleum ether: ethyl acetate = 6:1). A colorless oily liquid compound 6 was obtained.
[0070] Synthesis of compound 7
[0071] Compound 6 was dissolved in ethanol, 80% hydrazine hydrate (0.47 mL, 7.770 mmol) was added dropwise, and the reaction was carried out at 80°C for about 1 h. After the reaction was completed, the filtrate was filtered, and concentrated hydrochloric acid was added to adjust the pH to 4-5, and the filtrate was filtered again. The filtrate was concentrated and ethyl acetate was added for recrystallization to obtain 0.631 g (2.460 mmol, 63.32%) of compound 7. HRMS (ESI) (M+H) + m / z 402.2198, calcd. 22 H 29 FN3O3 402.2187. 1H NMR (CDCl3, 400MHz) δ: 8.94 (s, 1H), 7.96 (d, J = 13.1Hz, 1H), 7.32 (d, J = 7.1Hz, 1H), 3.79 (d, J = 12.4Hz, 2H), 3. 63(dt,J=3.3Hz,7.1Hz,1H),3.02-2.84(m,2H),2.66(t,J=6.8Hz,2H),1.86-1.77(m,2H),1.59-1.13(m,9H).
[0072]
[0073] Reaction conditions and reagents: a. Boc anhydride (di-tert-butyl dicarbonate), triethylamine, THF, ice bath; b. 60% NaH, acrylonitrile, ice bath; c. platinum dioxide, glacial acetic acid, hydrogen (4 atm), room temperature.
[0074] Synthesis of compound 9
[0075] Compound 8 (2.000 g, 19.773 mmol) and triethylamine (4.11 mL, 29.659 mmol) were dissolved in 70 mL of tetrahydrofuran, and Boc anhydride (4.315 g, 19.773 mmol) was added under ice bath. After the reaction was completed, the reaction solution was concentrated, 100 mL of dichloromethane was added, and the mixture was washed with saturated sodium bicarbonate, water, and saturated sodium chloride, respectively, and the organic phase was spin-dried to obtain compound 9.
[0076] General Synthesis Methods of Compounds 18-26
[0077] The BOC-protected raw material was dissolved in acrylonitrile, and 1.5 eq of NaH was added in batches under an ice bath. TLC monitored the reaction progress and the reaction was completed after about 10 min. 50 mL of dichloromethane was added, and water was added dropwise in an ice bath to quench the NaH. The reaction solution was filtered to remove solid insolubles, and the liquid was washed with saturated brine, and then the organic phase was spin-dried and purified by column chromatography to obtain the product.
[0078] Synthesis of compound 18
[0079] Using compound 9 (3.980 g, 19.773 mmol) as raw material according to the general synthesis method, about 4.312 g (16.068 mmol, 81.26%) of compound 18 was obtained.
[0080] Synthesis of compound 19
[0081] Using compound 10 (3.000 g, 13.935 mmol) as raw material according to the general synthesis method, about 3.600 g (13.415 mmol, 96.27%) of compound 19 was obtained.
[0082] Synthesis of compound 20
[0083] Using compound 11 (2.000 g, 8.721 mmol) as raw material according to the general synthesis method, about 2.400 g (8.853 mmol, 101.52%) of compound 20 was obtained.
[0084] Synthesis of compound 21
[0085] Using compound 12 (2.000 g, 10.681 mmol) as raw material according to the general synthesis method, about 2.100 g (8.739 mmol, 81.82%) of compound 21 was obtained.
[0086] Synthesis of compound 22
[0087] Using compound 13 (2.000 g, 10.681 mmol) as raw material according to the general synthesis method, about 2.200 g (9.155 mmol, 85.71%) of compound 22 was obtained.
[0088] Synthesis of compound 23
[0089] Using compound 14 (2.000 g, 9.937 mmol) as raw material according to the general synthesis method, about 2.640 g (10.380 mmol, 104.46%) of compound 23 was obtained.
[0090] Synthesis of compound 24
[0091] Using compound 15 (2.000 g, 9.937 mmol) as raw material according to the general synthesis method, about 2.400 g (9.436 mmol, 94.96%) of compound 24 was obtained.
[0092] Synthesis of compound 25
[0093] Using compound 16 (2.000 g, 9.937 mmol) as the starting material according to the general synthesis method, about 2.400 g (9.436 mmol, 94.96%) of compound 25 was obtained.
[0094] Synthesis of compound 26
[0095] Using compound 17 (2.000 g, 9.937 mmol) as raw material according to the general synthesis method, about 2.500 g (9.830 mmol, 98.92%) of compound 26 was obtained. General synthesis method of compounds 27-35
[0096] Compound 18-26 was used as raw material, dissolved in glacial acetic acid and transferred to an autoclave, 0.1 times the mass of the raw material PtO2 was added, and then the air was replaced, and hydrogen was charged to make the pressure of the reaction system reach 4 atmospheres and reacted at room temperature for 10-15 hours. After the reaction was completed, the filtrate was filtered and 50 mL of dichloromethane was added to the system, and the pH was adjusted to 10 with ammonia water, and then saturated brine was added to wash the organic phase, and the organic phase was spin-dried and column chromatography was performed to obtain the product compound 27-35.
[0097] Synthesis of compound 27
[0098]
[0099] Compound 18 (4.312 g, 16.068 mmol) was used as the raw material, and after the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol = 10: 0.6) was performed to obtain about 1.028 g (3.982 mmol, 24.78%) of compound 27. HRMS (ESI) (M+H) + m / z 259.2015, calcd. 13 H 27 N2O3 259.2016. 1 H NMR (CDCl3, 400MHz) δ: 3.84-3.71 (m, 2H), 3.55 (t, J = 6.2Hz, 2H), 3.44 (tt, J = 3.7Hz, 8.0Hz, 1H), 3.10 (ddd, J = 3.5Hz, 9.1Hz,13.1Hz,2H),2.82(t,J=6.8Hz,2H),1.90-1.79(m,2H),1.73(p,J=6.5Hz,2H),1.66-1.48(m,6H),1.47(s,9H).
[0100] Synthesis of compound 28
[0101]
[0102] Compound 19 (3.600 g, 13.415 mmol) was used as the raw material, and the reaction was completed according to the general synthesis method and then column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.6: 0.1) was performed to obtain about 1.199 g (4.406 mmol, 32.84%) of compound 28. HRMS (ESI) (M+H) + m / z 273.2167, calcd. 14 H 29 N2O3273.2173. 1H NMR (CDCl3, 400MHz) δ: 4.10 (s, 2H), 3.48 (t, J = 6.2Hz, 2H), 3.25 (d, J = 6.1Hz, 2H), 2.79 (t, J = 6.8 Hz,2H),2.69(t,J=12.9Hz,2H),1.80-1.62(m,5H),1.45(s,9H),1.21(s,2H),1.20-1.06(m,2H).
[0103] Synthesis of compound 29
[0104]
[0105] Compound 20 (2.400 g, 8.853 mmol) was used as the raw material. After the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.8: 0.1) was performed to obtain about 0.981 g (3.428 mmol, 38.72%) of compound 29. HRMS (ESI) (M+H) + m / z 287.2327, calcd. 15 H 31 N2O3287.2329. 1 H NMR (CDCl3, 400MHz) δ: 4.06 (s, 2H), 3.55-3.37 (m, 4H), 2.80 (t, J = 6.8Hz, 2H), 2.68 (t, J = 1 2.9Hz,2H),1.77-1.61(m,4H),1.59-1.48(m,3H),1.48-1.33(s,11H),1.20-1.02(m,2H).
[0106] Synthesis of compound 30
[0107]
[0108] Compound 21 (2.100 g, 8.739 mmol) was used as the raw material. After the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.7: 0.1) was performed to obtain about 0.923 g (3.781 mmol, 41.30%) of compound 30. HRMS (ESI) (M+H) + m / z 245.1860, calcd. 12 H 25 N2O3245.1860. 1H NMR (CDCl3, 400MHz) δ: 4.00 (s, 1H), 3.50 (t, J = 5.9Hz, 2H), 3.47-3.27 (m, 4H), 2.79 ( t,J=6.8Hz,2H),2.03-1.86(m,2H),1.72(q,J=6.5Hz,2H),1.46(s,9H),1.32(s,2H).
[0109] Synthesis of compound 31
[0110]
[0111] Compound 22 (2.200 g, 9.155 mmol) was used as the raw material. After the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.6: 0.1) was performed to obtain about 0.876 g (3.588 mmol, 39.20%) of compound 31. HRMS (ESI) (M+H) + m / z 245.1857, calcd. 12 H 25 N2O3245.1860. 1 H NMR (CDCl3, 400MHz) δ: 4.07-3.93 (m, 1H), 3.50 (t, J = 6.0Hz, 2H), 3.47-3.28 (m, 4H), 2.7 9(t,J=6.8Hz,2H),2.08-1.85(m,2H),1.72(q,J=6.5Hz,2H),1.49(s,2H),1.46(s,9H).
[0112] Synthesis of compound 32
[0113]
[0114] Compound 23 (2.640 g, 16.068 mmol) was used as the raw material, and the reaction was completed according to the general synthesis method and then column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.8: 0.1) was performed to obtain about 0.620 g (2.402 mmol, 14.95%) of compound 32. HRMS (ESI) (M+H) + m / z 259.2017, calcd. 13 H 27 N2O3259.2016. 1H NMR (CDCl3, 400MHz) δ: 3.50 (t, J = 6.2Hz, 2H), 3.47-3.23 (m, 4H), 3.14-2.98 (m, 1H), 2.79 (t,J=6.8Hz,2H),2.45(s,1H),1.95(s,1H),1.79-1.57(m,3H),1.46(s,9H),1.25(s,2H).
[0115] Synthesis of compound 33
[0116]
[0117] Compound 24 (2.400 g, 9.436 mmol) was used as the raw material, and after the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.6: 0.1) was performed to obtain about 0.679 g (2.630 mmol, 27.87%) of compound 33. HRMS (ESI) (M+H) + m / z 259.2015, calcd. 13 H 27 N2O3259.2016. 1 H NMR (CDCl3, 400MHz) δ: 3.50 (t, J=6.2Hz, 2H), 3.48-3.23 (m, 4H), 3.16-2.98 (m, 1H), 2.79 (t, J= 6.8Hz,2H),2.52-2.38(m,1H),2.01-1.98(m,1H),1.78-1.59(m,3H),1.46(s,9H),1.20(s,2H).
[0118] Synthesis of compound 34
[0119]
[0120] Compound 25 (2.400 g, 9.436 mmol) was used as the raw material. After the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.6: 0.1) was performed to obtain about 0.993 g (3.847 mmol, 40.76%) of compound 34. HRMS (ESI) (M+H) + m / z 259.2009, calcd. 13 H 27 N2O3259.2016. 1H NMR (CDCl3, 400MHz) δ: 3.91-3.66 (m, 1H), 3.66-3.47 (m, 3H), 3.28 (dt, J = 4.1Hz, 8.0Hz, 1H), 3.12-2.96 (m, 2H), 2.79 (t, J = 6.7Hz, 2H), 2.00-1.85 (m, 1H), 1.80-1.64 (m, 3H), 1.54-1.36 (s, 11H), 1.29 (s, 2H). Synthesis of compound 35
[0121]
[0122] Compound 26 (2.500 g, 9.830 mmol) was used as the raw material. After the reaction was completed according to the general synthesis method, column chromatography (dichloromethane: ethanol: ammonia water = 10: 0.7: 0.1) was performed to obtain about 1.031 g (3.994 mmol, 40.63%) of compound 35. HRMS (ESI) (M+H) + m / z 259.2012, calcd. 13 H 27 N2O3259.2016. 1 H NMR (CDCl3, 400MHz) δ: 3.90-3.60 (m, 1H), 3.68-3.47 (m, 3H), 3.28 (dt, J = 4.0Hz, 8.5Hz, 1H), 3.15-2.94 (m,2H),2.79(t,J=6.7Hz,2H),1.98-1.85(m,1H),1.97-1.63(m,3H),1.54-1.42(s,11H),1.39(s,2H).
[0123]
[0124] Reaction conditions and reagents: a. N-Boc-bromoethylamine, Ar-a, potassium carbonate, water / DMF=1:1, 50°C; b. 12M hydrochloric acid, ethyl acetate.
[0125] Preparation of Compound 100
[0126] N-Boc-bromoethylamine (2.000 g, 8.924 mmol) and compound Ar-a (2.957 g, 8.924 mmol) were dissolved in water / DMF = 10 mL: 10 mL, potassium carbonate (4.934 g, 35.698 mmol) was added, and the mixture was reacted at 50°C for 12 hours. After the reaction was completed, ethyl acetate was added, and the mixture was washed with water twice and saturated brine once, and the organic layer was dried to obtain a light yellow solid.
[0127] The solid obtained in the previous step was dissolved in 3 mL of ethyl acetate, and 2 mL of 12 M hydrochloric acid was added dropwise at room temperature. The mixture was stirred at room temperature for about 30 min. After the reaction was completed, 20 mL of ethyl acetate was slowly added while stirring, and the product 100 was filtered to obtain about 2.684 g (7.168 mmol, 80.32%). HRMS (ESI) (M+H) + m / z 375.1831, calcd. 19 H 24 FN4O3 375.1827. 1 HNMR(DMSO-d6,400MHz)δ:11.88(s,1H),8.69(s,1H),7.97(d,J=13.0Hz,1H),7.64(d,J=7.4Hz,1H),4.03- 3.63(m,5H),3.51(t,J=6.5Hz,4H),3.41(dq,J=7.0Hz,12.6Hz,4H),1.45-1.26(m,2H),1.26-1.15(m,2H).
[0128]
[0129] Reaction conditions and reagents: a. 2N NaOH solution, 80°C; b. Boric acid, acetic anhydride.
[0130] Synthesis of Compound Ar-n
[0131] Compound 101 (5.023 g, 13.109 mmol) was dissolved in 2N NaOH solution and stirred at 80°C for 2 hours. 2M HCl was used to adjust the pH to 5-6. Ice bath cooling, suction filtration and drying were performed to obtain a white solid (3.006 g, 64.58%). Boric acid (0.348 g, 5.632 mmol) and acetic anhydride (1.33 mL, 14.079 mmol) were added to a round-bottom flask and reacted at 90°C for half an hour. After the reaction was completed, the above white solid (1.000 g, 2.816 mmol) was added to the reaction system and the temperature was raised to 105°C for half an hour. After the reaction was completed, the temperature was slowly lowered to room temperature, and petroleum ether was added for crystallization to obtain compound Ar-n (0.876 g, 1.813 mmol, 41.95%).
[0132] 2. Preparation of intermediates
[0133]
[0134] Reaction conditions and reagents: a. CDI, DMAP, dichloromethane, room temperature; b. ethylenediamine or propylenediamine, DMF, room temperature; c. formic acid, NaNO2, ethylene glycol, -15°C; d. aminoalkyl alcohols of different carbon atom lengths, DBU (1,8-diazabicyclo[5.4.0]undec-7-ene), DMF, room temperature; e. compounds 7, 27-35, DBU, DMF, room temperature.
[0135] General Synthesis of Compounds 36 and 37
[0136] Compound (1 eq), DMAP (2 eq), CDI (3 eq) were added to a round-bottom flask, and anhydrous dichloromethane was added, and the mixture was reacted at room temperature for 12 h. After the reaction was completed under TLC monitoring, dichloromethane was added, and the mixture was washed with saturated ammonium chloride, saturated sodium bicarbonate, water, and saturated brine in sequence, and the organic phase was dried to obtain a white solid.
[0137] Synthesis of compound 36
[0138] Compound 1 (2.207 g, 3.213 mmol) was used as the starting material by a general synthetic method and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.05 / 0.05) to give about 1.384 g (1.775 mmol, 55.24%) of light yellow fluffy solid compound 36.
[0139] Synthesis of compound 37
[0140] According to the general synthesis method, compound 4 (3.080 g, 4.284 mmol) was used to obtain about 3.415 g (4.201 mmol, 98.06%) of white solid compound 37. General synthesis method of compound 38 and 39
[0141] Compound 37 (1 eq) was dissolved in DMF, and ethylenediamine (to prepare compound 38) or propylenediamine (to prepare compound 39) (5 eq) was added dropwise at room temperature, and the reaction was carried out for 6 h at room temperature. The reaction progress was monitored by TLC. After the reaction was complete, ethyl acetate was added, and the organic layer was washed three times with water and once with saturated brine. The organic phase was purified by spin column chromatography to obtain compounds 38 and 39.
[0142] Synthesis of compound 38
[0143] Compound 37 (1.000 g, 1.230 mmol) and ethylenediamine (0.41 mL, 6.150 mmol) were used according to the general synthesis method. The product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.8 / 0.1 to obtain about 0.670 g (0.956 mmol, 77.72%) of compound 38.
[0144] Synthesis of compound 39
[0145] Compound 37 (1.200 g, 1.476 mmol) and propylenediamine (0.61 mL, 7.381 mmol) were used according to the general synthesis method, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.8 / 0.1 to obtain about 0.721 g (1.008 mmol, 68.29%) of compound 39. General synthesis method of compounds 40 and 41
[0146] Compound 38 or 39 (1 eq) was dissolved in ethylene glycol (20-100 eq) as a solvent, the system was transferred to -20°C, formic acid (4.5 eq) was added dropwise, and then sodium nitrite (6 eq) was added in batches while stirring, the temperature was maintained overnight for reaction, and then the temperature was slowly raised to room temperature for reaction for 12 hours. After TLC monitoring of the reaction was complete, 20 mL of dichloromethane and 20 mL of distilled water were added to the system, and the organic phase was washed with saturated sodium bicarbonate, water, and saturated brine, respectively, the organic layer was spin-dried, and purified by column chromatography.
[0147] Synthesis of compound 40
[0148] Compound 38 (0.670 g, 0.956 mmol) was used according to the general synthesis method, and column chromatography (100-200 mesh silica gel, mobile phase petroleum ether / dichloromethane / ethanol / ammonia water = 3 / 7 / 0.2 / 0.1) was performed to obtain about 0.412 g (0.488 mmol, 51.05%) of compound 40. HRMS (ESI) (M+H) + m / z 850.4665, calculated value C 43 H 68 N3O 14 850.4696. 1HNMR(CDCl3,400MHz)δ:8.10-8.04(m,2H,2H-Bz),7.62-7.56(m,1H,2H-Bz),7.51-7.44(m,2H,2H-Bz),5.7 8(s,1H,11-NH),5.34(t,J=5.1Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),5.02-4.94(m ,1H,H-2′),4.88(d,J=11.0Hz,1H,H-3),4.31(d,J=7.5Hz,1H,H-1′),3.80(d,J=3.1Hz,1H,H-5),3.78-3.73 (m,2H,-CH2-OH),3.69(m,1H,H-11),3.67-3.54(m,5H,-CH2-O-CH2-,3-O-CO-NH-CH2),3.49-3.40(m,2H,H- 5′),3.39-3.30(m,1H,3-O-CO-NH-CH2),2.95(s,3H,6-O-CH3),2.94-2.84(m,1H,H-3′),2.83-2.70(m,2H,H -10,H-2),2.53-2.42(m,1H,H-8),2.28(s,6H,-N(CH3)2),1.99-1.82(m,2H,H-4,H-14eq),1.81-1.73(m,1H ,H-4′a),1.60-1.36(m,4H,H-7a,H-7b,H-14eq,H-4′a),1.31(s,3H,12-CH3),1.29-1.21(m,6H,6-CH3,5′-C H3),1.15-1.04(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.4Hz,3H,15-CH3),0.74(d,J=7.4Hz,3H,4-CH3).
[0149] Synthesis of compound 41
[0150] Compound 39 (0.721 g, 1.008 mmol) was used according to the general synthesis method, and column chromatography (100-200 mesh silica gel, mobile phase dichloromethane / ethanol / ammonia water = 10 / 0.2 / 0.1) was performed to obtain about 0.294 g (0.340 mmol, 33.73%) of compound 41. HRMS (ESI) (M+H) + m / z 872.4890, calculated value C 46 H 70 N3O 13 872.4903. 1H NMR(CDCl3,400MHz)δ:8.10-8.02(m,2H,2H-Bz),7.62-7.55(m,1H,2H-Bz),7.51-7.43(m,2H,2H-Bz),5.77(s,1 H,11-NH),5.45(t,J=5.7Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),5.00(dd,J=7.3Hz,10. 5Hz,1H,H-2′),4.89(d,J=11.0Hz,1H,H-3),4.30(d,J=7.5Hz,1H,H-1′),3.83(d,J=3.3Hz,1H,H-5),3.70(m,1H ,H-11),3.66-3.55(m,4H,-CH2-O-CH2-),),3.51-3.39(m,2H,H-5′,3-O-CO-NH-CH2),3.37-3.28(m,1H,3-O-CO -NH-CH2),2.96(s,3H,6-O-CH3),2.89-2.70(m,3H,H-3,H-10,H-2),2.55-2.41(m,3H,-CH2-C≡CH,H-8),2.27(s ,6H,-N(CH3)2),2.05(t,J=2.6Hz,1H,-CH2-C≡CH),1.98-1.81(m,2H,H-4,H-14eq),1.79-1.70(m,1H,H-4′a),1 .60-1.36 (m, 4H, H-7a, H-7b, H-14eq, H-4′a), 1.31 (s, 3H, 12-CH3), 1.28-1.23 (m, 6H, 6-CH3, 5′-CH3), 1.16-1.03 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.4 Hz, 3H, 15-CH3), 0.74 (d, J=7.5 Hz, 3H, 4-CH3). General synthesis method of compounds 42-51
[0151] Compound 36 or 37 (1 eq) was dissolved in DMF, and aminoalkyl alcohols (3 eq) of different carbon atom lengths and DBU (1 eq) were added dropwise at room temperature, and the reaction was carried out for 12 h at room temperature. The reaction progress was monitored by TLC. After the reaction was complete, ethyl acetate was added, and the organic layer was washed three times with water and once with saturated brine. The organic phase was purified by spin column chromatography to obtain the compound.
[0152] Synthesis of compound 42
[0153] According to the general synthesis method, compound 36 (0.5 g, 0.641 mmol), DBU (0.19 mL, 1.282 mmol) and 3-aminopropanol (0.098 mL, 1.282 mmol) were used as raw materials, and the obtained product was purified by column chromatography using 100-200 mesh silica gel and dichloromethane / ethanol / ammonia water = 10 / 0.3 / 0.1 to obtain about 0.338 g (0.453 mmol, 70.76%) of light yellow fluffy solid compound 42.
[0154] Synthesis of compound 43
[0155] According to the general synthesis method, compound 36 (0.6 g, 0.769 mmol), DBU (0.34 mL, 2.307 mmol) and 4-aminobutanol (0.21 mL, 2.307 mmol) were used as raw materials, and the obtained product was purified by column chromatography using 100-200 mesh silica gel and dichloromethane / ethanol / ammonia water = 10 / 0.3 / 0.1 to obtain about 0.290 g (0.382 mmol, 49.67%) of light yellow fluffy solid compound 43.
[0156] Synthesis of compound 44
[0157] According to the general synthesis method, compound 36 (0.6 g, 0.769 mmol), DBU (0.34 mL, 2.307 mmol) and 5-aminopentanol (0.24 mL, 2.307 mmol) were used as raw materials, and the obtained product was purified by column chromatography using 100-200 mesh silica gel and dichloromethane / ethanol / ammonia water = 10 / 0.2 / 0.1 to obtain about 0.332 g (0.429 mmol, 55.79%) of light yellow fluffy solid compound 44.
[0158] Synthesis of compound 45
[0159] Compound 37 (1.000 g, 1.230 mmol) was used as the starting material, 2-aminoethanol (0.15 mL, 2.460 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain about 0.408 g (0.547 mmol, 44.47%) of compound 45.
[0160] Synthesis of compound 46
[0161] Compound 37 (0.500 g, 0.615 mmol) was used as the raw material, 3-aminopropanol (0.094 mL, 1.230 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain about 0.282 g (0.371 mmol, 60.32%) of compound 46. HRMS (ESI) (M+H) + m / z 820.4589, calcd. 42 H 66 N3O 13 820.4590. 1 H NMR(CDCl3,400MHz)δ:8.09-8.02(m,2H,2H-Bz),7.61-7.55(m,1H,2H-Bz),7.49-7.43(m,2H,2H-Bz),5 .80(s,1H,11-NH),5.35(t,J=6.0Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.3Hz,11.0Hz,1H,H-13),4.99( dd, J=7.5Hz, 10.5Hz, 1H, H-2′), 4.88 (d, J=11.0Hz, 1H, H-3), 4.30 (d, J=7.5Hz, 1H, H-1′), 3.80 (d, J=3. 1Hz,1H,H-5),3.78-3.72(m,2H,-CH2-OH),3.70(s,1H,H-11),3.60-3.50(m,1H,3-O-CO-NH-CH2),3.47- 3.38(m,1H,H-5′),3.33-3.24(m,1H,3-O-CO-NH-CH2),2.96(s,3H,6-O-CH3),2.90-2.70(m,3H,H-3′,H -10,H-2),2.52-2.43(m,1H,H-8),2.28(s,6H,-N(CH3)2),1.99-1.69(m,5H,H-4,H-14eq,H-4′a,-CH2-) ,1.58-1.36(m,4H,H-7a,H-7b,H-14eq,H-4′a),1.31(s,3H,12-CH3),1.29-1.23(m,6H,6-CH3,5′-CH3) ,1.15-1.03(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.4Hz,3H,15-CH3),0.73(d,J=7.5Hz,3H,4-CH3).
[0162] Synthesis of compound 47
[0163] Compound 37 (0.768 g, 0.945 mmol) was used as the raw material, 4-aminobutanol (0.17 mL, 1.890 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain about 0.328 g (0.393 mmol, 41.59%) of compound 47. HRMS (ESI) (M+H) + m / z 834.4738, calcd. 43 H 68 N3O 13 834.4747. 1 H NMR(CDCl3,400MHz)δ:8.09-8.02(m,2H,2H-Bz),7.62-7.55(m,1H,2H-Bz),7.50-7.43(m,2H,2H-Bz),5. 78(s,1H,11-NH),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),5.10(t,J=6.0Hz,1H,3-O-CO-NH-CH2),4.98(dd ,J=7.5Hz,10.5Hz,1H,H-2′),4.88(d,J=11.0Hz,1H,H-3),4.29(d,J=7.5Hz,1H,H-1′),3.82(d,J=3.2Hz ,1H,H-5),3.75-3.66(m,3H,H-11,-CH2-OH),3.48-3.34(m,2H,H-5′,3-O-CO-NH-CH2),3.23-3.12(m,1H, 3-O-CO-NH-CH2),2.96(s,3H,6-O-CH3),2.89-2.70(m,3H,H-3′,H-10,H-2),2.53-2.42(m,1H,H-8),2.2 8(s,6H,-N(CH3)2),2.04-1.82(m,2H,H-4,H-14eq),1.81-1.74(m,1H,H-4′a),1.73-1.59(m,4H,2(-CH2- )),1.58-1.35(m,4H,H-7a,H-7b,H-14eq,H-4′a),1.31(s,3H,12-CH3),1.29-1.21(m,6H,6-CH3,5′-CH3 ),1.15-1.02(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.3Hz,3H,15-CH3),0.74(d,J=7.5Hz,3H,4-CH3).
[0164] Synthesis of compound 48
[0165] Compound 37 (1.317 g, 1.620 mmol) was used as the raw material, 5-aminopentanol (0.34 mL, 3.240 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain about 0.540 g (0.637 mmol, 39.32%) of compound 48. HRMS (ESI) (M+H) + m / z 848.4902, calcd. 44 H 70 N3O 13 848.4903. 1 H NMR(CDCl3,400MHz)δ:8.09-8.00(m,2H,2H-Bz),7.62-7.54(m,1H,2H-Bz),7.50-7.43(m,2H,2H-Bz),5 .79(s,1H,11-NH),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),5.03-4.91(m,2H,3-O-CO-NH-CH2,H-2′),4.8 8(d,J=11.0Hz,1H,H-3),4.29(d,J=7.5Hz,1H,H-1′),3.82(d,J=3.2Hz,1H,H-5),3.70(s,1H,H-11),3. 65(t,J=6.3Hz,2H,-CH2-OH),3.48-3.32(m,2H,H-5′,3-O-CO-NH-CH2),3.19-3.06(m,1H,3-O-CO-NH-C H2),2.96(s,3H,6-O-CH3),2.88-2.68(m,3H,H-3′,H-10,H-2),2.53-2.43(m,1H,H-8),2.28(s,6H,-N( CH3)2),1.97-1.83(m,2H,H-4,H-14eq),1.80-1.72(m,1H,H-4′a),1.66-1.56(m,4H,2(-CH2-)),1.54- 1.37(m,6H,H-7a,H-7b,H-14eq,H-4′a,-CH2-),1.31(s,3H,12-CH3),1.29-1.22(m,6H,6-CH3,5′-CH3) ,1.15-1.02(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.4Hz,3H,15-CH3),0.74(d,J=7.5Hz,3H,4-CH3).
[0166] Synthesis of compound 49
[0167] Compound 37 (0.600 g, 0.738 mmol) was used as the raw material, 6-aminohexanol (0.173 g, 1.476 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain about 0.332 g (0.385 mmol, 52.17%) of compound 49. HRMS (ESI) (M+H) + m / z 862.5057, calcd. 45 H 72 N3O 13 862.5060. 1 H NMR(CDCl3,400MHz)δ:8.08-8.01(m,2H,2H-Bz),7.62-7.54(m,1H,2H-Bz),7.50-7.43(m,2H,2H-Bz) ,5.75(s,1H,11-NH),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),4.99(dd,J=7.6Hz,10.4Hz,1H,H-2′),4. 90-4.82(m,2H,3-O-CO-NH-CH2,H-3),4.28(d,J=7.5Hz,1H,H-1′),3.83(d,J=3.2Hz,1H,H-5),3.70( s,1H,H-11),3.65(t,J=6.4Hz,2H,-CH2-OH),3.46-3.30(m,2H,H-5′,3-O-CO-NH-CH2),3.20-3.09(m, 1H,3-O-CO-NH-CH2),2.96(s,3H,6-O-CH3),2.86-2.67(m,3H,H-3′,H-10,H-2),2.53-2.41(m,1H,H- 8),2.28(s,6H,-N(CH3)2),1.98-1.83(m,2H,H-4,H-14eq),1.80-1.72(m,1H,H-4′a),1.68-1.37(m,1 0H,3(-CH2-),H-7a,H-7b,H-14eq,H-4′a),1.31(s,3H,12-CH3),1.28-1.24(m,6H,6-CH3,5′-CH3),1 .14-1.04(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.4Hz,3H,15-CH3),0.74(d,J=7.5Hz,3H,4-CH3).
[0168] Synthesis of compound 50
[0169] Compound 37 (0.600 g, 0.738 mmol) was used as the raw material, 7-aminoheptanol (0.194 g, 1.476 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain 0.235 g (0.268 mmol, 36.31%) of compound 50. HRMS (ESI) (M+H) + m / z 876.5218, calcd. 46 H 74 N3O 13 876.5216. 1 H NMR(CDCl3,400MHz)δ:8.08-8.00(m,2H,2H-Bz),7.61-7.55(m,1H,2H-Bz),7.50-7.43(m,2H,2H-Bz),5 .76(s,1H,11-NH),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),4.99(dd,J=7.4Hz,10.4Hz,1H,H-2′),4.91-4. 82(m,2H,3-O-CO-NH-CH2,H-3),4.28(d,J=7.4Hz,1H,H-1′),3.83(d,J=3.1Hz,1H,H-5),3.70(s,1H,H-1 1),3.63(t,J=6.5Hz,2H,-CH2-OH),3.48-3.39(m,1H,H-5′),3.37-3.27(1H,3-O-CO-NH-CH2),3.20-3.1 1(m,1H,3-O-CO-NH-CH2),2.95(s,3H,6-O-CH3),2.86-2.69(m,3H,H-3′,H-10,H-2),2.52-2.43(m,1H,H -8),2.28(s,6H,-N(CH3)2),1.98-1.83(m,2H,H-4,H-14eq),1.80-1.69(m,3H,H-4′a,-CH2-),1.61-1.3 4(m,10H,4(-CH2-),H-7a,H-7b,H-14eq,H-4′a),1.31(s,3H,12-CH3),1.28-1.23(m,6H,6-CH3,5′-CH3) ,1.14-1.03(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.4Hz,3H,15-CH3),0.73(d,J=7.5Hz,3H,4-CH3).
[0170] Synthesis of compound 51
[0171] Compound 37 (0.600 g, 0.738 mmol) was used as the raw material, 8-aminooctanol (0.214 g, 1.476 mmol) was added for reaction, and the product was purified by column chromatography using 100-200 mesh silica gel and a mobile phase of dichloromethane / ethanol / ammonia water = 10 / 0.7 / 0.1 to obtain 0.167 g (0.188 mmol, 25.27%) of compound 51. HRMS (ESI) (M+H) + m / z 890.5374, calcd. 47 H 76 N3O 13 890.5373. 1 H NMR(CDCl3,400MHz)δ:8.09-8.01(m,2H,2H-Bz),7.61-7.55(m,1H,2H-Bz),7.49-7.43(m,2H,2H-Bz),5 .76(s,1H,11-NH),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),4.99(dd,J=7.5Hz,10.5Hz,1H,H-2′),4.91-4 .81(m,2H,3-O-CO-NH-CH2,H-3),4.28(d,J=7.5Hz,1H,H-1′),3.83(d,J=3.2Hz,1H,H-5),3.70(s,1H,H -11),3.62(t,J=6.5Hz,2H,-CH2-OH),3.47-3.38(m,1H,H-5′),3.38-3.27(1H,3-O-CO-NH-CH2),3.19- 3.09(m,1H,3-O-CO-NH-CH2),2.95(s,3H,6-O-CH3),2.86-2.69(m,3H,H-3′,H-10,H-2),2.53-2.42(m, 1H,H-8),2.28(s,6H,-N(CH3)2),1.98-1.83(m,2H,H-4,H-14eq),1.80-1.72(m,1H,H-4′a),1.68-1.33 (m,10H,6(-CH2-),H-7a,H-7b,H-14eq,H-4′a),1.31(s,3H,12-CH3),1.28-1.24(m,6H,6-CH3,5′-CH3) ,1.15-1.04(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.3Hz,3H,15-CH3),0.73(d,J=7.5Hz,3H,4-CH3).
[0172] General Synthesis Methods of Compounds 52-62
[0173] Compound 36 or 37 and 1.5eq compound 7 or 27-35 are dissolved in anhydrous DMF, DBU is added and stirred at normal temperature for 12-18 hours, and TLC monitors the reaction process. After the reaction is completed, 50mL ethyl acetate is added, and the saturated common salt water is washed once with water three times, and the organic phase is spin-dried column chromatography to obtain the product. The upper step product is dissolved in 4mL ethanol, 12M HCl solution 3mL is slowly added dropwise, and the reaction is carried out at normal temperature for 5-20 minutes. After the reaction is completed, 50mL dichloromethane is added in the system, pH is adjusted to 10-11 with ammonia, and then washed with saturated common salt water, and the organic layer is spin-dried column chromatography after liquid separation to obtain the product.
[0174] Synthesis of compound 52
[0175] According to the general synthesis method, compound 36 (1.200 g, 1.538 mmol) and compound 27 (0.596 g, 2.308 mmol) were used, and the BOC protecting group was removed after the reaction was completed, and column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) was used for purification to obtain about 0.432 g (0.496 mmol, 32.24%) of compound 52. HRMS (ESI) (M+H) + m / z 871.5274, calculated value C 43 H 75 N4O 14 871.5274. 1H NMR(CDCl3,400MHz)δ:5.45(t,J=5.5Hz,1H,3-O-CO-NH-CH2),5.17(dd,J=2.4Hz,10.8Hz,1H,H-13),4.88-4.80(m, 2H,H-11,H-3),4.72(dd,J=7.5Hz,10.5Hz,1H,H-2′),4.32(d,J=7.5Hz,1H,H-1′),3.81(s,3H,9-O-CH3),3.74(d,J =3.3Hz,1H,H-5),3.70-3.62(m,1H,H-8),3.62-3.53(m,2H,O-CH2),3.45-3.21(m,4H,H-5′,3-O-CO-NH-CH2,-N-(C H2-CH2)2-CH-),3.08(dt,J=4.5Hz,12.3Hz,2H,-N-(CH2-CH2)2),3.00(s,3H,6-O-CH3),2.87-2.76(m,1H,H-2),2. 70-2.57(m,2H,-N-(CH2-CH2)2),3.16-3.06(m,3H,-N-(CH2-CH2)2,H-3′),2.47(d,J=6.8Hz,1H,H-10),2.25(s,6H ,-N(CH3)2),2.11-1.99(m,4H,H-4,2′-OAc),1.99-1.73(m,6H,H-14eq,CH2,-N-(CH2-CH2)2,H-4′a),1.73-1.52(m ,6H,H-7a,H-4′a,H-7b,H-14eq,-N-(CH2-CH2)2),1.48(s,3H,12-CH3),1.29(s,3H,6-CH3),1.27-1.17(m,7H,5′-C H3,H-4′b,2-CH3),1.14(d,J=6.8Hz,3H,10-CH3),0.97-0.89(m,6H,4-CH3,8-CH3),0.86(t,J=7.4Hz,3H,15-CH3).
[0176] Synthesis of compound 53
[0177] According to the general synthesis method, compound 37 (1.000 g, 1.230 mmol) and compound 7 (0.631 g, 2.460 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 53 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.231 g (0.256 mmol, 20.81%) of compound 53. HRMS (ESI) (M+H) +m / z 901.5535, calcd. 48 H 77 N4O 12 901.5533. 1 H NMR(CDCl3,400MHz)δ:8.10-8.03(m,2H,2H-Bz),7.64-7.57(m,1H,2H-Bz),7.52-7.44(m,2H,2H-Bz),5.79(s,1 H,11-NH),5.20(dd,J=2.3Hz,10.9Hz,1H,H-13),5.00(dd,J=7.6Hz,10.4Hz,1H,H-2′),4.93-4.84(m,2H,H-3,3- O-CO-NH-CH2),4.30(d,J=7.5Hz,1H,H-1′),3.84(d,J=3.2Hz,1H,H-5),3.71(s,1H,H-11),3.48-3.30(m,2H,H-5 ′,3-O-CO-NH-CH2),3.19-3.11(m,1H,3-O-CO-NH-CH2),3.07(dt,J=3.3Hz,12.0Hz,2H,-N-(CH2-CH2)2),2.99(s ,3H,6-O-CH3),2.88-2.70(m,3H,H-3′,H-10,H-2),2.58(dt,J=2.5Hz,12.0Hz,2H,-N-(CH2-CH2)2),2.53-2.45( m,1H,H-8),2.29(s,6H,-N(CH3)2),2.02-1.85(m,2H,H-4,H-14eq),1.80-1.35(m,11H,H-4′a,2(-CH2-),H-7a,H -7b,H-14eq,-CH-(CH2-CH2)2),1.33(s,3H,12-CH3),1.32-1.22(m,9H,6-CH3,5′-CH3,H-4′b,-CH2-),1.15-1.0 2(m,11H,2-CH3,10-CH3,8-CH3,-CH-(CH2-CH2)2),0.83(t,J=7.3Hz,3H,15-CH3),0.76(d,J=7.5Hz,3H,4-CH3).
[0178] Synthesis of compound 54
[0179] According to the general synthesis method
[0180] Compound 37 (1.000 g, 1.230 mmol) and compound 27 (0.476 g, 1.845 mmol) were used, and the BOC protecting group was removed after the reaction was completed, and column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) was used for purification to obtain about 0.520 g (0.576 mmol, 46.83%) of compound 54. HRMS (ESI) (M+H) + m / z 903.53256, calcd. 47 H 75 N4O 13 903.53251. 1HNMR(CDCl3,400MHz)δ:8.10-8.02(m,2H,2H-Bz),7.64-7.57(m,1H,2H-Bz),7.51-7.44(m,2H,2H-Bz),5.79(s,1H,11 -NH),5.48(t,J=5.5Hz,1H,3-O-CO-NH-CH2),5.20(dd,J=2.3Hz,10.9Hz,1H,H-13),5.02(dd,J=7.5Hz,10.5Hz,1H,H- 2′),4.90(d,J=11.0Hz,1H,H-3),4.32(d,J=7.5Hz,1H,H-1′),3.85(d,J=3.2Hz,1H,H-5),3.72(s,1H,H-11),3.68-3. 58(m,2H,O-CH2),3.52-3.36(m,4H,H-5′,3-O-CO-NH-CH2,-N-(CH2-CH2)2-CH-),3.35-3.25(m,1H,3-O-CO-NH-CH2), 3.16-3.06(m,2H,-N-(CH2-CH2)2),2.98(s,3H,6-O-CH3),2.90-2.72(m,3H,H-3′,H-10,H-2),2.71-2.60(m,2H,-N-( CH2-CH2)2),2.55-2.44(m,1H,H-8),2.30(s,6H,-N(CH3)2),2.02-1.73(m,7H,H-4,H-14eq,CH2,-N-(CH2-CH2)2,H-4 ′a),1.58-1.37(m,6H,H-7a,H-4′a,H-7b,H-14eq,-N-(CH2-CH2)2),1.33(s,3H,12-CH3),1.31-1.22(m,7H,6-CH3,5′ -CH3,H-4′b),1.17-1.04(m,9H,2-CH3,10-CH3,8-CH3),0.83(t,J=7.4Hz,3H,15-CH3),0.76(d,J=7.5Hz,3H,4-CH3).
[0181] Synthesis of compound 55
[0182] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 28 (0.602 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 55 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.6 / 0.1) to obtain about 0.300 g (0.327 mmol, 22.16%) of compound 55. HRMS (ESI) (M+H)+ m / z 917.5472, calcd. 48 H 77 N4O 13 917.5482. 1 H NMR(CDCl3,400MHz)δ:8.09-8.00(m,2H,2H-Bz),7.61-7.54(m,1H,H-Bz),7.50-7.43(m,2H,2H-Bz),5.76(s,1H,11-NH),5.3 9(t,J=5.5Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),4.99(dd,J=7.5Hz,10.5Hz,1H,H-2′),4.88(d,J=1 1.0Hz,1H,H-3),4.32(d,J=7.5Hz,1H,H-1′),3.84(d,J=3.2Hz,1H,H-5),3.69(s,1H,H-11),3.55(t,J=5.6Hz,2H,O-CH2),3. 48-3.39(m,4H,H-5′,3-O-CO-NH-CH2),3.36-3.23(m,3H,3-O-CO-NH-CH2,O-CH2),3.15-3.04(m,2H,-N-(CH2-CH2)2),2.96( s,3H,6-O-CH3),2.87-2.76(m,3H,H-3′,H-10),2.75-2.68(m,1H,H-2),2.67-2.56(m,2H,-N-(CH2-CH2)2),2.54-2.42(m,1H ,H-8),2.28(s,6H,-N(CH3)2),1.99-1.78(m,4H,H-4,H-14eq,CH,H-4′a),1.78-1.68(m,4H,-N-(CH2-CH2)2,CH2),1.64(s,1 H,NH),1.56-1.35(m,4H,H-7a,H-4′a,H-7b,H-14eq),1.31(s,3H,12-CH3),1.29-1.23(m,6H,6-CH3,5′-CH3),1.23-1.14(m, 2H,-N-(CH2-CH2)2),1.14-1.03(m,9H,2-CH3,10-CH3,8-CH3),0.81(t,J=7.3Hz,3H,15-CH3),0.74(d,J=7.5Hz,3H,4-CH3).
[0183] Synthesis of compound 56
[0184] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 29 (0.629 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 56 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.334 g (0.358 mmol, 24.25%) of compound 56. HRMS (ESI) (M+H) + m / z 931.5648, calcd. 49 H 79 N4O 13 931.5638. 1H NMR(CDCl3,400MHz)δ:8.09-8.00(m,2H,2H-Bz),7.62-7.54(m,1H,H-Bz),7.50-7.41(m,2H,2H-Bz),5.78(s,1H, 11-NH),5.34(t,J=5.6Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),4.99(dd,J=7.4Hz,10.4Hz, 1H,H-2′),4.88(d,J=11.0Hz,1H,H-3),4.29(d,J=7.5Hz,1H,H-1′),3.83(d,J=3.2Hz,1H,H-5),3.69(s,1H,H-11 ),3.57-3.37(m,6H,CH2OCH2,H-5′,3-O-CO-NH-CH2),3.33-3.21(m,1H,3-O-CO-NH-CH2),3.11-3.02(m,2H,-N-(C H2-CH2)2),2.97(s,3H,6-O-CH3),2.87-2.70(m,3H,H-3′,H-10,H-2),2.66-2.53(m,2H,-N-(CH2-CH2)2),2.53- 2.41(m,1H,H-8),2.28(s,6H,-N(CH3)2),1.99-1.61(m,9H,H-4,H-14eq,CH,H-4′a,2(CH2),H-7a,),1.61-1.36(m ,7H,-N-(CH2-CH2)2CH,NH,H-4′a,H-7b,H-14eq),1.32(s,3H,12-CH3),1.30-1.22(m,6H,6-CH3,5′-CH3),1.23-1 .03(m,11H,-N-(CH2-CH2)2,2-CH3,10-CH3,8-CH3),0.81(t,J=7.3Hz,3H,15-CH3),0.75(d,J=7.4Hz,3H,4-CH3).
[0185] Synthesis of compound 57
[0186] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 30 (0.540 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed, and column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) was used for purification to obtain about 0.382 g (0.430 mmol, 29.13%) of compound 57. HRMS (ESI) (M+H) + m / z 889.5169, calcd.46 H 73 N4O 13 889.5169. 1 H NMR(CDCl3,400MHz)δ:8.09-8.02(m,2H,2H-Bz),7.62-7.55(m,1H,H-Bz),7.51-7.42(m,2H,2H-Bz),5.77(s,1 H,11-NH),5.36(t,J=5.6Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),4.99(dd,J=7.4Hz,10. 4 Hz, 1H, H-2′), 4.87 (d, J=11.0 Hz, 1H, H-3), 4.29 (d, J=7.5 Hz, 1H, H-1′), 4.06-3.98 (s, 1H, H-tetrahydropyrrole), 3.84 (d, J=3.2 Hz, 1H, H-5), 3.69 (s, 1H, H-11), 3.57-3.37 (m, 4H, O-CH2, 2H-tetrahydropyrrole), 3.29-3.18 (m, 1H, 3-O-CO-NH-CH2), 3.1 5-2.99 (m, 2H, H-5′, H-tetrahydropyrrole), 2.96 (s, 3H, 6-O-CH3), 2.94-2.70 (m, 5H, 3-O-CO-NH-CH2, H-tetrahydropyrrole, H-10, H-2, H-3′), 2.52-2.41 (m, 1H, H-8), 2.28 (s, 6H, -N(CH3)2), 2.08-1.98 (m, 2H, CH2), 1.97-1.70 (m, 6H, H-4, H-14eq, 2H-tetrahydropyrrole Hydropyrrole,H-4′a,H-7a),1.59-1.36(m,4H,NH,H-4′a,H-7b,H-14eq),1.31(s,3H,12-CH3),1.29-1.22(m,6H,6-CH3,5 ′-CH3), 1.17-1.03 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.3Hz, 3H, 15-CH3), 0.75 (d, J=7.5Hz, 3H, 4-CH3).
[0187] Synthesis of compound 58
[0188] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 31 (0.540 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 58 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.400 g (0.450 mmol, 30.48%) of compound 58. HRMS (ESI) (M+H) + m / z 889.5166, calcd. 46 H 73 N4O 13 889.5169. 1 H NMR(CDCl3,400MHz)δ:8.09-8.01(m,2H,2H-Bz),7.63-7.55(m,1H,H-Bz),7.51-7.42(m,2H,2H-Bz),5.77(s,1 H,11-NH),5.41(t,J=5.6Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),4.99(dd,J=7.4Hz,10. 5Hz,1H,H-2′), 4.88(d, J=11.0Hz,1H,H-3), 4.30(d, J=7.5Hz,1H,H-1′), 4.05-3.97(m,1H,H-tetrahydropyrrole), 3.84(d, J=3.2Hz,1H,H-5), 3.69(s,1H,H-11), 3.55-3.37(m,4H,O-CH2,2H-tetrahydropyrrole), 3.29-3.19(m,1H,3-O-CO-NH-CH2), 3.1 8-2.99 (m, 2H, H-5′, H-tetrahydropyrrole), 2.96 (s, 3H, 6-O-CH3), 2.94-2.70 (m, 5H, 3-O-CO-NH-CH2, H-tetrahydropyrrole, H-10, H-2, H-3′), 2.53-2.40 (m, 1H, H-8), 2.28 (s, 6H, -N(CH3)2), 2.08-1.98 (m, 2H, CH2), 1.97-1.71 (m, 6H, H-4, H-14eq, 2H-tetrahydropyrrole Hydropyrrole,H-4′a,H-7a),1.61-1.35(m,4H,NH,H-4′a,H-7b,H-14eq),1.32(s,3H,12-CH3),1.29-1.21(m,6H,6-CH3,5 ′-CH3), 1.15-1.02 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.3Hz, 3H, 15-CH3), 0.75 (d, J=7.5Hz, 3H, 4-CH3).
[0189] Synthesis of compound 59
[0190] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 32 (0.578 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 59 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.200 g (0.221 mmol, 14.97%) of compound 59. HRMS (ESI) (M+H) + m / z 903.5338, calcd. 47 H 75 N4O 13 903.5325. 1H NMR(CDCl3,400MHz)δ:8.09-8.01(m,2H,2H-Bz),7.62-7.54(m,1H,H-Bz),7.50-7.43(m,2H,2H-Bz),5.75(s,1H,11 -NH),5.53(t,J=5.3Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),5.00(dd,J=7.5Hz,10.4Hz,1H,H -2′), 4.88 (d, J = 11.0 Hz, 1H, H-3), 4.31 (d, J = 7.5 Hz, 1H, H-1′), 3.83 (d, J = 3.2 Hz, 1H, H-5), 3.69 (s, 1H, H-11), 3.56 (t, J = 5.7 Hz, 2H, O-CH2), 3.50-3.38 (m, 3H, H-5′, O-CH2), 3.39-3.32 (m, 1H, H-tetrahydropyrrole), 3.30-3.20 (m, 1H, 3-O-CO-NH-C H2), 3.14-2.99 (m, 2H, 3-O-CO-NH-CH2, H-tetrahydropyrrole), 2.96 (s, 3H, 6-O-CH3), 2.94-2.84 (m, 2H, H-3′, H-tetrahydropyrrole), 2.82-2.70 (m, 3H, H-tetrahydropyrrole, H-10, H-2), 2.53-2.36 (m, 2H, H-tetrahydropyrrole, H-8), 2.28 (s, 6H, -N(CH3)2), 1.99-1.72 (m, 6H, H-4, H-14eq, H-tetrahydropyrrole, H-4′a, CH2), 1.58-1.36 (m, 5H, NH, H-7a, H-4′a, H-7b, H-14eq), 1.31 (s, 3H, 12-CH3), 1.29-1.22 (m, 6H, 6-CH3, 5′-CH3), 1.16-1.01 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.4 Hz, 3H, 15-CH3), 0.75 (d, J=7.5 Hz, 3H, 4-CH3).
[0191] Synthesis of compound 60
[0192] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 33 (0.578 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 60 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.328 g (0.363 mmol, 24.60%) of compound 60. HRMS (ESI) (M+H) +m / z 903.5327, calcd. 47 H 75 N4O 13 903.5325. 1 H NMR(CDCl3,400MHz)δ:8.10-7.99(m,2H,2H-Bz),7.62-7.55(m,1H,H-Bz),7.51-7.42(m,2H,2H-Bz),5.77(s,1H ,11-NH),5.45(t,J=5.6Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),5.00(dd,J=7.4Hz,10.5H z, 1H, H-2′), 4.88 (d, J=11.0 Hz, 1H, H-3), 4.30 (d, J=7.5 Hz, 1H, H-1′), 3.84 (d, J=3.2 Hz, 1H, H-5), 3.69 (s, 1H, H-11), 3.56 (t, J=5.8 Hz, 2H, O-CH2), 3.51-3.41 (m, 3H, H-5′, O-CH2), 3.39-3.32 (m, 2H, H-tetrahydropyrrole), 3.31-3.20 (m, 1H, 3-O-CO-NH-CH2), 3.12-2.99 (m, 2H, 3-O-CO-NH-CH2, H-tetrahydropyrrole), 2.97 (s, 3H, 6-O-CH3), 2.94-2.68 (m, 5H, H-3′, 2H-tetrahydropyrrole, H-10, H-2), 2.53-2.35 (m, 2H, H-tetrahydropyrrole, H-8), 2.28 (s, 6H, -N(CH3)2), 1.98-1.71 (m, 6H, H-4, H-14eq, H-tetrahydropyrrole pyro,H-4′a,CH2),1.61-1.34(m,5H,NH,H-7a,H-4′a,H-7b,H-14eq),1.31(s,3H,12-CH3),1.29-1.21(m,6H,6-CH3, 5′-CH3), 1.15-1.00 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.3Hz, 3H, 15-CH3), 0.75 (d, J=7.5Hz, 3H, 4-CH3).
[0193] Synthesis of compound 61
[0194] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 34 (0.571 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 61 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.368 g (0.407 mmol, 27.57%) of compound 61. HRMS (ESI) (M+H) + m / z 903.5330, calcd. 47 H 75 N4O 13 903.5325. 1 H NMR(CDCl3,400MHz)δ:8.09-8.00(m,2H,2H-Bz),7.63-7.53(m,1H,H-Bz),7.49-7.43(m,2H,2H-Bz),5.77(s,1 H,11-NH),5.69(t,J=5.6Hz,1H,3-O-CO-NH-CH2),5.18(dd,J=2.2Hz,10.9Hz,1H,H-13),4.99(dd,J=7.6Hz,10 .5Hz,1H,H-2′),4.88(d,J=11.0Hz,1H,H-3),4.30(d,J=7.5Hz,1H,H-1′),3.84(d,J=3.2Hz,1H,H-5),3.69(s, 1H,H-11),3.67-3.56(m,2H,O-CH2),3.54-3.38(m,2H,3-O-CO-NH-CH2,H-5′),3.37-3.31(m,1H,CH),3.30-3. 22 (m, 1H, 3-O-CO-NH-CH2), 3.12-3.05 (m, 1H, H-piperidinyl), 2.97 (s, 3H, 6-O-CH3), 2.89-2.65 (m, 6H, 3H-piperidinyl, H-10, H-2, H-3′), 2.53-2.41 (m, 1H, H-8), 2.28 (s, 6H, -N(CH3)2), 1.98-1.71 (m, 8H, CH2, H-4, H-14eq, 2H-tetrahydropyrrole, H-4′a ,H-7a),1.61-1.35(m,6H,NH,2H-tetrahydropyrrole,H-4′a,H-7b,H-14eq),1.32(s,3H,12-CH3),1.30-1.22(m,6H,6-CH3,5 ′-CH3), 1.16-1.01 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.3Hz, 3H, 15-CH3), 0.74 (d, J=7.5Hz, 3H, 4-CH3).
[0195] Synthesis of compound 62
[0196] According to the general synthesis method, compound 37 (1.200 g, 1.476 mmol) and compound 35 (0.571 g, 2.214 mmol) were used, and the BOC protecting group was removed after the reaction was completed. The compound 62 was purified by column chromatography (dichloromethane / ethanol / ammonia water=10 / 0.5 / 0.1) to obtain about 0.391 g (0.433 mmol, 29.33%) of compound 62. HRMS (ESI) (M+H) + m / z 903.5329, calcd. 47 H 75 N4O 13 903.5325. 1H NMR(CDCl3,400MHz)δ:8.09-8.01(m,2H,2H-Bz),7.62-7.55(m,1H,H-Bz),7.50-7.42(m,2H,2H-Bz),5.84(t,J =5.7Hz,1H,3-O-CO-NH-CH2),5.77(s,1H,11-NH),5.18(dd,J=2.3Hz,10.9Hz,1H,H-13),5.00(dd,J=7.4Hz,10. 4Hz,1H,H-2′),4.88(d,J=11.0Hz,1H,H-3),4.31(d,J=7.5Hz,1H,H-1′),3.84(d,J=3.2Hz,1H,H-5),3.69(s,1 H,H-11),3.60(t,J=3.6Hz,2H,O-CH2),3.49-3.40(m,2H,3-O-CO-NH-CH2,H-5′),3.39-3.33(m,1H,CH),3.33-3 .26 (m, 1H, 3-O-CO-NH-CH2), 3.07-3.00 (m, 1H, H-piperidinyl), 2.97 (s, 3H, 6-O-CH3), 2.90-2.70 (m, 6H, 3H-piperidinyl, H-10, H-2, H-3′), 2.51-2.43 (m, 1H, H-8), 2.28 (s, 6H, -N(CH3)2), 2.11-1.71 (m, 8H, CH2, H-4, H-14eq, 2H-tetrahydropyrrole, H-4′a ,H-7a),1.66-1.36(m,6H,NH,2H-tetrahydropyrrole,H-4′a,H-7b,H-14eq),1.31(s,3H,12-CH3),1.29-1.22(m,6H,6-CH3,5 ′-CH3), 1.16-1.02 (m, 9H, 2-CH3, 10-CH3, 8-CH3), 0.81 (t, J=7.3Hz, 3H, 15-CH3), 0.75 (d, J=7.5Hz, 3H, 4-CH3).
[0197] 3. Preparation of compounds of general formula
[0198]
[0199] Reaction conditions and reagents: a. methanesulfonyl chloride, triethylamine, dichloromethane, room temperature; b. ciprofloxacin, acetonitrile, 70°C; c. methanol reflux.
[0200] General Synthesis Method of Compound 63 and 64 Series
[0201] Compound 40 or 41 (1 eq) was dissolved in 20 mL of dichloromethane, and triethylamine (2 eq) was added. Methanesulfonyl chloride (1.5 eq) was added dropwise at room temperature, and stirred for about 10-20 min. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was washed with water twice and with saturated brine once. The organic phase was spin-dried and purified by column chromatography.
[0202] Disperse the intermediate (1 eq) and the quinolone with piperazine (5 eq) in anhydrous acetonitrile and stir at 70°C for 72 h. After the reaction is completed, spin dry the reaction solution, add 50 mL of dichloromethane, wash with water 3 times, and wash with saturated brine once. Spin dry the organic phase, add 20 mL of methanol and reflux to remove the protecting group. After the reaction is completed, monitor the reaction by TLC and spin dry the reaction solution and purify it by column chromatography.
[0203] Synthesis of compound 63a
[0204]
[0205] According to the synthesis method, compound 40 (0.412 g, 0.488 mmol) and methanesulfonyl chloride (0.044 mL, 0.533 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: petroleum ether / dichloromethane / ethanol / ammonia water = 7 / 3 / 0.05 / 0.05) was performed to obtain about 0.253 g (0.253 mmol, 51.84%) of compound 87.
[0206] Compound 87 (0.235 g, 0.253 mmol) was reacted with compound Ar-a (0.251 g, 0.758 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 31.1 mg (0.0295 mmol, 11.68%) of the general formula compound 63a. Melting point: 162.3-165.8°C. HRMS (ESI) (M+H) + m / z 1059.5662, calcd. 53 H 80 F6O 15 1059.5660. 1H NMR (CDCl3, 400MHz) δ: 8.76 (s, 1H, 2″-quinolyl), 8.00 (d, J=13.0Hz, 1H, 5″-quinolyl), 7.36 (s, 1H, 8″-quinolyl), 5.80 (s, 1H, 11-NH), 5.63 (s, 1H, 3-O-CO-NH-CH2), 5.22 (dd, J=2.3Hz, 10.9Hz, 1H, H-13), 4.93 (d, J=11.0Hz, 1H, H-3), 4.04 (d, J=7.1Hz, 1 H, H-1′), 3.79 (d, J=2.8 Hz, 1H, H-5), 3.77 (s, 1H, H-11), 3.66 (t, J=5.5 Hz, 2H, -O-CH2-CH2-piperazinyl), 3.62-3.48 (m, 5H, 1H-cyclopropyl, 3-O-CO-NH-CH2-CH2), 3.47-3.31 (m, 5H, H-5′, 4H-piperazinyl), 3.29-3.22 (m, 1H, 3-O-CO-NH-CH2), 3.18 (dd, J=7.3 Hz, 1 0.0Hz,1H,H-2′),2.98(s,3H,6-O-CH3),2.93-2.79(m,2H,H-10,H-2),2.75(s,4H,4H-piperazinyl),3.69(t,J=5.3Hz,2H,-O-CH2-CH2-piperazinyl),2.57-2.38(m,2H,H-8,H-3′),2.30(s,6H,-N(CH3)2),2.11-2.01(m,1H,H-4),1.98-1.85(m,1H,H-14eq ), 1.82-1.72 (m, 1H, H-7a), 1.69-1.49 (m, 3H, H-7b, H-14eq, H-4′a), 1.46-1.34 (m, 5H, 12-CH3, 2H-cyclopropyl), 1.31-1.17 (m, 9H, 6-CH3, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.17-1.07 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.83 (t, J=7.3Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.63,177.11,174.33,167.00,158.42,156.48,147.43,139.11,1 08.17,104.76,103.12,83.87,81.49,78.42,77.86,77.24,75.83,70.45,69.64,69.47,68 .19,66.08,58.12,57.57,53.16,49.82,49.62,45.30,43.36,41.01,40.35,39.11,37.29,35.82,35.32,28.64,22.03,21.20,19.30,18.27,15.07,13.87,13.29,10.25,9.12,8.26.
[0207] Synthesis of compound 64a
[0208]
[0209] According to the synthesis method, compound 41 (0.294 g, 0.340 mmol) and methanesulfonyl chloride (0.029 mL, 0.357 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: petroleum ether / dichloromethane / ethanol / ammonia water = 3 / 7 / 0.1 / 0.05) was performed to obtain about 0.233 g (0.247 mmol, 72.60%) of compound 88.
[0210] Compound 88 (0.233 g, 0.247 mmol) was reacted with compound Ar-a (0.410 g, 1.235 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 41.7 mg (0.0388 mmol, 15.73%) of the general formula compound 64a. Melting point: 163.6-164.7°C. HRMS (ESI) (M+H) + m / z 1073.5814, calculated value C 54 H 82 F6O 15 1073.5817. 1H NMR (CDCl3, 400MHz) δ: 8.74 (s, 1H, 2″-quinolyl), 7.97 (d, J = 13.0 Hz, 1H, 5″-quinolyl), 7.36 (d, J = 7.0 Hz, 1H, 8″-quinolyl), 5.81 (s, 1H, 11-NH), 5.56 (s, 1H, 3-O-CO-NH-CH2), 5.22 (dd, J = 2.4 Hz, 10.9 Hz, 1H, H-13), 4.92 (d, J = 10.9 Hz, 1H ,H-3), 4.05(d, J=7.2Hz,1H,H-1′), 3.85-3.73(m,2H,H-5,H-11), 3.68-3.51(m,4H,-CH2-O-CH2-CH2-piperazinyl)), 3.48-3.27(m,7H,H-5′,1H-cyclopropyl,4H-piperazinyl,3-O-CO-NH-CH2-), 3.25-3.13(m,2H,H-2′,3-O-CO-NH-CH2), 2.98(s ,3H,6-O-CH3),2.93-2.79(m,2H,H-10,H-2),2.79-2.62(m,6H,4H-piperazinyl,-O-CH2-CH2-piperazinyl),2.58-2.39(m,2H,H-8,H-3′),2.28(s,6H,-N(CH3)2),2.12-2.01(m,1H,H-4),1.98-1.86(m,1H,H-14eq),1.85-1.71(m,3H,H-7 a, -CH2-), 1.69-1.49 (m, 3H, H-7b, H-14eq, H-4′a), 1.47-1.35 (m, 5H, 12-CH3, 2H-cyclopropyl), 1.31-1.17 (m, 9H, 6-CH3, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.18-1.06 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.83 (t, J = 7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.62,177.05,174.37,166.96,158.40,156.43,152.37,147.37,139.11,1 19.72,112.43,112.20,108.10,104.77,103.15,83.88,81.46,78.09,77.88,77.25,75.76,70.48, 69.45,69.26,68.44,66.05,58.11,57.63,53.16,52.84,49.81,49.68,45.29,43.38,40.31,39.13,37.27,35.83,35.31,29.69,22.03,21.19,19.29,18.27,15.06,13.84,13.27,10.23,9.10,8.23.
[0211]
[0212] Reaction conditions and reagents: a. methanesulfonyl chloride or p-toluenesulfonyl chloride, triethylamine, dichloromethane, room temperature; b. quinolone with piperazine, acetonitrile, 70°C; c. methanol reflux.
[0213] General Synthesis Method of Compounds 65-73 Series
[0214] Compounds 42-44, 46-51 (1 eq) were dissolved in 20 mL of dichloromethane, and triethylamine (2 eq) was added. Methanesulfonyl chloride (1.5 eq) was added dropwise at room temperature, or p-toluenesulfonyl chloride (2 eq) was added and stirred for about 10-20 min. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was washed with water twice and with saturated brine once. The organic phase was spin-dried and purified by column chromatography.
[0215] Disperse the intermediate (1 eq) and the quinolone with piperazine (5 eq) in anhydrous acetonitrile and stir at 70°C for 72 h. After the reaction is completed, spin dry the reaction solution, add 50 mL of dichloromethane, wash with water 3 times, and wash with saturated brine once. Spin dry the organic phase, add 20 mL of methanol and reflux to remove the protecting group. After the reaction is completed, monitor the reaction by TLC and spin dry the reaction solution and purify it by column chromatography.
[0216] Synthesis of compound 65a
[0217]
[0218] According to the synthesis method, compound 42 (0.338 g, 0.453 mmol) was used and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.1 developing solvent) to obtain about 0.179 g (0.217 mmol, 47.90%) of white fluffy solid compound 89.
[0219] Compound 89 (0.179 g, 0.217 mmol) was reacted with compound Ar-a (0.360 g, 1.085 mmol), and the product was purified by column chromatography (100-200 mesh silica gel, mobile phase dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) to obtain about 71.5 mg (0.0675 mmol, 31.11%) of white fluffy solid compound 65a. Melting point: 182.9-184.0°C. HRMS (ESI) (M+H) + m / z 1059.5666, calculated value C 53 H 80 F6O 15 1059.5660. 1H NMR (CDCl3, 700 MHz) δ: 8.75 (s, 1H, 2″-quinolyl), 7.99 (d, J = 12.7 Hz, 1H, 5″-quinolyl), 7.36 (d, J = 6.7 Hz, 1H, 8″-quinolyl), 5.83 (br, 1H, 3-O-CO-NH-CH2), 5.16 (dd, J = 2.5 Hz, 10.8 Hz, 1H, H-13), 4.91-4.81 (m, 2H, H-3, H-11), 4.04 (d, J = 6.9 Hz, 1H, H-1′), 3.82 ( s, 3H, 9-O-CH3), 3.80-3.75 (m, 1H, H-5), 3.73-3.66 (m, 1H, H-8), 3.60-3.52 (m, 1H, H-5′), 3.50-3.25 (m, 6H, 1H-cyclopropyl, 3-O-CO-NH-CH2, 4H-piperazinyl), 3.25-3.15 (m, 1H, H-2′, 3-O-CO-NH-CH2), 3.03 (s, 3H, 6-O-CH3), 2.88-2.80 (m, 1H, H-2), 2.75-2.62 (m, 4H, 4H-piperazinyl), 2.60-2.51 (m, 2H, -CH2-piperazinyl), 2.50-2.37 (m, 2H, H-3′, H-10) 2.30 (s, 6H, -N(CH3)2), 2.11-2.02 (m, 1H, H-4), 1.94-1.85 (m, 1H, H-14eq), 1.84-1.70 (m, 2H, CH2), 1.70-1.62 (m, 1H, H-4′a), 1.60-1.50 (m, 1H, H-14ax) 1.47 (s, 3H, 1 2-CH3), 1.45-1.34 (m, 3H, 2H-cyclopropyl, H-4′b), 1.33 (s, 3H, 6-CH3), 1.30-1.17 (m, 10H, 2H-cyclopropyl, H-7a, H-7b, 5′-CH3, 10-CH3), 1.15 (d, J=6.8 Hz, 3H, 2-CH3), 1.06 (d, J=7.5 Hz, 3H, 4-CH3), 0.94 (d, J=7.0 Hz, 3H, 8-CH3), 0.85 (t, J=7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:177.06,174.05,167.00,164.54,156.35,154.66,147.41, 139.10,104.88,84.99,83.19,78.36,77.27,75.49,70.46,69.49,66.25,61.42, 56.44,52.84,49.82,43.42,40.39,37.32,35.99,35.36,32.72,29.69,28.66,26.44,25.60,22.22,21.21,19.34,18.86,15.59,14.97,13.02,10.18,8.96,8.25.
[0220] Synthesis of compound 66a
[0221]
[0222] According to the synthesis method, compound 43 (0.452 g, 0.595 mmol) was used and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.1 developing solvent) to obtain about 0.355 g (0.424 mmol, 71.26%) of white fluffy solid compound 90.
[0223] Compound 90 (0.249 g, 0.208 mmol) was reacted with compound Ar-a (0.346 g, 1.043 mmol), and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / methanol / ammonia water = 10 / 1 / 0.5 developing solvent) to obtain about 72.6 mg (0.0676 mmol, 32.52%) of white fluffy solid compound 66a. Melting point: 185.4-186.2°C. HRMS (ESI) (M+H) + m / z 1073.5828, calculated value C 54 H 82 F6O 15 1073.5817. 1H NMR (CDCl3, 700MHz) δ: 8.79 (s, 1H, 2"-quinolyl), 8.05 (d, J = 12.8 Hz, 1H, 5"-quinolyl), 7.73 (d, J = 6.9 Hz, 1H, 8"-quinolyl), 5.58 (br, 1H, 3-O-CO-NH-CH2), 5.18 (dd, J = 2.6 Hz, 10.5 Hz, 1H, H-13), 4.90 (d, J = 11.1 Hz, 1H, H-3), 4.87 (s, 1H, H-11), 4.04 (d, J = 7. 2Hz,1H,H-1′),3.83(s,3H,9-O-CH3),3.79-3.73(m,1H,H-5),3.72-3.66(m,1H,H-8),3.61-3.53(m,1H,1H-cyclopropyl),3.48-3.24(m,6H,H-5′,3-O-CO-NH-CH2,4H-piperazinyl),3.24-3.16(m,1H,H-2′),3.15-3.06(m,1H,3-O-CO-NH-CH2),3.03(s,3H,6- O-CH3), 2.89-2.80 (m, 1H, H-2), 2.75-2.60 (m, 4H, 4H-piperazinyl), 2.54-2.36 (m, 4H, H-3′, H-10, -CH2-piperazinyl), 2.30 (s, 6H, -N(CH3)2), 2.13-2.04 (m, 1H, H-4), 1.95-1.83 (m, 1H, H-14eq), 1.73-1.53 (m, 6H, 2(-CH2-), H-4′a, H-14ax), 1.49 (s, 3H, 12- CH3), 1.46-1.36 (m, 3H, 2H-cyclopropyl, H-4′b), 1.34 (s, 3H, 6-CH3), 1.31-1.19 (m, 10H, 2H-cyclopropyl, H-7a, H-7b, 5′-CH3, 10-CH3), 1.16 (d, J=6.8 Hz, 3H, 2-CH3), 1.07 (d, J=7.6 Hz, 3H, 4-CH3), 0.94 (d, J=7.0 Hz, 3H, 8-CH3), 0.84 (t, J=7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:174.04,167.02,164.49,154.66,147.42,139.12,112.56, 108.19,104.78,84.98,83.20,78.34,77.25,75.46,70.44,69.45,66.23,61.43, 57.86,52.80,49.83,43.37,41.07,40.40,37.34,35.98,35.32,32.72,28.10,25.60,24.22,22.24,21.21,19.33,18.87,15.61,14.96,13.03,10.21,9.05,8.25.
[0224] Synthesis of compound 66g
[0225]
[0226] According to the synthesis method, compound 43 (0.452 g, 0.595 mmol) was used and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.1 mobile phase) to obtain about 0.355 g (0.424 mmol, 71.26%) of white fluffy solid compound 90.
[0227] Compound 90 (0.201 g, 0.250 mmol) was reacted with compound Ar-g (0.415 g, 1.250 mmol), and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / methanol / ammonia water = 10 / 0.9 / 0.5 developing solvent) to obtain white fluffy solid compound 66g (about 13.9 mg, 0.0129 mmol, 5.18%). Melting point: 165.6-165.9°C. HRMS (ESI) (M+2H) 2+ m / z(z=2)537.7910, calculated value C 53 H 82 F7O 15 537.7921. 1H NMR (CDCl3, 700 MHz) δ: 8.75 (s, 1H, 2″-quinolyl), 8.09 (d, J = 13.3 Hz, 1H, 5″-quinolyl), 5.61 (br, 1H, 3-O-CO-NH-CH2), 5.18 (dd, J = 2.5 Hz, 10.7 Hz, 1H, H-13), 4.89 (d, J = 11.2 Hz, 1H, H-3), 4.87 (s, 1H, H-11), 4.03 (d, J = 7.3 Hz, 1H, H-1′), 3.99-3.91 (m, 4H, 4H-piperidinyl) oxazine), 3.83 (s, 3H, 9-O-CH3), 3.77 (s, 1H, H-5), 3.73-3.63 (m, 1H, H-8), 3.63 (tt, J = 4.2 Hz, 7.5 Hz, 1H, 1H-cyclopropyl), 3.45-3.33 (m, 2H, H-5′, -O-CO-NH-CH2), 3.21 (dd, J = 7.3 Hz, 10.1 Hz, 1H, H-2′), 3.15-3.08 (m, 1H, 3-O-CO-NH-CH2), 3.03 (s, 3H, 6-O-CH3), 2.89-2.81 (m, 1H, H-2), 2.65-2.55 (m, 4H, 4H-piperazinyl), 2.52-2.38 (m, 4H, H-3′, H-10, -CH2-piperazinyl), 2.30 (s, 6H, -N(CH3)2), 2.13-2.05 (m, 1H, H-4), 1.96-1.87 (m, 1H, H-14eq), 1.71-1.53 (m, 6H, 2(-CH2-), H-4′a, H-14ax), 1.49 (s, 3H, 12-CH3), 1.44-1.3 6 (m, 1H, H-4′b), 1.34 (s, 3H, 6-CH3), 1.30-1.19 (m, 10H, H-7a, H-7b, 5′-CH3, 2H-cyclopropyl, 10-CH3), 1.16 (d, J = 6.8 Hz, 3H, 2-CH3), 1.09 (d, J = 4.2 Hz, 2H, 2H-cyclopropyl), 1.08 (d, J = 7.4 Hz, 3H, 4-CH3), 0.94 (d, J = 7.0 Hz, 3H, 8-CH3), 0.87 (t, J = 7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:177.15,174.00,166.81,164.48,154.65,146.55,120.2 4,108.97,84.98,83.21,78.34,78.34,77.24,75.55,70.44,61.44,57.84,53. 00,49.81,46.87,43.41,41.04,40.40,37.36,35.98,34.65,32.73,28.07,25.59,24.21,22.25,21.22,19.34,18.86,15.61,14.96,13.03,10.20,8.98,7.47.
[0228] Synthesis of compound 66h
[0229]
[0230] According to the synthesis method, compound 43 (0.452 g, 0.595 mmol) was used and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.1 mobile phase) to obtain about 0.355 g (0.424 mmol, 71.26%) of white fluffy solid compound 90.
[0231] Compound 90 (0.150 g, 0.179 mmol) was reacted with compound Ar-h (0.321 g, 0.890 mmol), and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / methanol / ammonia water = 10 / 1 / 0.5 developing solvent) to obtain about 17.8 mg (0.0161 mmol, 9.01%) of white fluffy solid compound 66h. Melting point: 153.0-154.1°C. HRMS (ESI) (M+H) + m / z 1103.5912, calculated value C 55 H 84 F6O 16 1103.5922. 1H NMR (CDCl3, 700MHz) δ: 8.82 (s, 1H, 2″-quinolyl), 7.88 (d, J = 12.1 Hz, 1H, 5″-quinolyl), 5.70 (br, 1H, 3-O-CO-NH-CH2), 5.18 (dd, J = 2.5 Hz, 10.8 Hz, 1H, H-13), 4.90 (d, J = 11.0 Hz, 1H, H-3), 4.87 (s, 1H, H-11), 4.08-4.00 (m, 2H, H-1′, 1H-cyclopropyl), 3.83 (s, 3H, 9- O-CH3),3.79(s,3H,O-CH3),3.78(d,J=3.0Hz,1H,H-5),3.74-3.67(m,1H,H-8),3.47(br,4H,4H-piperazinyl),3.43-3.32(m,2H, H-5′,-O-CO-NH-CH2),3.21(dd,J=7.3Hz,10.1Hz,1H,H-2′),3.16-3.09(m,1H,3-O-CO-NH-CH2),3.03(s,3H,6-O-CH3),2. 89-2.81(m,1H,H-2),2.62(br,4H,4H-piperazinyl),2.53-2.40(m,4H,H-3′,H-10,-CH2-piperazinyl),2.31(s,6H,-N(CH3)2),2.12-2.04(m,1H,H-4),1.96-1.87(m,1H,H-14eq),1.72-1.53(m,6H,2(-CH2-),H-4′a,H-14ax),1.50(s,3H,12-CH3),1.43-1.35(m ,1H,H-4′b),1.34(s,3H,6-CH3),1.31-1.19(m,10H,H-7a,H-7b,5′-CH3,2H-cyclopropyl,10-CH3),1.17(d,J=6.8Hz,3H,2-CH3),1.08(d,J=7.5Hz,3H,4-CH3),1.01(d,J=4.0Hz,2H,2H-cyclopropyl),0.94(d,J=7.0Hz,3H,8-CH3),0.87(t,J=7.4Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:177.05,174.05,166.73,164.51,156.40,154.67,149.94,145.38,139.44,133. 92,121.90,108.41,108.17,107.82,103.30,85.00,83.21,81.32,78.34,78.15,77.24,75.53,70.46, 69.46,66.19,62.33,61.44,58.12,53.79,50.66,49.81,43.40,41.07,40.54,40.37,37.35,36.00,32.73,28.70,28.04,25.60,24.24,22.25,21.23,19.34,18.86,15.61,14.97,13.04,10.20,9.56,8.98.
[0232] Synthesis of compound 66i
[0233]
[0234] According to the synthesis method, compound 43 (0.452 g, 0.595 mmol) was used and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.1 mobile phase) to obtain about 0.355 g (0.424 mmol, 71.26%) of white fluffy solid compound 90.
[0235] Compound 90 (0.150 g, 0.179 mmol) was reacted with compound Ar-i (0.310 g, 0.890 mmol), and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / methanol / ammonia water = 10 / 1 / 0.5 developing solvent) to obtain about 19.0 mg (0.0174 mmol, 9.74%) of white fluffy solid compound 66i. Melting point: 163.7-163.9°C. HRMS (ESI) (M+H) + m / z 1089.5768, calculated value C 54 H 82 F6O 16 1089.5766. 1H NMR (CDCl3, 700MHz) δ: 8.65 (s, 1H, 2″-quinolyl), 7.73 (d, J = 12.1 Hz, 1H, 5″-quinolyl), 5.92 (t, J = 5.7 Hz, 1H, 3-O-CO-NH-CH2), 5.18 (dd, J = 2.5 Hz, 10.8 Hz, 1H, H-13), 4.90 (d, J = 11.0 Hz, 1H, H-3), 4.87 (s, 1H, H-11), 4.55 (s, 1H, N-CH), 4.47 (d, J = 12.3 Hz, O-CH2-), 4. 37 (d, J = 11.3 Hz, O-CH2-), 4.05 (d, J = 7.3 Hz, 1H, H-1'), 3.83 (s, 3H, 9-O-CH3), 3.79 (d, J = 3.1 Hz, 1H, H-5), 3.74-3.66 (m, 1H, H-8), 3.49-3.37 (m, 5H, H-5', 4H-piperazinyl), 3.37-3.30 (m, 1H, 3-O-CO-NH-CH2), 3.21 (dd, J = 7.3 Hz, 10.1 Hz, 1H, H-2'), 3.17-3.10 (m, 1 H,3-O-CO-NH-CH2), 3.03 (s, 3H, 6-O-CH3), 2.90-2.82 (m, 1H, H-2), 2.66-2.54 (m, 4H, 4H-piperazinyl), 2.53-2.40 (m, 4H, H-3′, H-10, -CH2-piperazinyl), 2.31 (s, 6H, -N(CH3)2), 2.12-2.05 (m, 1H, H-4), 1.96-1.87 (m, 1H, H-14eq), 1.72-1.53 (m, 9H, 2(-CH2-), H-4′a, H-14 ax,N-CH-CH3),1.50(s,3H,12-CH3),1.45-1.36(m,1H,H-4′b),1.34(s,3H,6-CH3),1.30-1.20(m,8H,H-7a,H-7b,5′-CH3,10- CH3),1.17(d,J=6.8Hz,3H,2-CH3),1.08(d,J=7.5Hz,3H,4-CH3),0.94(d,J=7.0Hz,3H,8-CH3),0.87(t,J=7.4Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:177.14,174.08,167.14,164.52,156.38,154.67,144.68,139.34,133.06,12 4.72,107.90,105.46,105.22,103.22,85.01,83.22,81.17,78.34,78.06,78.06,77.24,75.51,70.4 4,69.45,68.18,66.25,61.43,58.10,55.52,53.76,50.59,49.81,43.39,41.10,40.40,37.35,36.00,32.73,28.05,25.60,24.28,22.25,21.22,19.34,18.86,18.36,15.61,14.97,13.04,10.21,8.98.
[0236] Synthesis of compound 67a
[0237]
[0238] According to the synthesis method, compound 44 (0.332 g, 0.429 mmol) was used and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.1 mobile phase) to obtain about 0.197 g (0.132 mmol, 30.77%) of white fluffy solid compound 91.
[0239] Compound 91 (0.197 g, 0.231 mmol) was reacted with compound Ar-a (0.383 g, 1.155 mmol), and the product was purified by column chromatography (100-200 mesh silica gel, dichloromethane / methanol / ammonia water = 10 / 1 / 0.5 developing solvent) to obtain about 68.5 mg (0.0630 mmol, 27.27%) of white fluffy solid compound 67a. Melting point: 153.9-154.5°C. HRMS (ESI) (M+H) + m / z 1087.5970, calculated value C 55 H 84 F6O 15 1087.5973. 1H NMR (CDCl3, 700 MHz) δ: 8.77 (s, 1H, 2″-quinolyl), 8.01 (d, J = 12.8 Hz, 1H, 5″-quinolyl), 7.37 (d, J = 6.9 Hz, 1H, 8″-quinolyl), 5.17 (dd, J = 2.8 Hz, 10.4 Hz, 1H, H-13), 5.02 (br, 1H, 3-O-CO-NH-CH2), 4.91-4.81 (m, 2H, H-3, H-11), 4.02 (br, 1H, H-1′), 3.82 ( s, 3H, 9-O-CH3), 3.76-3.65 (m, 2H, H-5, H-8), 3.61-3.52 (m, 1H, H-5′), 3.49-3.30 (m, 5H, 1H-cyclopropyl, 4H-piperazinyl), 3.30-3.23 (m, 1H, 3-O-CO-NH-CH2), 3.23-3.17 (m, 1H, H-2′), 3.12-3.05 (m, 1H, 3-O-CO-NH-CH2), 3.03 (s, 3H, 6-O-CH3), 2.90-2 .80(m,1H,H-2),2.75-2.58(m,4H,4H-piperazinyl),2.53-2.38(m,4H,-CH2-piperazinyl,H-3′,H-10),2.30(s,6H,-N(CH3)2),2.13-2.04(m,1H,H-4),1.95-1.86(m,1H,H-14eq),1.71-1.52(m,6H,H-4′a,2(-CH2-),H-14ax),1.49(s,3H,12-CH3),1.46 -1.36 (m, 5H, 2H-cyclopropyl, H-4′b, CH2), 1.33 (s, 3H, 6-CH3), 1.30-1.18 (m, 10H, 2H-cyclopropyl, H-7a, H-7b, 5′-CH3, 10-CH3), 1.16 (d, J = 6.8 Hz, 3H, 2-CH3), 1.08 (d, J = 7.5 Hz, 3H, 4-CH3), 0.94 (d, J = 7.0 Hz, 3H, 8-CH3), 0.86 (t, J = 7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:177.10,174.08,167.04,164.56,154.67,152.43,147.41, 139.11,108.15,104.76,85.03,83.21,78.34,77.25,75.50,70.47,61.42,58.30 ,52.87,49.83,43.35,41.06,40.37,37.33,35.97,35.30,32.72,30.10,26.47,25.61,24.63,22.23,21.21,19.33,18.87,15.61,14.91,13.02,10.20,8.94,8.25.
[0240] Synthesis of compound 68a
[0241]
[0242] According to the synthesis method, compound 46 (0.282 g, 0.371 mmol) and methanesulfonyl chloride (0.033 mL, 0.408 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.241 g (0.268 mmol, 72.24%) of compound 92.
[0243] Compound 92 (0.120 g, 0.134 mmol) was reacted with compound Ar-a (0.133 g, 0.401 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 21.8 mg (0.212 mmol, 15.81%) of the general formula compound 68a. Melting point: 162.2-164.4°C. HRMS (ESI) (M+H) + m / z 1029.5548, calcd. 52 H 78 F6O 14 1029.5555. 1H NMR (CDCl3, 400MHz) δ: 8.77 (s, 1H, 2″-quinolyl), 8.01 (d, J=12.9 Hz, 1H, 5″-quinolyl), 7.36 (d, J=5.2 Hz, 1H, 8″-quinolyl), 5.80 (s, 1H, 3-O-CO-NH-CH2), 5.73 (s, 1H, 11-NH), 5.23 (dd, J=2.3 Hz, 10.9 Hz, 1H, H-13), 4.92 (d, J=11.0 Hz, 1H, H-3), 4.0 6 (d, J = 7.0 Hz, 1H, H-1′), 3.81 (d, J = 2.8 Hz, 1H, H-5), 3.78 (s, 1H, H-11), 3.61-3.51 (m, 1H, 1H-cyclopropyl), 3.50-3.25 (m, 6H, H-5′, 4H-piperazinyl, 3-O-CO-NH-CH2), 3.24-3.12 (m, 2H, H-2′, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3), 2.93-2.80 (m, 2 H, H-10, H-2), 2.69 (s, 4H, 4H-piperazinyl), 2.60-2.46 (m, 3H, H-8, -CH2-piperazinyl), 2.46-2.37 (m, 1H, H-3′), 2.30 (s, 6H, -N(CH3)2), 2.11-2.01 (m, 1H, H-4), 1.97-1.85 (m, 1H, H-14eq), 1.84-1.72 (m, 3H, -CH2-CH2-piperazinyl, H-7a), 1.70-1.62 (m, 1H , H-7b), 1.62-1.48 (m, 2H, H-14eq, H-4′a), 1.46-1.37 (m, 5H, 12-CH3, 2H-cyclopropyl), 1.32-1.21 (m, 7H, 6-CH3, H-4′b, 5′-CH3), 1.21-1.18 (m, 2H, 2H-cyclopropyl), 1.17-1.07 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.84 (t, J=7.3Hz, 3H, 15-CH3). 13CNMR(CDCl3,100MHz)δ:217.64,174.36,167.05,158.43,156.34,147.47,108.19,83.87,77.87,77.24,75.82,70.49,66.24,58.13,56.38,52. 85,49.83,45.29,43.44,40.36,40.17,39.13,37.30,35.82,35.34,29. 70,22.04,21.22,19.32,18.27,15.09,13.88,13.31,10.25,9.10,8.27.
[0244] Synthesis of compound 69a
[0245]
[0246] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.210 g (0.231 mmol, 58.78%) of compound 93.
[0247] Compound 93 (0.210 g, 0.231 mmol) was reacted with compound Ar-a (0.230 g, 0.693 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 49.0 mg (0.0470 mmol, 20.33%) of compound 69a. Melting point: 186.7-187.5°C. HRMS (ESI) (M+H) + m / z 1043.5717, calcd. 53 H 80 F6O 14 1043.5711. 1H NMR (CDCl3, 400MHz) δ: 8.76 (s, 1H, 2″-quinolyl), 8.00 (d, J=13.1Hz, 1H, 5″-quinolyl), 7.36 (s, 1H, 8″-quinolyl), 5.80 (s, 1H, 11-NH), 5.63 (s, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J=2.3Hz, 10.9Hz, 1H, H-13), 4.93 (d, J=11.0Hz, 1H, H-3), 4.04 (d, J = 7.2 Hz, 1H, H-1′), 3.80 (d, J = 2.8 Hz, 1H, H-5), 3.77 (s, 1H, H-11), 3.61-3.52 (m, 1H, 1H-cyclopropyl), 3.46-3.29 (m, 6H, H-5′, 4H-piperazinyl, 3-O-CO-NH-CH2), 3.23-3.15 (m, 1H, H-2′), 3.14-3.04 (m, 1H, 3-O-CO-NH-CH2), 2.98 (s, 3H ,6-O-CH3), 2.94-2.79(m,2H,H-10,H-2), 2.68(s,4H,4H-piperazinyl), 2.56-2.37(m,4H,H-8,-CH2-piperazinyl,H-3′), 2.29(s,6H,-N(CH3)2), 2.12-2.02(m,1H,H-4), 1.97-1.87(m,1H,H-14eq), 1.83-1.72(m,1H,H-7a), 1.70-1.48(m,7 H,-CH2-CH2-CH2-piperazinyl, H-7b, H-14eq, H-4′a), 1.42 (s, 3H, 12-CH3), 1.40 (br, 2H, 2H-cyclopropyl), 1.32-1.18 (m, 9H, 6-CH3, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.18-1.04 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.84 (t, J=7.3Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.62,177.13,174.35,167.00,158.41,156.37,147.43,139.11,112 .56,112.32,108.18,104.78,103.19,83.87,81.67,78.19,77.85,77.24,75.82,70.46,69.5 1,66.24,58.13,57.85,52.79,49.82,45.30,43.40,41.08,40.38,39.13,37.29,35.80,35.32,28.65,28.07,24.20,22.04,21.23,19.31,18.28,15.08,13.88,13.31,10.26,9.16,8.26.
[0248] Synthesis of compound 69b
[0249]
[0250] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.210 g (0.231 mmol, 58.78%) of compound 93.
[0251] Compound 93 (0.300 g, 0.329 mmol) was reacted with compound Ar-b (0.229 g, 0.717 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 144.2 mg (0.140 mmol, 42.50%) of the general formula compound 69b. Melting point: 162.3-163.6°C. HRMS (ESI) (M+H) + m / z 1031.5722, calculated value C 52 H 80 F6O 14 1031.5711. 1H NMR (CDCl3, 400MHz) δ: 8.68 (s, 1H, 2″-quinolyl), 8.03 (d, J = 13.0 Hz, 1H, 5″-quinolyl), 6.86 (d, J = 6.7 Hz, 1H, 8″-quinolyl), 5.81 (s, 1H, 11-NH), 5.79 (s, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J = 2.3 Hz, 10.9 Hz, 1H, H-13), 4.93 (d, J = 11.0 Hz, 1H, H-3), 4.35(br,2H,N-CH2CH3),4.05(d,J=7.2Hz,1H,H-1′),3.80(d,J=2.9Hz,1H,H-5),3.77(s,1H,H-11),3.44-3.29( m,6H,H-5′,4H-piperazinyl,3-O-CO-NH-CH2),3.19(dd,J=7.2Hz,10.1Hz,1H,H-2′),3.13-3.03(m,1H,3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3), 2.94-2.79 (m, 2H, H-10, H-2), 2.68 (s, 4H, 4H-piperazinyl), 2.56-2.38 (m, 4H, H-8, -CH2-piperazinyl, H-3′), 2.30 (s, 6H, -N(CH3)2), 2.11-2.01 (m, 1H, H-4), 1.96-1.86 (m, 1H, H-14eq), 1.82-1.72 (m, 1H, H-7a), 1.71-1.4 8(m,10H,-CH2-CH2-CH2-piperazinyl,H-7b,H-14eq,H-4′a,N-CH2CH3),1.42(s,3H,12-CH3),1.28(s,3H,6-CH3),1.23(d ,J=6.1Hz,3H,5′-CH3),1.19-1.04(m,13H,H-4′b,2-CH3,10-CH3,4-CH3,8-CH3),0.84(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:217.63,176.99,174.37,167.22,158.43,156.37,154.78,152.28,147.15,146.0 5,145.95,137.14,120.60,112.84,112.61,108.36,103.90,103.10,83.88,81.54,78.12,77.85,77.25 ,75.80,70.47,69.49,66.26,58.13,57.82,52.76,49.81,49.75,45.29,43.39,41.08,40.37,39.11,37.29,35.79,28.68,28.05,24.23,22.04,21.22,19.31,18.27,15.06,14.49,13.87,13.31,10.26,9.20.
[0252] Synthesis of compound 69c
[0253]
[0254] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for the reaction. After the reaction was completed, the mixture was purified by column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) to obtain about 0.210 g (0.231 mmol, 58.78%) of compound 93.
[0255] Compound 93 (0.149 g, 0.150 mmol) was reacted with compound Ar-c (0.149 g, 0.450 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 58.8 mg (0.0578 mmol, 38.54%) of the general formula compound 69c. HRMS (ESI) (M+2H) 2+ m / z(z=2)509.2821, calculated value C 51 H 79 F6O 14 509.2813. 1H NMR (CD3OD, 400 MHz) δ: 8.73 (s, 1H, 2″-quinolyl), 7.87 (d, J=13.1 Hz, 1H, 5″-quinolyl), 7.05 (s, 1H, 8″-quinolyl), 5.18 (dd, J=2.5 Hz, 10.7 Hz, 1H, H-13), 4.90 (d, J=11.1 Hz, 1H, H-3), 4.14 (d, J=7.1 Hz, 1H, H-1′) ,4.02(s,3H,N-CH3),3.87(d,J=3.1Hz,1H,H-5),3.80(s,1H,H-11),3.50-3.34(m,5H,H-5′,4H-piperazinyl),3.29-3.22(m,2H,H-2′,3-O-CO-NH-CH2),3.12-3.02(m,2H,H-10,3-O-CO-NH-CH2),2.99(s ,3H,6-O-CH3),2.94-2.88(m,1H,H-2),2.78-2.64(m,5H,H-3′,4H-piperazinyl),2.55-2.43(m,3H,H-8,-CH2-piperazinyl),2.40(s,6H,-N(CH3)2),2.17-2.08(m,1H,H-4),1.92-1.73(m,3H,H-14eq,H-7a,H-4′ a),1.68-1.54(m,6H,2(-CH2-),H-7b,H-14eq),1.47(s,3H,12-CH3),1.34-1.18(m,7H,H-4′b,6 -CH3,5′-CH3),1.17-1.08(m,12H,2-CH3,10-CH3,4-CH3,8-CH3),0.85(t,J=7.4Hz,3H,15-CH3). 13 C NMR(CD3OD,100MHz)δ:217.98,174.82,159.44,157.38,101.75,84.49,7 8.66,77.89,77.47,75.50,70.73,68.76,64.55,58.05,57.79,52.61,49 .22,48.94,45.35,43.20,40.40,39.53,38.66,37.42,35.71,30.89,27. 60,23.40,21.80,20.03,18.43,17.17,14.04,12.93,12.22,9.43,8.14.
[0256] Synthesis of compound 69d
[0257]
[0258] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain compound 93 0.210 g (0.231 mmol, 58.78%).
[0259] Compound 93 (0.150 g, 0.164 mmol) was reacted with compound Ar-d (0.0852 g, 0.426 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 32.8 mg (0.0310 mmol, 18.91%) of the general formula compound 69d. Melting point: 158.5-160.8°C. HRMS (ESI) (M+H) + m / z 1057.5861, calcd. 54 H 82 F6O 14 1057.5868. 1H NMR (CDCl3, 400 MHz) δ: 8.74 (s, 1H, 2″-quinolyl), 7.98 (d, J = 13.0 Hz, 1H, 5″-quinolyl), 7.34 (d, J = 7.2 Hz, 1H, 8″-quinolyl), 5.80 (s, 1H, 11-NH), 5.67 (br, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J = 2.3 Hz, 10.9 Hz, 1H, H-13), 4.94 (d, J = 11.0 Hz, 1H, H-3), 4.04 (d, J = 7.4 Hz, 1H, H-4). z, 1H, H-1′), 3.80 (d, J=2.8 Hz, 1H, H-5), 3.77 (s, 1H, H-11), 3.63-3.55 (m, 1H, 1H-cyclopropyl), 3.54-3.44 (m, 2H, 2H-piperazinyl), 3.44-3.33 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.30-3.14 (m, 2H, H-2′, 1H-piperazinyl), 3.11-3.03 (m, 1H, 3-O-CO-NH-CH2), 3.02-2.94 (m, 4H ,6-O-CH3,1H-piperazinyl), 2.94-2.67 (m,5H,H-10,H-2,3H-piperazinyl), 2.59-2.47 (m,2H,H-8,H-3′), 2.46-2.33 (m,2H,-CH2-piperazinyl), 2.29 (s,6H,-N(CH3)2), 2.13-2.01 (m,1H,H-4), 1.97-1.87 (m,1H,H-14eq), 1.83-1.72 (m,1H,H-7a), 1.69-1.49 (m,7H,-CH2 -CH2-CH2-piperazinyl, H-7b, H-14eq, H-4′a), 1.42 (s, 3H, 12-CH3), 1.42-1.36 (m, 2H, 2H-cyclopropyl), 1.28 (s, 3H, 6-CH3), 1.26-1.18 (m, 9H, H-4′b, 5′-CH3, 2H-cyclopropyl, -piperazinyl-CH3), 1.18-1.06 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.84 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.64,177.08,174.37,167.02,158.42,156.38,147.36,139.14,112.46, 112.22,108.10,104.71,103.17,83.88,81.65,78.20,77.85,77.25,75.80,70.45,69.48,66.18,5 8.13,56.59,54.64,52.98,50.01,49.81,45.30,43.40,41.13,40.32,39.12,37.28,35.79,35.33,28.65,28.23,23.68,22.03,21.22,19.31,18.27,15.28,15.08,13.87,13.30,10.26,9.20,8.24.
[0260] Synthesis of compound 69e
[0261]
[0262] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.210 g (0.231 mmol, 58.78%) of compound 93.
[0263] Compound 93 (0.150 g, 0.164 mmol) was reacted with compound Ar-e (0.0852 g, 0.426 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 13.5 mg (0.0128 mmol, 7.79%) of the general formula compound 69e. Melting point: 162.5-163.6°C. HRMS (ESI) (M+H) + m / z 1057.5859, calcd. 54 H 82 F6O 14 1057.5868. 1H NMR (CDCl3, 400MHz) δ: 8.76 (s, 1H, 2″-quinolyl), 8.01 (d, J = 13.0 Hz, 1H, 5″-quinolyl), 7.33 (d, J = 7.1 Hz, 1H, 8″-quinolyl), 5.79 (s, 1H, 11-NH), 5.41 (br, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J = 2.4 Hz, 10.9 Hz, 1H, H-13), 4.93 (d, J = 11.0 Hz, 1H, H-3), 4.03 (d, J = 7.4 Hz, 1H, H-1′), 3.83-3.74 (m, 2H, H-5, H-11), 3.61-3.43 (m, 3H, 1H-cyclopropyl, 2H-piperazinyl), 3.43-3.30 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.25-3.14 (m, 2H, H-2′, 1H-piperazinyl), 3.13-3.04 (m, 1H, 3-O-CO-NH-CH2), 3.02-2.67 (m, 9H, 6- O-CH3,H-10,H-2,4H-piperazinyl), 2.59-2.46 (m,2H,H-8,H-3′), 2.44-2.34 (m,2H,-CH2-piperazinyl), 2.28 (s,6H,-N(CH3)2), 2.12-2.01 (m,1H,H-4), 1.97-1.86 (m,1H,H-14eq), 1.82-1.73 (m,1H,H-7a), 1.69-1.49 (m,7H,-CH2-CH2-CH2-piperazinyl, H-7b, H-14eq, H-4′a), 1.42 (s, 3H, 12-CH3), 1.41-1.35 (m, 2H, 2H-cyclopropyl), 1.28 (s, 3H, 6-CH3), 1.27-1.18 (m, 9H, H-4′b, 5′-CH3, 2H-cyclopropyl, -piperazinyl-CH3), 1.18-1.07 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.84 (t, J=7.3Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.65,177.13,174.36,167.06,158.43,156.39,154.36,152.93,147.41,145.83,145 .78,139.14,119.73,112.53,112.40,108.19,104.63,103.23,83.87,81.65,78.27,77.86,75.82,70.48,69.5 5,66.17,58.13,56.58,54.52,52.99,49.93,49.83,45.30,43.38,41.08,40.37,39.13,37.29,35.80,35.28,29.71,28.57,28.22,23.50,22.03,21.23,19.31,18.28,15.26,15.08,13.88,13.30,10.26,9.14,8.26,8.24.
[0264] Synthesis of compound 69f
[0265]
[0266] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.210 g (0.231 mmol, 58.78%) of compound 93.
[0267] Compound 93 (0.156 g, 0.171 mmol) was reacted with compound Ar-f (0.161 g, 0.513 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 35.9 mg (0.0350 mmol, 20.47%) of the general formula compound 69f. Melting point: 161.8-164.2°C HRMS (ESI) (M+H) + m / z 1052.5785, calculated value C 53 H 81 N6O 14 1025.5805. 1H NMR (CDCl3, 400MHz) δ: 8.70 (s, 1H, 2"-quinolyl), 8.26 (d, J = 9.1 Hz, 1H, 5"-quinolyl), 7.18 (s, 1H, 8"-quinolyl), 7.13 (d, J = 9.4 Hz, 1H, 6"-quinolyl), 5.81 (s, 1H, 11-NH), 5.76 (t, J = 6.2 Hz, 1H, 3-O-CO-NH-CH2), 5.22 (dd, J = 2.3 Hz, 10.9 Hz, 1H, H-13), 4.93 (d, J = 11. 0Hz,1H,H-3),4.04(d,J=7.3Hz,1H,H-1′),3.79(d,J=3.1Hz,1H,H-5),3.77(s,1H,H-11),3.57-3.44(m,5H,1H-cyclopropyl,4H-piperazinyl),3.43-3.30(m,2H,H-5′,3-O-CO-NH-CH2),3.19(dd,J=7.3Hz,10.1Hz,1H,H-2′),3.14-3.06(m,1H,3-O-CO-NH-CH2) ,2.98(s,3H,6-O-CH3),2.89(q,J=6.4Hz,1H,H-10),2.85-2.77(m,1H,H-2),2.65(s,4H,4H-piperazinyl),2.57-2.38(m,4H,H-8,-CH2-piperazinyl,H-3′),2.30(s,6H,-N(CH3)2),2.10-2.01(m,1H,H-4),1.97-1.86(m,1H,H-14eq),1.83-1.72(m,1H,H-7a),1 .70-1.48 (m, 7H, -CH2-CH2-CH2-piperazinyl, H-7b, H-14eq, H-4′a), 1.41 (s, 3H, 12-CH3), 1.40-1.33 (m, 2H, 2H-cyclopropyl), 1.30-1.20 (m, 9H, 6-CH3, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.20-1.06 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.83 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.69,177.43,174.37,167.49,158.45,156.39,154.55,147.63,143.24, 127.96,117.18,114.54,108.05,103.16,98.56,83.89,81.69,78.17,77.84,77.26,75.78,70.45, 69.48,66.16,58.12,57.88,52.66,49.82,47.21,45.31,43.38,41.07,40.35,39.11,37.28,35.78,34.92,28.66,28.09,24.27,22.03,21.24,19.32,18.28,15.10,13.89,13.29,10.27,9.18,8.18.
[0268] Synthesis of compound 69g
[0269]
[0270] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain compound 93 0.210 g (0.231 mmol, 58.78%).
[0271] Compound 93 (0.208 g, 0.249 mmol) was reacted with compound Ar-g (0.413 g, 1.243 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 104.5 mg (0.100 mmol, 40.21%) of the general formula compound 69g. Melting point: 187.0-188.1°C. HRMS (ESI) (M+H) + m / z 1044.5668, calcd. 52 H 79 F7O 14 1044.5664. 1H NMR (CD3OD, 400 MHz) δ: 8.77 (s, 1H, 2″-quinolyl), 8.02 (d, J = 13.6 Hz, 1H, 5″-quinolyl), 5.20 (dd, J = 2.4 Hz, 10.7 Hz, 1H, H-13), 4.91 (d, J = 11.2 Hz, 1H, H-3), 4.17 (d, J = 7.2 Hz, 1H, H-1′), 3.95 (s, 4H, 4H-piperazinyl), 3.88 (d, J=3.0Hz,1H,H-5),3.81(s,1H,H-11),3.74-3.63(m,1H,1H-cyclopropyl),3.41-3.41(m,1H,H-5′),3.31-3.25(m,2H,H-2′,3-O-CO-NH-CH2),3.16-3.03(m,2H,H-10,3-O-CO-NH-CH2),3.01(m,3H,6-O-CH3),2.97 -2.88 (m, 1H, H-2), 2.84-2.74 (m, 1H, H-3′), 2.66 (s, 4H, 4H-piperazinyl), 2.56-2.40 (m, 9H, H-8, -CH2-piperazinyl, -N(CH3)2), 2.21-2.09 (m, 1H, H-4), 1.96-1.77 (m, 3H, H-7a, H-14eq, H-4′a), 1.68-1.53 (m, 6H, 2(-CH2- ), H-7b, H-14eq), 1.49 (s, 3H, 12-CH3), 1.37-1.25 (m, 6H, 2H-cyclopropyl, H-4′b, 6-CH3), 1.22 (d, J=6.0 Hz, 3H, 5′-CH3), 1.20-1.02 (m, 14H, 2H-cyclopropyl, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.88 (t, J=7.3 Hz, 3H, 15-CH3). 13 C NMR(CDCl3,100MHz)δ:217.70,180.59,174.33,166.84,161.69,158.46,1 56.34,146.27,103.17,83.88,77.84,75.80,70.51,69.58,66.25,58.13, 53.47,53.00,49.83,46.87,45.32,43.38,40.40,39.12,37.27,35.80,34 .66,22.03,21.25,19.32,18.30,15.10,13.90,13.30,10.28,9.12,7.48.
[0272] Synthesis of Compound 69j
[0273]
[0274] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain compound 93 0.210 g (0.231 mmol, 58.78%).
[0275] Compound 93 (0.180 g, 0.197 mmol) was reacted with compound Ar-j (0.189 g, 0.591 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 79.2 mg (0.0767 mmol, 38.95%) of the general formula compound 69j. Melting point: 152.2-153.7°C HRMS (ESI) (M+H) + m / z 1032.5683, calcd. 51 H 79 F7O 14 1032.5664. 1H NMR (CDCl3, 400MHz) δ: 8.70 (s, 1H, 2″-quinolyl), 8.10 (d, J=13.3 Hz, 1H, 5″-quinolyl), 5.81 (s, 1H, 11-NH), 5.64 (t, J=5.7 Hz, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J=2.3 Hz, 10.9 Hz, 1H, H-13), 4.93 (d, J=11.0 Hz, 1H, H-3), 4.41 (q, J=7.2 Hz, 2H, N-CH2CH3), 4.0 3 (d, J = 7.3 Hz, 1H, H-1'), 3.95-3.84 (m, 4H, 4H-piperazinyl), 3.82-3.75 (m, 2H, H-5, H-11), 3.43-3.30 (m, 2H, H-5', 3-O-CO-NH-CH2), 3.19 (dd, J = 7.3 Hz, 10.1 Hz, 1H, H-2'), 3.13-3.04 (m, 1H, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3), 2.90 (q, J = 6.6 Hz, 1 H, H-10), 2.87-2.79 (m, 1H, H-2), 2.60 (t, J = 4.9 Hz, 4H, 4H-piperazinyl), 2.56-2.47 (m, 1H, H-8), 2.48-2.35 (m, 3H, -CH2-piperazinyl, H-3′), 2.30 (s, 6H, -N(CH3)2), 2.11-2.03 (m, 1H, H-4), 1.98-1.88 (m, 1H, H-14eq), 1.83-1.74 (m, 1H, H-7a), 1.69-1.53 (m, 7 H,-CH2-CH2-CH2-piperazinyl,H-7b,H-14eq,H-4′a),1.51(t,J=7.2Hz,3H,N-CH2CH3),1.43(s,3H,12-CH3),1.28(m,3H,6-CH3) ,1.23(d,J=6.2Hz,3H,5′-CH3),1.18-1.06(m,13H,H-4′b,2-CH3,10-CH3,4-CH3,8-CH3),0.85(t,J=7.4Hz,3H,15-CH3). 13C NMR(CDCl3,176MHz)δ:217.65,177.06,174.34,166.97,158.43,156.36,146.41,145.07,120.32,120.20,113.80,109.32 ,103.21,83.88,81.77,78.25,77.85,77.82,75.81,75.78,70.45,69.50,66.18,58.14,57.80,52.95,52.92,49.81,49.7 8,47.76,46.97,46.92,45.29,43.41,41.04,40.34,40.32,39.12,37.29,37.26,35.78,28.62,28.02,24.17,22.04,22.01,21.23,21.20,19.31,19.28,18.26,18.23,15.07,15.05,14.98,14.95,13.88,13.85,13.30,13.27,10.26,10.23,9.11.
[0276] Synthesis of compound 69k
[0277]
[0278] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain compound 93 0.210 g (0.231 mmol, 58.78%).
[0279] Compound 93 (0.150 g, 0.164 mmol) was reacted with compound Ar-k (0.149 g, 0.492 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 36.9 mg (0.0363 mmol, 22.26%) of compound 69k. HRMS (ESI) (M+H) + m / z 1015.5708, calcd. 50 H 79 N8O 14 1015.5710. 1HNMR (CD3OD, 400MHz)δ:9.18(s,1H,5″-quinolyl),8.74(s,1H,2″-quinolyl),5.18(dd,J=2.4Hz,10.8Hz,1H,H-13),4.89(d,J=11.1Hz,1H,H-3),4.75(q,J=7.3Hz,2H,N-CH2CH3),4.15(d,J=7.2Hz,1H,H-1′),4. 00 (s, 4H, 4H-piperazinyl), 3.86 (d, J = 3.1 Hz, 1H, H-5), 3.79 (s, 1H, H-11), 3.50-3.40 (m, 1H, H-5′), 3.30-3.23 (m, 2H, H-2′, 3-O-CO-NH-CH2), 3.11-3.02 (m, 2H, H-10, 3-O-CO-NH-CH2), 2.99 (s, 3H, 6-O-CH3), 2 .94-2.86 (m, 1H, H-2), 2.85-2.74 (m, 1H, H-3′), 2.57 (s, 4H, 4H-piperazinyl), 2.52-2.39 (m, 9H, H-8, -CH2-piperazinyl, -N(CH3)2), 2.17-2.08 (m, 1H, H-4), 1.92-1.78 (m, 3H, H-14eq, H-7a, H-4′a), 1.68-1.52 (m, 6H, 2 (-CH2-),H-7b,H-14eq),1.47(s,3H,12-CH3),1.43(t,J=7.1Hz,N-CH2CH3),1.35-1.23(m,7H,H-4′ b,6-CH3,5′-CH3),1.23-1.08(m,12H,2-CH3,10-CH3,4-CH3,8-CH3),0.86(t,J=7.3Hz,3H,15-CH3). 13 CNMR(CD3OD,100MHz)δ:217.89,174.80,159.42,157.37,101.65,84.49, 78.75,77.88,77.47,75.52,70.58,68.69,64.66,58.06,57.67,52.48,4 8.94,45.34,43.56,43.21,40.36,39.45,38.68,37.42,35.70,27.55,23 .41,21.82,19.99,18.42,17.17,14.03,13.55,12.92,12.23,9.44,8.09.
[0280] Synthesis of compound 69p
[0281]
[0282] According to the synthesis method, compound 47 (0.328 g, 0.393 mmol) and methanesulfonyl chloride (0.035 mL, 0.432 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.210 g (0.231 mmol, 58.78%) of compound 93.
[0283] Compound 93 (0.150 g, 0.164 mmol) was reacted with compound Ar-p (0.177 g, 0.492 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.2 / 0.1) was performed to obtain 16.8 mg (0.0156 mmol, 9.51%) of compound 69p. Melting point: 154.9-155.9°C. HRMS (ESI) (M+H) + m / z 1071.6019, calcd. 55 H 84 F6O 14 1071.6024. 1H NMR (CDCl3, 400MHz) δ: 8.52 (s, 1H, 2"-quinolyl), 8.04 (d, J = 13.3 Hz, 1H, 5"-quinolyl), 7.26 (d, J = 7.6 Hz, 1H, 8"-quinolyl), 5.80 (s, 1H, 11-NH), 5.76 (t, J = 6.6 Hz, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J = 2.3 Hz, 10.9 Hz, 1H, H-13), 4.93 (d, J = 11.0 Hz, 1H, H-3), 4.39 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.04 (d, J = 7.3 Hz, 1H, H-1′), 3.80 (d, J = 2.9 Hz, 1H, H-5), 3.77 (s, 1H, H-11), 3.49-3.40 (m, 1H, 1H-cyclopropyl), 3.40-3.25 (m, 6H, H-5′, 4H-piperazinyl, 3-O-CO-NH-CH2), 3.17 (dd, J = 7.3 Hz, 10.1 Hz, 1H, H-2′), 3.13-3.05 (m, 1H, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH 3), 2.89 (q, J = 6.8 Hz, 1H, H-10), 2.87-2.77 (m, 1H, H-2), 2.67 (s, 4H, 4H-piperazinyl), 2.56-2.49 (m, 1H, H-8), 2.48-2.42 (m, 2H, -CH2-piperazinyl), 2.42-2.32 (m, 1H, H-3′), 2.27 (s, 6H, -N(CH3)2), 2.12-2.01 (m, 1H, H-4), 1.97-1.86 (m, 1H, H-14eq), 1.81-1.71 (m, 1H, H-7a) ,1.69-1.48 (m,7H,-CH2-CH2-CH2-piperazinyl,H-7b,H-14eq,H-4′a),1.45-1.36 (m,6H,12-CH3,OCH2CH3),1.35-1.29 (m,2H,2H-cyclopropyl,1.29-1.18 (m,7H,6-CH3,H-4′b,5′-CH3),1.19-1.05 (m,14H,2-CH3,10-CH3,4-CH3,8-CH3,2H-cyclopropyl),0.84 (t,J=7.3Hz,3H,15-CH3). 13CNMR(CDCl3,100MHz)δ:217.65,174.34,173.15,165.88,158.43,156.35,148.12,138.05,113.48 ,113.25,110.54,104.68,103.18,83.88,81.61,78.15,77.85,77.25,75.81,70.44,69.54,66.27, 60.92,58.13,57.89,52.92,49.82,45.30,43.41,41.12,40.38,39.12,37.29,35.80,34.48,29.70,28.57,28.08,24.29,22.04,21.24,19.31,18.27,15.09,14.45,13.88,13.31,10.26,9.17,8.17.
[0284] Synthesis of compound 70a
[0285]
[0286] According to the synthesis method, compound 48 (0.540 g, 0.637 mmol) and methanesulfonyl chloride (0.057 mL, 0.701 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.512 g (0.552 mmol, 86.66%) of compound 94.
[0287] Compound 94 (0.256 g, 0.276 mmol) was reacted with compound Ar-a (0.274 g, 0.828 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 34.8 mg (0.0329 mmol, 11.92%) of compound 70a. Melting point: 160.1-163.5°C. HRMS (ESI) (M+H) + m / z 1057.5875, calculated value C 54 H 82 F6O 14 1057.5868. 1H NMR (CDCl3, 400 MHz) δ: 8.74 (s, 1H, 2″-quinolyl), 7.98 (d, J = 13.1 Hz, 1H, 5″-quinolyl), 7.36 (d, J = 6.8 Hz, 1H, 8″-quinolyl), 5.82 (s, 1H, 11-NH), 5.23 (dd, J = 2.3 Hz, 10.9 Hz, 1H, H-13), 5.04 (s, 1H, 3-O-CO-NH-CH2), 4.92 (d, J = 11.0 Hz, 1H, H-3), 4.0 3 (d, J = 7.2 Hz, 1H, H-1'), 3.94-3.74 (m, 2H, H-5, H-11), 3.61-3.50 (m, 1H, 1H-cyclopropyl), 3.46-3.27 (m, 6H, H-5', 4H-piperazinyl, 3-O-CO-NH-CH2), 3.19 (dd, J = 7.2 Hz, 10.0 Hz, 1H, H-2'), 3.12-3.02 (m, 1H, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3), 2.94-2.81 (m, 2H, H-10, H-2), 2.66 (s, 4H, 4H-piperazinyl), 2.56-2.47 (m, 1H, H-8), 2.48-2.36 (m, 3H, -CH2-piperazinyl, H-3′), 2.29 (s, 6H, -N(CH3)2), 2.12-2.03 (m, 1H, H-4), 1.97-1.86 (m, 1H, H-14eq), 1.84-1.74 (m, 1H, H-7a), 1.69-1.49 (m, 7H, 2(-CH2-), H-7b, H-14eq, H-4′a), 1.43(s, 3H, 12-CH3), 1.40(br, 4H, -CH2-, 2H-cyclopropyl), 1.28(s, 3H, 6-CH3), 1.25-1.18(m, 6H, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.18-1.05(m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.85(t, J=7.3Hz, 3H, 15-CH3). 13CNMR(CDCl3,100MHz)δ:217.67,177.08,174.40,167.01,158.43,156.40,154.93,152.43,147.39,145.95, 145.86,139.11,119.77,119.69,112.47,112.23,108.11,104.76,103.23,83.91,81.63,78.26,77.86,77. 26,75.76,70.48,69.52,66.13,58.29,58.13,52.87,49.83,45.32,43.37,41.09,40.37,39.13,37.28,35.79,35.30,30.09,28.62,26.49,24.65,22.03,21.23,19.31,18.29,15.03,13.88,13.29,10.26,9.06,8.24.
[0288] Synthesis of compound 70b
[0289]
[0290] According to the synthesis method, compound 48 (0.540 g, 0.637 mmol) and methanesulfonyl chloride (0.057 mL, 0.701 mmol) were reacted. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain compound 94 0.512 g (0.552 mmol, 86.66%).
[0291] Compound 94 (0.256 g, 0.276 mmol) was reacted with compound Ar-b (0.264 g, 0.828 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 134.6 mg (0.128 mmol, 46.66%) of compound 70b. Melting point: 159.8-160.7°C. HRMS (ESI) (M+H) + m / z 1045.5874, calculated value C 53 H 82 F6O 14 1045.5868. 1H NMR (CDCl3, 400 MHz) δ: 8.67 (s, 1H, 2″-quinolyl), 8.01 (d, J = 13.0 Hz, 1H, 5″-quinolyl), 6.84 (s, 1H, 8″-quinolyl), 5.83 (s, 1H, 11-NH), 5.23 (dd, J = 2.3 Hz, 11.0 Hz, 1H, H-13), 5.12 (t, J = 5.9 Hz, 1H, 3-O-CO-NH-CH2), 4.92 (d, J = 11.0 Hz, 1H, H-3), 4.34 (br, 2H, N-CH2CH3), 4.04 (d, J = 7.2 Hz, 1H, H-1′), 3.83-3.74 (m, 2H, H-5, H-11), 3.44-3.27 (m, 6H, H-5′, 4H-piperazinyl, 3-O-CO-NH-CH2), 3.19 (dd, J = 7.3 Hz, 10.1 Hz, 1H, H-2′), 3.12-3.03 (m, 1H, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3), 2.9 4-2.81(m,2H,H-10,H-2),2.66(s,4H,4H-piperazinyl),2.57-2.47(m,1H,H-8),2.47-2.35(m,3H,-CH2-piperazinyl,H-3′),2.29(s,6H,-N(CH3)2),2.11-2.03(m,1H,H-4),1.96-1.86(m,1H,H-14eq),1.84-1.74(m,1H,H-7a),1.69-1.49(m,10H,2( -CH2-),H-7b,H-14eq,H-4′a,N-CH2CH3),1.43(s,3H,12-CH3),1.41-1.36(m,2H,-CH2-),1.28(s,3H,6-CH3),1.23 (d,J=6.1Hz,3H,5′-CH3),1.19-1.06(m,13H,H-4′b,2-CH3,10-CH3,4-CH3,8-CH3),0.84(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:217.69,176.96,174.43,167.24,158.45,156.41,147.12,137.15,112 .76,112.53,108.29,103.17,83.92,81.53,78.20,77.86,77.27,75.74,70.49,69.50,66.09 ,58.25,58.12,52.84,49.86,49.82,45.31,43.36,41.07,40.36,39.11,37.27,35.78,30.05,28.63,26.44,24.61,22.02,21.21,19.30,18.28,15.02,14.44,13.87,13.29,10.25,9.06.
[0292] Synthesis of compound 71a
[0293]
[0294] According to the synthesis method, compound 49 (0.332 g, 0.385 mmol) and methanesulfonyl chloride (0.038 mL, 0.462 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.163 g (0.174 mmol, 54.19%) of compound 95.
[0295] Compound 95 (0.163 g, 0.174 mmol) was reacted with compound Ar-a (0.173 g, 0.521 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 63.0 mg (0.0588 mmol, 33.80%) of compound 71a. Melting point: 165.5-166.7°C. HRMS (ESI) (M+H) + m / z 1071.6022, calculated value C 55 H 84 F6O 14 1071.6024. 1H NMR (CDCl3, 400MHz) δ: 8.74 (s, 1H, 2″-quinolyl), 7.98 (d, J=13.0Hz, 1H, 5″-quinolyl), 7.36 (d, J=7.0Hz, 1H, 8″-quinolyl), 5.82 (s, 1H, 11-NH), 5.23 (dd, J=2.3Hz, 10.9Hz, 1H, H-13), 5.03 (s, 1H, 3-O-CO-NH-CH2), 4.92 (d, J=11.1Hz, 1H, H-3), 4.04 ( d, J = 7.3 Hz, 1H, H-1′), 3.84-3.73 (m, 2H, H-5, H-11), 3.61-3.50 (m, 1H, 1H-cyclopropyl), 3.45-3.24 (m, 6H, H-5′, 4H-piperazinyl, 3-O-CO-NH-CH2), 3.19 (dd, J = 7.3 Hz, 10.2 Hz, 1H, H-2′), 3.11-3.01 (m, 1H, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3), 2.94 -2.79(m,2H,H-10,H-2),2.66(s,4H,4H-piperazinyl),2.56-2.46(m,1H,H-8),2.47-2.35(m,3H,-CH2-piperazinyl,H-3′),2.29(s,6H,-N(CH3)2),2.12-2.02(m,1H,H-4),1.97-1.86(m,1H,H-14eq),1.84-1.73(m,1H,H-7a),1.68-1.48(m,7H,2(-CH 2-), H-7b, H-14eq, H-4′a), 1.43 (s, 3H, 12-CH3), 1.42-1.32 (m, 6H, 2(-CH2-), 2H-cyclopropyl), 1.28 (s, 3H, 6-CH3), 1.26-1.18 (m, 6H, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.18-1.06 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.85 (t, J=7.3Hz, 3H, 15-CH3). 13CNMR(CDCl3,100MHz)δ:217.68,177.10,174.43,167.04,158.44,156.41,154.93,152.43,147.39,145.98,1 45.87,139.11,119.75,119.67,112.45,112.22,108.10,104.75,103.18,83.92,81.59,78.20,77.86,77.26, 75.75,70.50,69.48,66.06,58.40,58.13,52.87,49.82,45.32,43.37,41.07,40.35,39.13,37.28,35.79,35.30,30.17,28.64,27.16,26.78,26.70,22.03,21.21,19.30,18.29,15.02,13.87,13.29,10.25,9.05,8.23.
[0296] Synthesis of compound 71j
[0297]
[0298] According to the synthesis method, compound 49 (0.300 g, 0.348 mmol) and p-toluenesulfonyl chloride (0.0995 g, 0.522 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.265 g (0.261 mmol, 75.00%) of compound 96.
[0299] Compound 96 (0.265 g, 0.261 mmol) was reacted with compound Ar-j (0.251 g, 0.782 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 16.5 mg (0.0156 mmol, 5.96%) of compound 71j. HRMS (ESI) (M+H) + m / z 1060.5978, calcd. 53 H 83 F7O 14 1060.5977. 1HNMR (CD3OD, 400MHz)δ:8.79(s,1H,2″-quinolyl),8.03(d,J=13.6Hz,1H,5″-quinolyl),5.18(dd,J=2.4Hz,10.4Hz,1H,H-13),4.88(d,J=11.1Hz,1H,H-3),4.47(q,J=7.2Hz,2H,N-CH2CH3),4.14(d,J=7.2Hz,1H,H-1′) ,3.89(s,4H,4H-piperazinyl),3.85(d,J=3.1Hz,1H,H-5),3.80(s,1H,H-11),3.48-3.38(m,1H,H-5′),3.29-3.17(m,2H,H-2′,3-O-CO-NH-CH2),3.14-3.00(m,2H,H-10,3-O-CO-NH-CH2),2.98(s,3H,6-O-CH3),2.94- 2.87 (m, 1H, H-2), 2.76-2.57 (m, 5H, H-3′, 4H-piperazinyl), 2.52-2.35 (m, 9H, H-8, -CH2-piperazinyl, -N(CH3)2), 2.16-2.08 (m, 1H, H-4), 1.93-1.72 (m, 3H, H-14eq, H-7a, H-4′a), 1.66-1.51 (m, 6H, 2(-CH2-), H-7b, H-14eq), 1 .50-1.43(m,6H,12-CH3,N-CH2CH3),1.42-1.28(m,5H,2(-CH2-),H-4′b),1.26(s,3H,6-CH3),1.20(d, J=6.1Hz,3H,5′-CH3),1.17-1.09(m,12H,2-CH3,10-CH3,4-CH3,8-CH3),0.86(t,J=7.4Hz,3H,15-CH3). 13 C NMR(CD3OD,100MHz)δ:217.96,174.83,159.43,157.39,101.74,84.50,78 .76,77.90,77.44,75.50,70.76,68.72,64.52,58.07,52.71,48.92,45.35 ,43.25,40.41,39.53,38.69,37.42,35.71,30.91,29.51,26.83,26.32,2 6.02,21.82,20.01,18.43,17.17,14.01,13.89,12.92,12.23,9.42,8.07.
[0300] Synthesis of compound 71k
[0301]
[0302] According to the synthesis method, compound 49 (0.300 g, 0.348 mmol) and p-toluenesulfonyl chloride (0.0995 g, 0.522 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.265 g (0.261 mmol, 75.00%) of compound 96.
[0303] Compound 96 (0.150 g, 0.148 mmol) was reacted with compound Ar-k (0.134 g, 0.443 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 24.9 mg (0.0239 mmol, 16.13%) of the general formula compound 71k. HRMS (ESI) (M+H) + m / z 1043.6017, calcd. 52 H 83 F8O 14 1043.6023. 1H NMR (CD3OD, 400 MHz) δ: 9.21 (s, 1H, 5″-quinolyl), 8.78 (s, 1H, 2″-quinolyl), 5.18 (dd, J=2.4 Hz, 10.8 Hz, 1H, H-13), 4.89 (d, J=11.1 Hz, 1H, H-3), 4.38 (q, J=7.4 Hz, 2H, N-CH2CH3), 4.15 (d, J=7.2 Hz, 1H, H-1′), 4.02 (s ,4H,4H-piperazinyl), 3.86 (d, J=3.2 Hz,1H,H-5), 3.80 (s,1H,H-11), 3.50-3.39 (m,1H,H-5′), 3.29-3.21 (m,2H,H-2′,3-O-CO-NH-CH2), 3.14-3.01 (m,2H,H-10,3-O-CO-NH-CH2), 2.99 (s,3H,6-O-CH3), 2.96-2.8 7 (m, 1H, H-2), 2.86-2.74 (m, 1H, H-3′), 2.58 (s, 4H, 4H-piperazinyl), 2.54-2.39 (m, 9H, H-8, -CH2-piperazinyl, -N(CH3)2), 2.16-2.08 (m, 1H, H-4), 1.93-1.76 (m, 3H, H-14eq, H-7a, H-4′a), 1.66-1.51 (m, 6H, 2(-CH2-), H- 7b,H-14eq),1.48(s,3H,12-CH3),1.47(t,J=7.1Hz,3H,N-CH2CH3),1.41-1.17(m,11H,2(-CH2-),H-4 ′b,6-CH3,5′-CH3),1.17-1.09(m,12H,2-CH3,10-CH3,4-CH3,8-CH3),0.86(t,J=7.3Hz,3H,15-CH3). 13 C NMR(CD3OD,100MHz)δ:217.89,174.83,157.40,101.59,84.50,78.75,77.88,77.43,75.52,70.44,68.63,58.07,48.93,45.34,43.55,43 .22,40.40,39.34,38.68,37.43,35.70,29.51,26.81,26.30,26.07, 21.81,19.94,18.41,17.17,13.99,13.49,12.91,12.22,9.41,8.04.
[0304] Synthesis of compound 72a
[0305]
[0306] According to the synthesis method, compound 50 (0.235 g, 0.268 mmol) and p-toluenesulfonyl chloride (0.0492 g, 0.403 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.182 g (0.177 mmol, 65.91%) of compound 97.
[0307] Compound 97 (0.182 g, 0.177 mmol) was reacted with compound Ar-a (0.176 g, 0.531 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 89.7 mg (0.0826 mmol, 46.69%) of compound 72a. HRMS (ESI) (M+H) + m / z 1085.6187, calcd. 56 H 86 F6O 14 1085.6181. 1H NMR (CD3OD, 400 MHz) δ: 8.75 (s, 1H, 2″-quinolyl), 7.80 (d, J = 13.4 Hz, 1H, 5″-quinolyl), 7.46 (s, 1H, 8″-quinolyl), 5.17 (dd, J = 2.5 Hz, 10.7 Hz, 1H, H-13), 4.87 (d, J = 11.0 Hz, 1H, H-3), 4.15 (d, J = 7.2 Hz, 1H, H-1′), 3.84 (d, J = 3.0 Hz, 1H, H-1′). z, 1H, H-5), 3.79 (s, 1H, H-11), 3.72-3.62 (m, 1H, 1H-cyclopropyl), 3.49-3.41 (m, 1H, H-5′), 3.36 (m, 4H, 4H-piperazinyl), 3.29-3.17 (m, 2H, H-2′, 3-O-CO-NH-CH2), 3.12-3.01 (m, 2H, H-10, 3-O-CO-NH-CH2), 2.98 (s, 3H, 6-O-CH3) ,2.94-2.86(m,1H,H-2),2.81-2.65(m,5H,H-3′,4H-piperazinyl),2.53-2.36(m,9H,H-8,-CH2-piperazinyl,-N(CH3)2),2.16-2.07(m,1H,H-4),1.92-1.74(m,3H,H-14eq,H-7a,H-4′a),1.66-1.49(m,6H,2(-CH2-),H-7b,H-14eq ), 1.47 (s, 3H, 12-CH3), 1.43-1.27 (m, 9H, 3 (-CH2-), 2H-cyclopropyl, H-4′b), 1.25 (s, 3H, 6-CH3), 1.19 (d, J = 6.1 Hz, 3H, 5′-CH3), 1.17-1.07 (m, 14H, 2H-cyclopropyl, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.85 (t, J = 7.3 Hz, 3H, 15-CH3). 13 C NMR(CD3OD,100MHz)δ:217.97,174.83,159.39,157.38,101.69,84.49,78.78, 77.90,77.41,75.49,70.75,68.68,64.52,58.19,58.07,52.61,49.16,48.95,4 5.35,43.24,40.48,39.55,38.69,37.41,35.69,30.97,29.53,28.88,27.17,26.45,25.94,21.82,20.03,18.44,17.19,14.03,12.95,12.25,9.45,8.10,7.17.
[0308] Synthesis of compound 73a
[0309]
[0310] According to the synthesis method, compound 51 (0.167 g, 0.188 mmol) and p-toluenesulfonyl chloride (0.0460 g, 0.376 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.120 g (0.115 mmol, 61.12%) of compound 98.
[0311] Compound 98 (0.120 g, 0.115 mmol) was reacted with compound Ar-a (0.114 g, 0.345 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain about 17.9 mg (0.0163 mmol, 14.16%) of compound 73a. HRMS (ESI) (M+H) + m / z 1099.6334, calcd. 57 H 88 F6O 14 1099.6337. 1H NMR (CD3OD, 400 MHz) δ: 8.75 (s, 1H, 2″-quinolyl), 7.84 (s, 1H, 5″-quinolyl), 7.51 (s, 1H, 8″-quinolyl), 5.18 (dd, J=2.4 Hz, 10.8 Hz, 1H, H-13), 4.88 (d, J=11.1 Hz, 1H, H-3), 4.14 (d, J=7.2 Hz, 1H, H-1′), 3.85 (d, J=3.0 Hz, 1H ,H-5),3.80(s,1H,H-11),3.76-3.66(m,1H,1H-cyclopropyl),3.50-3.33(m,5H,H-5v,4H-piperazinyl),3.29-3.17(m,2H,H-2′,3-O-CO-NH-CH2),3.13-3.00(m,2H,H-10,3-O-CO-NH-CH2),2.98(s,3H,6-O-CH3),2.94-2.86 (m, 1H, H-2), 2.78-2.65 (m, 5H, H-3′, 4H-piperazinyl), 2.54-2.36 (m, 9H, H-8, -CH2-piperazinyl, -N(CH3)2), 2.16-2.07 (m, 1H, H-4), 1.91-1.73 (m, 3H, H-14eq, H-7a, H-4′a), 1.66-1.49 (m, 6H, 2(-CH2-), H-7b, H-14eq), 1.4 7 (s, 3H, 12-CH3), 1.43-1.28 (m, 9H, 3 (-CH2-), 2H-cyclopropyl, H-4'b), 1.25 (s, 3H, 6-CH3), 1.20 (d, J = 6.0 Hz, 3H, 5'-CH3), 1.17-1.08 (m, 14H, 2H-cyclopropyl, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.86 (t, J = 7.4 Hz, 3H, 15-CH3). 13 C NMR(CD3OD,100MHz)δ:217.96,174.83,159.41,157.39,101.72,84.49,78.80,77 .90,77.43,75.50,70.73,68.70,64.54,58.26,58.07,52.63,49.16,48.93,45.3 5,43.25,40.51,39.51,38.69,37.42,35.70,30.88,29.55,29.16,28.95,27.15,26.43,26.03,21.82,20.02,18.43,17.17,14.01,12.93,12.24,9.44,8.08,7.16.
[0312]
[0313] Reaction conditions and reagents: a. methanesulfonyl chloride, triethylamine, dichloromethane, room temperature; b. compound 100, acetonitrile, 70°C; c. methanol reflux.
[0314] General Synthesis Method of Compound 74-75 Series
[0315] Compounds 45 and 46 (1 eq) were dissolved in 20 mL of dichloromethane, and triethylamine (2 eq) was added. Methanesulfonyl chloride (1.5 eq) was added dropwise at room temperature, or p-toluenesulfonyl chloride (2 eq) was added and stirred for about 10-20 min. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was washed with water twice and with saturated brine once. The organic phase was spin-dried and purified by column chromatography.
[0316] The intermediate (1 eq) and compound 100 (5 eq) were dispersed in anhydrous acetonitrile and stirred at 80°C for 72 h. After the reaction was completed, the reaction solution was dried by spin drying, 50 mL of dichloromethane was added, and the mixture was washed with water 3 times and once with saturated brine. The organic phase was dried by spin drying, and 20 mL of methanol was added to reflux to remove the protecting group. After the reaction was completed under TLC monitoring, the reaction solution was dried by spin drying and purified by column chromatography.
[0317] Synthesis of compound 74a
[0318]
[0319] According to the synthesis method, compound 45 (0.408 g, 0.547 mmol) and methanesulfonyl chloride (0.049 mL, 0.602 mmol) were used for the reaction. After the reaction was completed, the mixture was purified by column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) to obtain about 0.200 g (0.226 mmol, 41.32%) of compound 99.
[0320] Compound 99 (0.200 g, 0.226 mmol) was reacted with compound 100 (0.102 g, 0.271 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 15.3 mg (0.0144 mmol, 6.40%) of the general formula compound 74a. Melting point: 163.4-164.9°C. HRMS (ESI) (M+H) + m / z 1058.5786, calcd. 53 H 81 F7O 14 1058.5802. 1H NMR (CDCl3, 400MHz) δ: 8.76 (s, 1H, 2″-quinolyl), 8.00 (d, J=13.0Hz, 1H, 5″-quinolyl), 7.35 (s, 1H, 8″-quinolyl), 5.80 (s, 1H, 11-NH), 5.49 (s, 1H, 3-O-CO-NH-CH2), 5.23 (dd, J=2.3Hz, 10.9Hz, 1H, H-13), 4.92 (d, J=11.0Hz, 1H, H-3), 4 .05 (d, J = 7.2 Hz, 1H, H-1′), 3.83-3.74 (m, 2H, H-5, H-11), 3.60-3.40 (m, 2H, 1H-cyclopropyl, 3-O-CO-NH-CH2-), 3.40-3.28 (m, 5H, H-5′, 4H-piperazinyl), 3.24-3.13 (m, 2H, 3-O-CO-NH-CH2, H-2′), 2.98 (s, 3H, 6-O-CH3), 2.93-2.79 (m, 6 H,H-10,H-2,-CH2-N-CH2-CH2-piperazinyl), 2.69 (s, 4H,4H-piperazinyl), 3.64-2.57 (m, 2H,-N-CH2-CH2-piperazinyl), 2.56-2.44 (m, 2H,H-8,H-3′), 2.30 (s, 6H,-N(CH3)2), 2.12-2.03 (m, 1H,H-4), 1.98-1.88 (m, 1H,H-14eq), 1.83-1.74 (m, 1 H, H-7a), 1.68-1.50 (m, 3H, H-7b, H-14eq, H-4′a), 1.46-1.35 (m, 5H, 12-CH3, 2H-cyclopropyl), 1.31-1.17 (m, 9H, 6-CH3, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.17-1.07 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.84 (t, J=7.3Hz, 3H, 15-CH3). 13 C NMR(CDCl3,100MHz)δ:217.67,177.02,158.44,147.47,139.05,103.06,83.89,78.36,77.87,77.25,75.80,70.53,58.14,52.8 8,49.81,45.31,43.41,40.38,39.12,37.29,35.83,35.23,22.03,21.21,19.31,18.28,15.12,13.88,13.30,10.26,9.08,8.25.
[0321] Synthesis of compound 75a
[0322]
[0323] According to the synthesis method, compound 46 (0.282 g, 0.371 mmol) and methanesulfonyl chloride (0.033 mL, 0.408 mmol) were used for reaction. After the reaction was completed, column chromatography purification (100-200 mesh silica gel, mobile phase: dichloromethane / ethanol / ammonia water = 10 / 0.1 / 0.05) was performed to obtain about 0.241 g (0.268 mmol, 72.24%) of compound 92.
[0324] Compound 92 (0.241 g, 0.268 mmol) was reacted with compound 100 (0.0979 g, 0.282 mmol), and column chromatography (100-200 mesh silica gel, mobile phase: dichloromethane / methanol / ammonia water = 10 / 1 / 0.5) was performed to obtain 12.5 mg (0.0116 mmol, 4.35%) of the general formula compound 75a. Melting point: 163.6-164.2°C. HRMS (ESI) (M+H) + m / z 1072.5975, calculated value C 54 H 83 F7O 14 1072.5977. 1H NMR (CDCl3, 400 MHz) δ: 8.77 (s, 1H, 2″-quinolyl), 8.01 (d, J = 13.0 Hz, 1H, 5″-quinolyl), 7.35 (d, J = 7.0 Hz, 1H, 8″-quinolyl), 5.81 (s, 1H, 11-NH), 5.72 (s, 1H, 3-O-CO-NH-CH2), 5.22 (dd, J = 2.3 Hz, 10.8 Hz, 1H, H-13), 4.90 (d, J = 11.0 Hz, 1H, H-3 ), 4.05(d, J=7.2Hz,1H,H-1′),3.83-3.72(m,2H,H-5,H-11),3.58-3.49(m,1H,1H-cyclopropyl),3.49-3.26(m,6H,H-5′,4H-piperazinyl,3-O-CO-NH-CH2-),3.23-3.12(m,2H,H-2′,3-O-CO-NH-CH2),2.97(s,3H,6-O-CH3),2.93-2.83(m,2H, H-10, H-2), 2.82-2.73 (m, 4H, -CH2-N-CH2-CH2-piperazinyl), 2.72-2.57 (m, 6H, 4H-piperazinyl, -N-CH2-CH2-piperazinyl), 2.55-2.41 (m, 2H, H-8, H-3′), 2.30 (s, 6H, -N(CH3)2), 2.11-2.02 (m, 1H, H-4), 1.97-1.88 (m, 1H, H-14eq), 1.83-1.70 (m, 3H, H-7a, -CH2-), 1.68-1.51 (m, 3H, H-7b, H-14eq, H-4′a), 1.45-1.35 (m, 5H, 12-CH3, 2H-cyclopropyl), 1.31-1.17 (m, 9H, 6-CH3, H-4′b, 5′-CH3, 2H-cyclopropyl), 1.18-1.07 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.84 (t, J = 7.2 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.79,177.23,174.56,167.29,158.57,147.59,145.94,139. 21,120.01,112.67,112.53,108.47,104.82,103.25,84.01,81.65,78.30,77.98,75. 91,70.63,58.24,52.99,49.92,49.88,45.41,43.50,40.48,39.24,37.40,35.93,35.37,29.82,22.14,21.32,19.42,18.40,18.35,15.20,14.00,13.41,10.38,9.17,8.37.
[0325]
[0326] General Synthesis Method of Compound 76-86 Series
[0327] Compound 52-62 (1 eq) and compound (1.5 eq) were dissolved in acetonitrile, and triethylamine (2 eq) was added to the system. The reaction was carried out at 70°C for 2-4 hours. After the reaction was completed, the reaction solution was dried and purified by column chromatography. The product was then dissolved in 2 mL of ethanol and 2 mL of 2NNaOH aqueous solution was added. After the reaction was completed, dichloromethane was added for extraction. The organic phase was dried and methanol was added to reflux for 12-14 hours. After the reaction was completed, column chromatography was performed to purify to obtain compound 76-86 series.
[0328] Synthesis of compound 76o
[0329]
[0330] According to the general synthesis method, compound 52 (0.216 g, 0.248 mmol) was reacted with compound Ar-o (0.153 g, 0.372 mmol) to obtain about 179.3 mg (0.167 mmol, 67.24%) of compound 76o. Melting point: 155.7-156.4°C. HRMS (ESI) (M+H) + m / z 1075.5617, calcd. 53 H 80 F6O 16 1075.5609. 1H NMR (CD3OD, 400 MHz) δ: 8.70 (s, 1H, 2″-quinolyl), 7.97 (d, J = 13.7 Hz, 1H, 5″-quinolyl), 5.13 (dd, J = 2.4 Hz, 11.2 Hz, 1H, H-13), 4.89-4.81 (m, 2H, H-3, H-11), 4.26-4.16 (m, 2H, N-(CH2-CH2)2), 4.14 (d, J = 7.3 Hz, 1H, H-1′), 3.88-3.80 (m 4H, H-5, 9-O-CH3), 3.79-3.65 (m, 5H, 1H-cyclopropyl, -N-(CH2-CH2)2-CH, H-8), 3.62 (d, J = 6.0 Hz, 2H, O-CH2) 3.51-3.36 (m, 2H, 3-O-CO-NH-CH2, H-5′), 3.28 (dd, J = 7.3 Hz, 10.2 Hz ,1H,H-2′),3.21-3.12(m,1H,3-O-CO-NH-CH2),3.05(s,3H,6-O-CH3),2.97-2.86(m ,1H,H-2),2.82-2.70(m,1H,H-3′),2.66(q,J=6.8Hz,1H,H-10),2.43(s,6H,-N(CH3) 2),2.16-1.99(m,1H,H-4,CH2),1.91-1.62(m,1H,H-14eq,-N-(CH2-CH2)2,H-4′a,H -14eq),1.56(s,3H,12-CH3),1.52-1.36(m,3H,H-7b,H-7b,H-4′b),1.32(s,3H,6-CH 3), 1.31-1.25 (m, 2H, 2H-cyclopropyl), 1.25-1.18 (m, 6H, 5′-CH3, 2-CH3), 1.18-1.06 (m, 8H, 2-CH3, 4-CH3, 2H-cyclopropyl), 0.98 (d, J = 7.1 Hz, 3H, 8-CH3), 0.89 (t, J = 7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:177.08,174.01,166.87,165.97,164.53,156.34,154.67,150.22,150.17,148.17,146.93,146.69,14 6.47,134.24,129.49,119.99,119.87,113.22,108.87,103.34,85.00,83.20,81.25,78.34,78.22,75.54,74.05,70.45,69. 52,66.36,66.16,61.43,49.82,44.41,44.36,43.37,40.39,39.31,38.91,37.33,35.98,34.65,32.72,31.11,31.08,30.57,30.19,28.99,28.56,25.60,23.99,22.97,22.23,21.21,19.33,18.86,15.61,14.94,14.05,13.01,11.10,10.20,8.86,7.46.
[0331] Synthesis of compound 77l
[0332]
[0333] According to the general synthesis method, compound 53 (0.231 g, 0.256 mmol) was reacted with compound Ar-1 (0.210 g, 0.512 mmol) to obtain about 139.3 mg (0.134 mmol, 52.21%) of compound 771. Melting point: 186.7-187.0°C. HRMS (ESI) (M+H) + m / z 1042.5772, calcd. 54 H 81 F5O 14 1042.5759. 1H NMR (CD3OD, 400 MHz) δ: 8.72 (s, 1H, 2″-quinolyl), 7.79 (s, 1H, 5″-quinolyl), 7.48 (s, 1H, 8″-quinolyl), 5.18 (dd, J=2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J=11.1 Hz, 1H, H-3), 4.15 (d, J=7.2 Hz, 1H, H-1′), 3.85 (d, J=3.0 Hz, 1H, H- 5), 3.80 (s, 1H, H-11), 3.77-3.59 (m, 3H, -N-(CH2-CH2)2, 1H-cyclopropyl), 3.50-3.39 (m, 1H, H-5′), 3.29-3.21 (m, 2H, H-2′, 3-O-CO-NH-CH2), 3.14-3.01 (m, 2H, H-10, 3-O-CO-NH-CH2), 2.99 (s, 3H, 6-O-CH3), 2.95-2. 70(m,4H,H-2,H-3′,-N-(CH2-CH2)2),2.54-2.47(m,1H,H-8),2.43(s,6H,-N(CH3)2),2.17-2.06(m,1H ,H-4),1.92-1.75(m,5H,-CH-(CH2-CH2)2,H-14eq,H-7a),1.60-1.45(m,8H,H-7b,H-4′a,H-14eq,-CH-( CH2-CH2)2,12-CH3), 1.44-1.28 (m,9H,3(-CH2-),2H-cyclopropyl,H-4′b), 1.25 (m,3H,6-CH3), 1.20 (d, J=6.1Hz,3H,5′-CH3), 1.18-1.06 (m,14H,2-CH3,10-CH3,4-CH3,8-CH3,2H-cyclopropyl), 0.86 (t, J=7.4Hz,3H,15-CH3). 13 C NMR(CDCl3,100MHz)δ:217.69,177.09,167.17,158.45,147.28,146.42,139.1 9,108.04,104.73,83.93,77.87,77.25,75.78,70.54,58.14,50.53,49.85,45. 33,43.36,41.05,40.38,39.15,37.28,36.08,35.80,35.49,35.28,32.09,30.53,23.84,22.05,21.22,19.30,18.30,15.01,13.88,13.29,10.26,9.07,8.22.
[0334] Synthesis of compound 77o
[0335]
[0336] According to the general synthesis method, compound 53 (0.155 g, 0.172 mmol) and compound Ar-o (0.212 g, 0.516 mmol) were used to obtain about 53.1 mg (0.0509 mmol, 29.59%) of compound 77o. Melting point: 152.0-152.4°C. HRMS (ESI) (M+H) + m / z 1043.5710, calcd. 53 H 80 F6O 14 1043.5711. 1H NMR (CD3OD, 400 MHz) δ: 8.64 (s, 1H, 2″-quinolyl), 7.90 (s, 1H, 5″-quinolyl), 5.18 (dd, J=2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J=11.1 Hz, 1H, H-3), 4.68 (d, J=13.2 Hz, 2H, -N-(CH2-CH2)2), 4.13 (d, J=7.3 Hz, 1H, H-1′), 3.85 (d, J=3.1 Hz, 1H, H- 5), 3.79 (s, 1H, H-11), 3.73-3.63 (m, 1H, 1H-cyclopropyl), 3.47-3.35 (m, 1H, H-5′), 3.29-3.21 (m, 2H, H-2′, 3-O-CO-NH-CH2), 3.15 (td, J=2.7 Hz, 13.2 Hz, 2H, -N-(CH2-CH2)2), 3.11-3.01 (m, 2H, H-10, 3-O-CO-NH-CH2), 2.99 (s, 3H, 6-O-CH 3),2.95-2.70(m,4H,H-2),2.94-2.86(m,1H,H-3′,),2.52-2.45(m,1H,H-8),2.40(s,6H,-N(CH3)2),2.16-2.08( m,1H,H-4),1.93-1.80(m,4H,H-14eq,H-7a,CH2),1.80-1.71(m,1H,H-4′a),1.71-1.50(m,5H,H-7b,H-14eq,-CH- (CH2-CH2)2, CH2), 1.47 (s, 3H, 12-CH3), 1.45-1.27 (m, 9H, 3 (-CH2-), 2H-cyclopropyl, H-4'b), 1.25 (m, 3H, 6-CH3), 1.20 (d, J = 6.1 Hz, 3H, 5'-CH3), 1.17-1.06 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J = 7.4 Hz, 3H, 15-CH3). 13CNMR(CDCl3,100MHz)δ:217.66,177.04,174.40,167.00,158.45,156.43,150.24,150.16,148.71,147 .02,146.33,146.12,119.81,119.59,112.85,108.75,103.21,83.91,81.69,78.29,77.87,70.52,69.5 0,66.07,58.15,49.82,47.71,47.62,45.31,43.38,41.05,40.35,39.15,37.30,36.11,36.06,35.78,34.63,32.40,30.48,28.67,23.81,22.04,21.21,19.30,18.28,14.99,13.88,13.30,10.25,9.06,7.44.
[0337] Synthesis of compound 78l
[0338]
[0339] According to the general synthesis method, compound 54 (0.200 g, 0.221 mmol) and compound Ar-1 (0.272 g, 0.664 mmol) were used to obtain about 73.3 mg (0.0702 mmol, 31.76%) of compound 781. Melting point: 181.1-181.6°C. HRMS (ESI) (M+H) + m / z 1044.55559, calculated value C 53 H 79 F5O 15 1044.55512. 1H NMR (CD3OD, 400 MHz) δ: 8.72 (s, 1H, 2″-quinolyl), 7.79 (d, J = 13.2 Hz, 1H, 5″-quinolyl), 7.50 (s, 1H, 8″-quinolyl), 5.17 (dd, J = 2.5 Hz, 10.8 Hz, 1H, H-13), 4.88 (d, J = 11.5 Hz, 1H, H-3), 4.15 (d, J = 7.2 Hz, 1H, H-1′), 3.85 (d, J = 3.0 Hz, 1H, H-5), 3.79 (s, 1H ,H-11), 3.75-3.65 (m,1H,1H-cyclopropyl), 3.64-3.50 (m,5H,-N-(CH2-CH2)2-CH-O-CH2), 3.49-3.41 (m,1H,H-5′), 3.41-3.33 (m,1H,3-O-CO-NH-CH2), 3.27 (dd, J=7.4Hz,10.1Hz,1H,H-2′), 3.22-3.11 (m,3H,3-O-CO-NH-CH2,-N-(CH2-CH2)2 ),3.08(q,J=6.7Hz,H-10),2.98(s,3H,6-O-CH3),2.94-2.84(m,1H,H-2),2.81-2.71(m,1H,H-3′),2.53-2.45(m,1H ,H-8),2.42(s,6H,-N(CH3)2),2.16-2.00(m,3H,H-4,CH2),1.92-1.70(m,7H,-N-(CH2-CH2)2,H-14eq,H-7a,H-4′a) ,1.66-1.54(m,2H,H-7b,H-14eq),1.47(s,3H,12-CH3),1.42-1.27(m,3H,2H-cyclopropyl,H-4′b),1.25(m,3H,6-CH3),1.20(d,J=6.1Hz,3H,5′-CH3),1.17-1.07(m,14H,2-CH3,10-CH3,4-CH3,8-CH3,2H-cyclopropyl),0.85(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,176MHz)δ:220.00,178.75,163.36,161.27,105.62,88.42,82.65,8 1.82,81.39,79.44,79.42,77.72,74.61,72.64,69.01,68.44,61.98,52.89,49. 28,47.14,43.44,42.58,41.94,41.35,39.63,34.88,34.73,34.65,33.93,25.74,23.99,22.39,22.37,21.11,18.02,16.88,16.18,16.16,13.39,12.03,11.11.
[0340] Synthesis of Compound 78m
[0341]
[0342] According to the general synthesis method, compound 54 (0.150 g, 0.166 mmol) was reacted with compound Ar-m (0.097 g, 0.249 mmol) to obtain about 34.9 mg (0.0338 mmol, 20.37%) of compound 78m. Melting point: 172.8-173.0°C. HRMS (ESI) (M+H) + m / z 1032.5559, calculated value C 52 H 79 F5O 15 1032.5551. 11H NMR (CD3OD, 400 MHz) δ: 8.82 (s, 1H, 2v - quinolinyl), 7.93 (d, J = 13.3 Hz, 1H, 5″ - quinolinyl), 7.13 (s, 1H, 8″ - quinolinyl), 5.20 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H - 13), 4.91 (d, J = 11.5 Hz, 1H, H - 3), 4.50 (s, 2H, NCH2CH3), 4.16 (d, J = 7.3 Hz, 1H, H - 1′), 3.87 (d, J = 3.1 Hz, 1H, H - 5), 3.81 (s, 1H, H - 11), 3.85 - 3.76 (m, 3H, -N-(CH2 - CH2)2 - CH), 3.69 - 3.52 (m, 5H, O - CH2, N-(CH2 - CH2)2CH), 3.49 - 3.36 (m, 5H, H - 5′, 3 - O - CO - NH - CH2), N-(CH2 - CH2)2), 3.27 (dd, J = 7.3 Hz, 10.2 Hz, 1H, H - 2′), 3.25 - 3.04 (m, 4H, 3 - O - CO - NH - CH2, H - 10, N-(CH2 - CH2)2), 3.00 (s, 3H, 6 - O - CH3), 2.96 - 2.87 (m, 1H, H - 2), 2.79 - 2.69 (m, 1H, H - 3′), 2.56 - 2.47 (m, 1H, H - 8), 2.43 (s, 6H, -N(CH3)2), 2.19 - 2.00 (m, 3H, H - 4, CH2), 1.94 - 1.63 (m, 7H, -N-(CH2 - CH2)2, H - 14eq, H - 7a, H - 4′a), 1.69 - 1.58 (m, 2H, H - 7b, H - 14eq), 1.58 - 1.51 (m, 3H, NCH2CH3), 1.49 (s, 3H, 12 - CH3), 1.39 - 1.30 (m, 1H, H - 4′b), 1.28 (s, 3H, 6 - CH3), 1.22 (d, J = 6.1 Hz, 3H, 5′ - CH3), 1.19 - 1.09 (m, 12H, 2 - CH3, 10 - CH3, 4 - CH3, 8 - CH3), 0.87 (t, J = 7.4 Hz, 3H, 15 - CH3). 13C NMR(CDCl3,176MHz)δ:217.66,176.96,174.40,167.27,158.44,154.23,152.80,147.05,146. 36,146.30,137.18,108.32,103.90,103.17,83.89,77.86,75.78,73.74,70.46,69.51,66.27, 66.10,58.12,49.83,49.73,47.38,45.31,43.37,40.36,39.12,37.28,35.80,30.89,30.15,29.70,22.03,21.21,19.31,18.29,15.06,14.53,14.47,13.88,13.84,13.29,10.26,9.24,9.06.
[0343] Synthesis of compound 78n
[0344]
[0345] According to the general synthesis method, compound 54 (0.150 g, 0.166 mmol) was reacted with compound Ar-n (0.126 g, 0.332 mmol) to obtain about 28.2 mg (0.0275 mmol, 16.55%) of compound 78n. Melting point: 164.5-165.0°C. HRMS (ESI) (M+H) + m / z 1026.5648, calcd. 53 H 80 N5O 15 1026.5645. 1H NMR (CD3OD, 400 MHz) δ: 8.73 (s, 1H, 2″-quinolyl), 8.17 (d, J = 9.16 Hz, 1H, 5″-quinolyl), 7.37 (s, 1H, 8″-quinolyl), 7.30 (d, J = 9.3 Hz, 1H, 6″-quinolyl), 5.19 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.88 (d, J = 11.5 Hz, 1H, H-3), 4.14 (d, J = 7.2 Hz, 1H, H-1′), 3.87 (d, J = 4.7 Hz, 1H, H-2′). =3.2Hz,1H,H-5),3.85-3.76(m,3H,H-11,1H-cyclopropyl,-N-(CH2-CH2)2-CH),3.74-3.56(m,4H,O-CH2,N-(CH2-CH2)2),3.4 8-3.36(m,4H,H-5′,3-O-CO-NH-CH2,N-(CH2-CH2)2),3.27(dd,J=7.2Hz,10.1Hz,1H,H-2′),3.21-3.04(m,2H,3-O-CO- NH-CH2,H-10),3.00(s,3H,6-O-CH3),2.93-2.82(m,2H,H-2),2.76-2.63(m,1H,H-3′),2.56-2.45(m,1H,H-8),2.41( s,6H,-N(CH3)2),2.18-2.09(m,1H,H-4),2.09-2.00(m,2H,CH2),1.95-1.69(m,7H,-N-(CH2-CH2)2,H-14eq,H-7a,H-4 'a), 1.68-1.56 (m, 2H, H-7b, H-14eq), 1.49 (s, 3H, 12-CH3), 1.45-1.29 (m, 3H, 2H-cyclopropyl, H-4'b), 1.27 (s, 3H, 6-CH3), 1.21 (d, J = 6.1 Hz, 3H, 5'-CH3), 1.19-1.09 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J = 7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.66,177.28,174.37,167.52,158.44,156.33,154.31,147.50,143.35,127.92 ,116.65,114.67,107.92,103.10,98.42,83.89,81.56,78.17,77.84,75.78,73.91,70.44,69.45,66.33, 66.12,58.12,49.82,45.30,44.82,44.79,43.35,40.33,39.35,39.10,37.28,35.77,34.87,30.41,30.23,30.12,29.70,28.68,22.02,21.20,19.30,18.28,18.25,15.06,13.88,13.27,10.26,10.24,9.04,8.15.
[0346] Synthesis of compound 78o
[0347]
[0348] According to the general synthesis method, compound 54 (0.200 g, 0.221 mmol) was reacted with compound Ar-o (0.454 g, 1.105 mmol) to obtain about 105.6 mg (0.101 mmol, 45.71%) of compound 78o. Melting point: 140.5-141.2°C. HRMS (ESI) (M+H) + m / z 1045.55057, calculated value C 52 H 78 F6O 15 1045.55037. 1H NMR (CD3OD, 400MHz) δ: 8.67 (s, 1H, 2″-quinolyl), 7.90 (d, J=13.9Hz, 1H, 5″-quinolyl), 5.17 (dd, J=2.5Hz, 10.7Hz, 1H, H-13), 4.87 (d, J=11.5Hz, 1H, H-3), 4.23-4.09 (m, 3H, H-1′, -N-(CH2-CH2)2), 3.84 (d, J=3.0Hz, 1H, H-5), 3. 79 (s, 1H, H-11), 3.37-3.61 (m, 4H, 1H-cyclopropyl, -N-(CH2-CH2)2-CH), 6.01 (t, J = 3.6 Hz, 1H, O-CH2), 3.51-3.41 (m, 1H, H-5′), 3.40-3.32 (m, 1H, 3-O-CO-NH-CH2), 3.30-3.24 (m, 1H, H-2′), 3.20-3.04 (m, 2H, 3-O-CO-NH-CH2, H -10),2.98(s,3H,6-O-CH3),2.92-2.78(m,2H,H-2,H-3′),2.54-2.40(m,7H,H-8,-N(CH3)2),2.16-2.06(m, 1H,H-4),2.05-1.94(m,2H,CH2),1.90-1.74(m,5H,-N-(CH2-CH2)2,H-14eq,H-7a,H-4′a),1.74-1.54(m,4H, H-7b, H-14eq, -N-(CH2-CH2)2), 1.46 (s, 3H, 12-CH3), 1.35-1.22 (m, 6H, 2H-cyclopropyl, H-4′b, 6-CH3), 1.19 (d, J=6.0 Hz, 3H, 5′-CH3), 1.16-0.98 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.85 (t, J=7.3 Hz, 3H, 15-CH3). 13CNMR(CDCl3,176MHz)δ:220.00,180.44,178.73,163.32,161.25,105.53,88.41,82.63, 81.81,81.33,79.42,79.40,77.94,74.54,72.57,69.10,68.48,61.98,52.92,51.93,49 .29,48.23,48.18,47.12,43.59,43.45,42.57,41.91,41.34,39.61,34.92,34.84,33.97,25.75,23.98,22.40,22.39,21.14,18.04,16.92,16.21,16.19,13.43,12.04,10.45.
[0349] Synthesis of compound 79l
[0350]
[0351] According to the general synthesis method, compound 55 (0.150 g, 0.164 mmol) was reacted with compound Ar-1 (0.100 g, 0.246 mmol) to obtain 100.7 mg (0.0952 mmol, 43.06%) of compound 791. Melting point: 173.5-174.8°C. HRMS (ESI) (M+H) + m / z 1058.5710, calcd. 54 H 81 F5O 15 1058.5708. 1H NMR (CD3OD, 400 MHz) δ: 8.78 (s, 1H, 2″-quinolyl), 7.85 (d, J = 13.2 Hz, 1H, 5″-quinolyl), 7.52 (s, 1H, 8″-quinolyl), 5.18 (dd, J = 2.5 Hz, 10.7 Hz, 1H, H-13), 4.86 (d, J = 11.5 Hz, 1H, H-3), 4.16 (d, J = 7.2 Hz, 1H, H-1′), 3.87 (d, J = 3.0 Hz, 1H, H-5), 3.80 (s, 1H, H-11) ,3.77-3.67 (m, 3H, 1H-cyclopropyl, -N-(CH2-CH2)2-), 3.55 (t, J = 6.0 Hz, 2H, O-CH2), 3.51-3.43 (m, 1H, H-5′), 3.44-3.35 (m, 1H, 3-O-CO-NH-CH2, O-CH2), 3.29 (dd, J = 7.3 Hz, 10.3 Hz, 1H, H-2′), 3.22-3.03 (m, 1H, 3-O-CO-NH-CH2), 3.09 (q, J = 6.5 Hz, 1H ,H-10),2.99(s,3H,6-O-CH3),2.97-2.86(m,3H,H-2,N-(CH2-CH2)2),2.83-2.69(m,1H,H-3′),2.56-2.38(m,7H,H-8,- N(CH3)2),2.18-2.07(m,1H,H-4),1.98-1.74(m,7H,-N-(CH2-CH2)2-CH-CH2-O-CH2CH2,H-14eq,H-4′a),1.69-1.50(m, 4H, H-7a, H-14eq, -N-(CH2-CH2)2), 1.45 (s, 3H, 12-CH3), 1.43-1.29 (m, 4H, 2H-cyclopropyl, H-4′b, H-7b), 1.27 (s, 3H, 6-CH3), 1.22 (d, J=6.1 Hz, 3H, 5′-CH3), 1.19-1.06 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.65,177.08,174.38,173.69,167.08,158.43,147.32, 146.37,139.16,104.85,104.82,103.12,83.89,81.42,77.86,75.79,70.46,69.5 5,58.12,50.20,49.83,45.31,43.40,40.37,39.14,37.28,36.14,35.79,35.28,29.12,29.05,22.04,21.21,19.30,18.29,15.06,13.88,13.26,10.26,8.97,8.23.
[0352] Synthesis of compound 79o
[0353]
[0354] According to the general synthesis method, compound 55 (0.150 g, 0.164 mmol) was reacted with compound Ar-o (0.101 g, 0.246 mmol) to obtain about 132.3 mg (0.125 mmol, 76.16%) of compound 79o. Melting point: 174.8-175.3°C. HRMS (ESI) (M+H) + m / z 1059.5653, calcd. 53 H 80 F6O 15 1059.5660. 1H NMR (CD3OD, 400 MHz) δ: 8.74 (s, 1H, 2v-quinolyl), 7.98 (d, J = 13.8 Hz, 1H, 5″-quinolyl), 5.19 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.89 (d, J = 11.5 Hz, 1H, H-3), 4.70 (d, J = 13.1 Hz, 2H, -N-(CH2-CH2)2-), 4.15 (d, J = 7.2 Hz, 1H, H-1′), 3.86 (d, J = 3.0 Hz, 1 H,H-5),3.81(s,1H,H-11),3.73-3.63(m,1H,1H-cyclopropyl),3.52(td,J=2.0Hz,5.9Hz,2H,O-CH2),3.48-3.40(m,2H,H-5′, 3-O-CO-NH-CH2),3.39-3.34(m,1H,O-CH2),3.28(dd,J=7.3Hz,10.3Hz,1H,H-2′),3.24-3.06(m,4H,3-O-CO-NH-CH2, N-(CH2-CH2)2,H-10),3.00(s,3H,6-O-CH3),2.94-2.86(m,3H,H-2),2.81-2.69(m,1H,H-3′),2.56-2.38(m,7H,H-8, -N(CH3)2),2.17-2.08(m,1H,H-4),2.06-1.74(m,8H,-N-(CH2-CH2)2-CH-CH2-O-CH2CH2,H-14eq,H-4′a,H-7a),1.69 -1.54 (m, 4H, H-14eq, H-7b), 1.53-1.38 (m, 5H, 12-CH3, N-(CH2-CH2)2), 1.36-1.24 (m, 6H, 2H-cyclopropyl, H-4′b, 6-CH3), 1.19 (d, J=6.2 Hz, 3H, 5′-CH3), 1.17-1.04 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.87 (t, J=7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,100MHz)δ:217.67,177.06,176.59,174.39,166.92,158.43,150. 30,146.99,146.36,108.80,83.90,81.48,77.85,75.58,70.49,69.54,58.11 ,49.83,47.26,45.31,43.37,40.36,39.13,37.26,36.66,35.81,34.64,29.33,29.26,22.02,21.19,19.29,18.29,15.05,13.87,13.26,10.26,8.99,7.44.
[0355] Synthesis of compound 801
[0356]
[0357] According to the general synthesis method, compound 56 (0.167 g, 0.179 mmol) was reacted with compound Ar-1 (0.110 g, 0.268 mmol) to obtain about 77.7 mg (0.0725 mmol, 40.48%) of compound 801. Melting point: 168.2-168.8°C. HRMS (ESI) (M+H) + m / z 1072.5868, calcd. 55 H 83 F5O 15 1072.5864. 1H NMR (CD3OD, 400 MHz) δ: 8.77 (s, 1H, 2″-quinolyl), 7.85 (d, J = 11.8 Hz, 1H, 5″-quinolyl), 7.52 (s, 1H, 8″-quinolyl), 5.19 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.89 (d, J = 11.5 Hz, 1H, H-3), 4.17 (d, J = 7.2 Hz, 1H, H-1′), 3.87 (d, J = 3.1 Hz, 1H, H-5), 3.80 (s, 1 H, H-11), 3.79-3.63 (m, 3H, 1H-cyclopropyl, -N-(CH2-CH2)2-), 3.61-3.48 (m, 4H, CH2-O-CH2), 3.48-3.43 (m, 1H, H-5′), 3.41-3.35 (m, 1H, 3-O-CO-NH-CH2), 3.29 (dd, J=7.3Hz, 10.3Hz, 1H, H-2′), 3.20-3.05 (m, 2H, 3-O-CO-NH-CH2, H-10), 2.99 (s,3H,6-O-CH3),2.97-2.86(m,3H,H-2,N-(CH2-CH2)2),2.84-2.69(m,1H,H-3′),2.55-2.40(m,7H,H-8,-N(CH3)2 ),2.18-2.09(m,1H,H-4),1.99-1.69(m,9H,-N-(CH2-CH2)2-CH,H-14eq,2(CH2),H-4′a),1.68-1.56(m,5H,H-7a,H- 7b, H-14eq, -N-(CH2-CH2)2), 1.48 (s, 3H, 12-CH3), 1.46-1.29 (m, 5H, 2H-cyclopropyl, H-4′b, CH2), 1.27 (s, 3H, 6-CH3), 1.23 (d, J = 6.1 Hz, 3H, 5′-CH3), 1.19-1.10 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J = 7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.77,217.69,177.07,174.43,167.13,158.44,154.43,153.00,147.27,146.47,146.41,139 .18,119.32,112.31,112.17,108.02,104.75,103.18,83.90,77.85,75.74,70.47,69.53,69.15,68.65,58.11,58.07, 53.45,50.47,50.44,49.84,45.31,43.35,40.37,39.12,37.27,36.17,35.82,35.28,32.68,32.12,32.08,29.92,22.02,21.96,21.21,19.30,19.28,18.29,18.23,15.06,13.88,13.86,13.27,13.23,10.25,10.22,9.07,8.24,8.23,8.10.
[0358] Synthesis of compound 80o
[0359]
[0360] According to the general synthesis method, compound 56 (0.167 g, 0.179 mmol) was reacted with compound Ar-o (0.110 g, 0.268 mmol) to obtain about 133.8 mg (0.125 mmol, 69.64%) of compound 80o. Melting point: 141.2-142.4°C. HRMS (ESI) (M+H) + m / z 1073.5824, calculated value C 54 H 82 F6O 15 1073.5817. 1H NMR (CD3OD, 400 MHz) δ: 8.71 (s, 1H, 2″-quinolyl), 7.97 (d, J = 13.8 Hz, 1H, 5″-quinolyl), 5.20 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.90 (d, J = 11.5 Hz, 1H, H-3), 4.71 (d, J = 13.2 Hz, 2H, -N-(CH2-CH2)2-), 4.16 (d, J = 7.2 Hz, 1H, H-1′), 3.88 (d, J = 3.2 Hz ,1H,H-5),3.81(s,1H,H-11),3.75-3.66(m,1H,1H-cyclopropyl),3.57-3.48(m,4H,CH2OCH2),3.48-3.36(m,2H,H-5′,3-O- CO-NH-CH2),3.29(dd,J=7.3Hz,10.2Hz,1H,H-2′),3.24-3.06(m,4H,3-O-CO-NH-CH2,N-(CH2-CH2)2,H-10),3.00(s ,3H,6-O-CH3),2.97-2.87(m,3H,H-2),2.80-2.68(m,1H,H-3′),2.56-2.47(m,1H,H-8),2.44(s,6H,-N(CH3)2),2. 18-2.09(m,1H,H-4),1.97-1.74(m,8H,-N-(CH2-CH2)2-CH-CH2O-CH2CH2,H-14eq,H-4′a,H-7a),1.69-1.54(m,4H,C H2, H-14eq, H-7b), 1.49 (s, 3H, 12-CH3), 1.45-1.29 (m, 5H, N-(CH2-CH2)2, 2H-cyclopropyl, H-4′b), 1.27 (s, 3H, 6-CH3), 1.23 (d, J=6.1 Hz, 3H, 5′-CH3), 1.20-1.07 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.88 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.66,177.05,177.03,174.38,166.95,158.43,156.32,150.20,150.15,148.15,147.0 2,146.67,146.34,119.82,119.69,112.92,112.90,108.79,103.23,83.88,81.59,78.21,77.86,75.79,70.45,6 9.54,69.19,68.49,66.12,58.12,49.83,47.64,47.59,45.31,43.39,40.36,39.32,39.13,37.28,36.18,35.82,34.63,33.17,32.42,32.39,29.94,28.52,22.03,21.22,19.31,18.28,15.05,13.88,13.29,10.26,9.05,7.45.
[0361] Synthesis of compound 811
[0362]
[0363] According to the general synthesis method, compound 57 (0.191 g, 0.215 mmol) was reacted with compound Ar-1 (0.132 g, 0.323 mmol) to obtain about 77.3 mg (0.0750 mmol, 34.90%) of compound 811. Melting point: 167.7-168.4°C. HRMS (ESI) (M+H) + m / z 1030.5395, calcd. 52 H 77 F5O 15 1030.5395. 1H NMR (CD3OD, 400 MHz) δ: 8.67 (s, 1H, 2″-quinolyl), 7.75 (d, J = 14.3 Hz, 1H, 5″-quinolyl), 7.07 (d, J = 7.3 Hz, 1H, 8″-quinolyl), 5.16 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.83 (d, J = 11.1 Hz, 1H, H-3), 4.29 (s, 1H, H-tetrahydropyrrole), 4.11 (d, J = 7.3 Hz, 1H, H-1′), 3.90 (d, J = 2.4 Hz, 10.8 Hz, 1H, H-13). 3.80 (m, 2H, H-5, H-tetrahydropyrrole), 3.77 (s, 1H, H-11), 3.76-3.64 (m, 5H, 1H-cyclopropyl, O-CH2, 2H-tetrahydropyrrole), 3.62-3.53 (m, 1H, H-tetrahydropyrrole), 3.46-3.35 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.25 (dd, J=7.3Hz, 10.2Hz, 1H, H-2′), 3.18-3.04 (m, 2H, 3-O-CO-NH-CH2, H-10), 2.97 (s, 3H, 6-O-CH3), 2.80-2.59 (m, 2H, H-2, H-3′), 2.54-2.45 (m, 1H, H-8), 2.38 (s, 6H, -N(CH3)2), 2.33-2.22 (m, 1H, H-tetrahydropyrrole), 2.21-2.11 (m, 1H, H-tetrahydropyrrole), 2.11-2.03 (m, 1H, H-4), 1.94-1.68 (m, 5H, CH2, H-14eq, H-7a, H-4′a) ,1.67-1.55(m,2H,H-7b,H-14eq),1.45(s,3H,12-CH3),1.43-1.27(m,3H,2H-cyclopropyl,H-4′b),1.25(s,3H,6-CH3),1.17(d,J=6.2Hz,3H,5′-CH3),1.16-1.02(m,14H,2-CH3,10-CH3,4-CH3,8-CH3,2H-cyclopropyl),0.84(t,J=7.4Hz,3H,15-CH3). 13C NMR(CDCl3,176MHz)δ:217.68,176.40,174.35,167.33,158.45,156.36,151.19,149.78,146.81,142.02,141.95,13 9.73,115.47,115.43,111.75,111.61,107.39,103.21,99.47,99.44,83.91,81.62,78.20,78.06,77.84,75.78,70.4 4,69.49,67.17,66.08,58.11,55.59,55.55,53.45,49.80,47.98,47.95,45.31,43.34,40.31,39.20,39.09,37.28,35.74,35.14,30.47,29.99,28.54,22.01,21.19,19.29,18.27,15.03,13.88,13.30,13.26,10.26,8.91,8.11,8.08.
[0364] Synthesis of compound 81o
[0365]
[0366] According to the general synthesis method, compound 57 (0.191 g, 0.215 mmol) was reacted with compound Ar-o (0.132 g, 0.323 mmol) to obtain about 162.6 mg (0.158 mmol, 73.34%) of compound 81o. Melting point: 159.6-160.6°C. HRMS (ESI) (M+H) + m / z 1031.5345, calculated value C 51 H 76 F6O 15 1031.5347. 1H NMR (CD3OD, 400MHz) δ: 8.67 (s, 1H, 2″-quinolyl), 7.91 (d, J=12.6Hz, 1H, 5″-quinolyl), 5.17 (dd, J=2.3Hz, 10.8Hz, 1H, H-13), 4.85 (d, J=11.2Hz, 1H, H-3), 4.27 (s, 1H, H-tetrahydropyrrole), 4.11 (d, J=7.3Hz, 1H, H-1′), 4.09-3.99 (m, 2H, O-CH2), 3. 98-3.86 (m, 2H, H-tetrahydropyrrole), 3.83 (d, J = 3.1 Hz, 1H, H-5), 3.78 (s, 1H, H-11), 3.76-3.65 (m, 2H, 1H-cyclopropyl, H-tetrahydropyrrole), 3.62-3.54 (m, 1H, H-tetrahydropyrrole), 3.45-3.36 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.26 (dd, J = 7.3 Hz, 10.2 Hz, 1H, H-2′), 3.18-3. 05(m,2H,3-O-CO-NH-CH2,H-10),2.97(s,3H,6-O-CH3),2.82-2.64(m,2H,H-2,H-3′),2.55-2.44(m,1H,H-8),2.40(s,6H,-N(CH3)2),2.32-2.21(m,1H,H-tetrahydropyrrole),2.18-2.05(m,2H,H-tetrahydropyrrole,H-4),1.93-1.70(m,5H,CH2,H-14eq ,H-7a,H-4′a),1.68-1.55(m,2H,H-7b,H-14eq),1.47(s,3H,12-CH3),1.35-1.27(m,3H,2H-cyclopropyl,H-4′b),1.26(s,3H,6-CH3),1.21-1.04(m,17H,2-CH3,5′-CH3,10-CH3,4-CH3,8-CH3,2H-cyclopropyl),0.84(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,176MHz)δ:217.68,176.93,174.31,167.00,158.44,156.35,149.23,149.16,147. 49,147.25,145.99,145.78,118.10,117.98,111.74,108.67,103.27,83.90,81.70,78.28,77 .84,75.81,70.42,69.52,67.18,66.11,58.11,49.80,45.31,43.34,40.32,39.09,37.28,35.74,34.66,30.03,28.50,22.01,21.19,19.29,18.27,15.02,13.88,13.27,10.26,8.91,7.42.
[0367] Synthesis of compound 821
[0368]
[0369] According to the general synthesis method, compound 58 (0.200 g, 0.225 mmol) was reacted with compound Ar-1 (0.138 g, 0.338 mmol) to obtain about 91.6 mg (0.0889 mmol, 39.52%) of compound 821. Melting point: 164.5-165.0°C. HRMS (ESI) (M+H) + m / z 1030.5389, calcd. 52 H 77 F5O 15 1030.5395. 1H NMR (CD3OD, 400 MHz) δ: 8.65 (s, 1H, 2″-quinolyl), 7.74 (d, J = 14.3 Hz, 1H, 5″-quinolyl), 7.06 (d, J = 7.4 Hz, 1H, 8″-quinolyl), 5.18 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J = 11.5 Hz, 1H, H-3), 4.27 (s, 1H, H-tetrahydropyrrole), 4.11 (d, J = 7.3 Hz, 1H, H-1′) ,3.91-3.82 (m, 2H, H-5, H-tetrahydropyrrole),3.79 (s, 1H, H-11),3.77-3.58 (m, 6H, 1H-cyclopropyl, O-CH2, 3H-tetrahydropyrrole),3.46-3.35 (m, 2H, H-5′, 3-O-CO-NH-CH2),3.24 (dd, J=7.3Hz, 10.2Hz, 1H, H-2′),3.17-3.05 (m, 2H, 3-O-CO-NH-CH2, H-10),2.99 (s, 3H, 6-O-CH3), 2.85-2.74 (m, 2H, H-2), 2.71-2.59 (m, 1H, H-3′), 2.56-2.44 (m, 1H, H-8), 2.37 (s, 6H, -N(CH3)2), 2.33-2.23 (m, 1H, H-tetrahydropyrrole), 2.21-2.13 (m, 1H, H-tetrahydropyrrole), 2.13-2.04 (m, 1H, H-4), 1.93-1.68 (m, 5H, CH2, H-14eq ,H-7a,H-4′a),1.67-1.56(m,2H,H-7b,H-14eq),1.47(s,3H,12-CH3),1.43-1.29(m,3H,2H-cyclopropyl,H-4′b),1.26(s,3H,6-CH3),1.24-1.06(m,17H,2-CH3,10-CH3,5′-CH3,4-CH3,8-CH3,2H-cyclopropyl),0.85(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,176MHz)δ:217.68,176.35,176.33,174.38,167.30,158.44,156.40,151.20,149.79,146.75,142.07,1 42.00,139.72,115.38,115.34,111.64,111.50,107.33,103.15,99.48,99.45,83.90,81.47,78.24,78.16,77.84, 75.78,70.45,69.51,66.89,66.07,58.11,55.39,55.35,49.81,48.03,48.01,45.31,43.32,40.33,39.10,38.82,37.27,35.75,35.12,30.69,29.98,28.50,22.02,21.19,19.29,18.28,15.02,13.88,13.27,10.26,8.94,8.09,8.06.
[0370] Synthesis of compound 82o
[0371]
[0372] According to the general synthesis method, compound 58 (0.200 g, 0.225 mmol) was reacted with compound Ar-o (0.138 g, 0.338 mmol) to obtain about 154.5 mg (0.150 mmol, 66.59%) of compound 82o. Melting point: 164.9-165.9°C. HRMS (ESI) (M+H) + m / z 1031.5349, calcd. 51 H 76 F6O 15 1031.5347. 1H NMR (CD3OD, 400 MHz) δ: 8.67 (s, 1H, 2″-quinolyl), 7.91 (d, J = 12.8 Hz, 1H, 5″-quinolyl), 5.18 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J = 11.2 Hz, 1H, H-3), 4.27 (s, 1H, H-tetrahydropyrrole), 4.12 (d, J = 7.3 Hz, 1H, H-1′), 4.08-3.96 (m, 2H, 2H-tetrahydropyrrole) ,3.96-3.87 (m, 2H, H-tetrahydropyrrole), 3.83 (d, J = 3.1 Hz, 1H, H-5), 3.80 (s, 1H, H-11), 3.77-3.56 (m, 3H, 1H-cyclopropyl, O-CH2), 3.45-3.35 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.26 (dd, J = 7.2 Hz, 10.2 Hz, 1H, H-2′), 3.18-3.05 (m, 2H, 3-O-CO-NH-C H2, H-10), 2.99 (s, 3H, 6-O-CH3), 2.89-2.79 (m, 1H, H-2), 2.76-2.64 (m, 1H, H-3′), 2.56-2.44 (m, 1H, H-8), 2.39 (s, 6H, -N(CH3)2), 2.31-2.21 (m, 1H, H-tetrahydropyrrole), 2.18-2.05 (m, 2H, H-tetrahydropyrrole, H-4), 1.92-1.71 (m, 5H, CH2, H-14eq, H-7a, H-4′a), 1.68-1.54 (m, 2H, H-7b, H-14eq), 1.48 (s, 3H, 12-CH3), 1.35-1.27 (m, 3H, 2H-cyclopropyl, H-4′b), 1.26 (s, 3H, 6-CH3), 1.20-1.07 (m, 17H, 2-CH3, 5′-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.85 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.67,176.93,174.32,167.00,158.44,156.37,149.25,149.18,147.49,14 7.25,145.99,145.78,118.11,118.00,111.75,108.69,103.29,83.89,81.70,78.31,77.85,77.22,7 5.83,70.44,69.54,67.00,66.12,58.13,49.80,45.31,43.35,40.34,40.31,39.11,38.94,37.28,35.76,34.65,30.06,28.48,22.02,21.19,19.30,18.27,15.03,13.88,13.29,10.27,8.97,7.43,7.41.
[0373] Synthesis of compound 831
[0374]
[0375] According to the general synthesis method, compound 59 (0.100 g, 0.110 mmol) was reacted with compound Ar-1 (0.0679 g, 0.166 mmol) to obtain about 43.3 mg (0.0415 mmol, 37.70%) of compound 831. Melting point: 157.9-158.6°C. HRMS (ESI) (M+H) + m / z 1044.5557, calcd. 53 H 79 F5O 15 1044.5551. 1H NMR (CD3OD, 400 MHz) δ: 8.64 (s, 1H, 2″-quinolyl), 7.72 (d, J = 14.4 Hz, 1H, 5″-quinolyl), 7.04 (d, J = 7.4 Hz, 1H, 8″-quinolyl), 5.18 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J = 11.5 Hz, 1H, H-3), 4.13 (d, J = 7.3 Hz, 1H, H-1′), 3.86 (d, J = 3.1 Hz, 1H, H-5), 3.80 (s ,1H,H-11),3.77-3.64(m,3H,1H-cyclopropyl,2H-tetrahydropyrrole),3.63-3.52(m,3H,O-CH2,H-tetrahydropyrrole),3.55-3.47(m,2H,O-CH2,),3.46-3.36(m,2H,H-5′,3-O-CO-NH-CH2),3.26(dd,J=7.3Hz,10.2Hz,1H,H-2′),3.20-3.12(m,1H,3-O-CO-NH-CH2),3.09(q,J=6 .5Hz,1H,H-10),2.99(s,3H,6-O-CH3),2.91-2.82(m,1H,H-2),2.74-2.63(m,2H,H-tetrahydropyrrole,H-3′),2.56-2.45(m,1H,H-8),2.40(s,6H,-N(CH3)2),2.25-2.16(m,1H,H-tetrahydropyrrole),2.15-2.06(m,1H,H-4),1.98-1.71(m,6H,H-tetrahydropyrrole,CH2,H-14eq,H-4 'a, H-7a,), 1.68-1.55 (m, 2H, H-14eq, H-7a), 1.47 (s, 3H, 12-CH3), 1.44-1.29 (m, 3H, 2H-cyclopropyl, H-4'b), 1.27 (s, 3H, 6-CH3), 1.24-1.18 (m, 5H, 5'-CH3, 2H-cyclopropyl), 1.17-1.07 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.86 (t, J = 7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.67,176.41,174.39,167.36,158.44,156.34,151.18,149.77,146.75,142.09,142 .03,139.74,115.33,111.70,111.57,107.40,103.18,99.38,83.90,81.60,78.24,77.85,75.79,72.56,70.4 6,69.51,69.45,66.11,58.12,52.94,49.82,49.53,49.50,45.31,43.39,40.34,39.17,39.12,38.82,37.28,35.78,35.12,29.85,28.59,28.03,22.02,21.20,19.31,18.28,15.05,13.88,13.27,10.27,9.00,8.10,8.07.
[0376] Synthesis of compound 83o
[0377]
[0378] According to the general synthesis method, compound 59 (0.100 g, 0.110 mmol) was reacted with compound Ar-o (0.0679 g, 0.166 mmol) to obtain about 88.9 mg (0.0850 mmol, 77.32%) of compound 83o. Melting point: 151.0-152.2°C. HRMS (ESI) (M+H) + m / z 1045.5509, calculated value C 52 H 78 F6O 15 1045.5504. 1H NMR (CD3OD, 400 MHz) δ: 8.65 (s, 1H, 2″-quinolyl), 7.86 (d, J = 12.8 Hz, 1H, 5″-quinolyl), 5.18 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.89 (d, J = 11.5 Hz, 1H, H-3), 4.14 (d, J = 7.3 Hz, 1H, H-1′), 4.09-3.93 (m, 2H, 2H-tetrahydropyrrole), 3.89-3.83 (m, 2H, H -5,1H-cyclopropyl), 3.81(s,1H,H-11),3.78-3.62(m,2H,2H-tetrahydropyrrole),3.61-3.48(m,4H,CH2-O-CH2),3.46-3.35(m,2H,H-5′,3-O-CO-NH-CH2),3.27(dd,J=7.3Hz,10.1Hz,1H,H-2′),3.20-3.05(m,2H,3-O-CO-NH-CH2,H-10),3.00( s, 3H, 6-O-CH3), 2.93-2.82 (m, 1H, H-2), 2.76-2.61 (m, 2H, H-tetrahydropyrrole, H-3′), 2.55-2.45 (m, 1H, H-8), 2.42 (s, 6H, -N(CH3)2), 2.24-2.08 (m, 1H, H-tetrahydropyrrole, H-4), 1.96-1.73 (m, 6H, H-tetrahydropyrrole, CH2, H-14eq, H-4′a, H-7a,), 1.69-1.53 (m, 2H, H-14eq, H-7a), 1.48 (s, 3H, 12-CH3), 1.38-1.29 (m, 3H, 2H-cyclopropyl, H-4′b), 1.28 (s, 3H, 6-CH3), 1.21 (d, J=6.1 Hz, 3H, 5′-CH3), 1.17-1.07 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J=7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.69,176.84,174.38,167.04,158.44,156.34,149.15,149.08,147 .50,147.24,145.85,145.76,117.86,117.74,111.52,108.55,103.19,83.91,81.57,78.22,7 7.85,75.77,72.37,70.46,69.49,66.10,58.12,49.82,45.31,43.38,40.35,39.11,37.27,35.79,34.65,29.90,22.02,21.20,19.30,18.28,15.04,13.88,13.28,10.26,9.00,7.44,7.34.
[0379] Synthesis of compound 841
[0380]
[0381] According to the general synthesis method, compound 60 (0.164 g, 0.181 mmol) was reacted with compound Ar-1 (0.112 g, 0.272 mmol) to obtain about 88.7 mg (0.0849 mmol, 46.93%) of compound 841. Melting point: 165.2-166.3°C. HRMS (ESI) (M+H) + m / z 1044.5553, calcd. 53 H 79 F5O 15 1044.5551. 1H NMR (CD3OD, 400 MHz) δ: 8.62 (s, 1H, 2″-quinolyl), 7.69 (d, J = 14.4 Hz, 1H, 5″-quinolyl), 7.03 (d, J = 7.0 Hz, 1H, 8″-quinolyl), 5.18 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J = 11.5 Hz, 1H, H-3), 4.14 (d, J = 7.3 Hz, 1H, H-1′), 3.85 (d, J = 3.1 Hz, 1H, H-5), 3.79 (s ,1H,H-11),3.77-3.64(m,3H,1H-cyclopropyl,2H-tetrahydropyrrole),3.63-3.55(m,3H,O-CH2,H-tetrahydropyrrole),3.56-3.48(m,2H,O-CH2,),3.48-3.35(m,2H,H-5′,3-O-CO-NH-CH2),3.27(dd,J=7.3Hz,10.2Hz,1H,H-2′),3.22-3.12(m,1H,3-O-CO-NH-CH2),3.09(q,J=6 .4Hz,1H,H-10),2.99(s,3H,6-O-CH3),2.89-2.79(m,1H,H-2),2.75-2.63(m,2H,H-tetrahydropyrrole,H-3′),2.54-2.45(m,1H,H-8),2.40(s,6H,-N(CH3)2),2.25-2.14(m,1H,H-tetrahydropyrrole),2.14-2.06(m,1H,H-4),1.98-1.73(m,6H,H-tetrahydropyrrole,CH2,H-14eq,H- 4′a, H-7a), 1.67-1.53 (m, 2H, H-14eq, H-7a), 1.46 (s, 3H, 12-CH3), 1.42-1.30 (m, 3H, 2H-cyclopropyl, H-4′b), 1.28 (s, 3H, 6-CH3), 1.24-1.17 (m, 5H, 5′-CH3, 2H-cyclopropyl), 1.18-1.08 (m, 12H, 2-CH3, 10-CH3, 4-CH3, 8-CH3), 0.85 (t, J=7.3Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.68,176.35,176.33,174.38,167.32,158.44,156.33,151.16,149.75,146.68,142.08,1 42.01,139.72,115.24,115.20,111.59,111.46,107.33,103.15,99.38,99.34,83.90,81.52,78.19,77.85,72.37, 70.45,69.52,69.45,66.09,58.11,52.84,52.81,49.82,49.57,49.54,45.31,43.37,40.34,39.20,39.11,38.74,37.27,35.77,35.12,29.84,28.58,28.08,22.01,21.21,19.30,18.28,15.05,13.88,13.25,10.26,8.99,8.08,8.05.
[0382] Synthesis of compound 84o
[0383]
[0384] According to the general synthesis method, compound 60 (0.164 g, 0.181 mmol) was reacted with compound Ar-o (0.112 g, 0.272 mmol) to obtain about 137.8 mg (0.132 mmol, 72.84%) of compound 84o. Melting point: 144.2-145.3°C. HRMS (ESI) (M+H) + m / z 1045.5501, calculated value C 52 H 78 F6O 15 1045.5504. 1H NMR (CD3OD, 400 MHz) δ: 8.63 (s, 1H, 2″-quinolyl), 7.83 (d, J = 12.8 Hz, 1H, 5″-quinolyl), 5.17 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.86 (d, J = 11.5 Hz, 1H, H-3), 4.14 (d, J = 7.3 Hz, 1H, H-1′), 4.09-3.95 (m, 2H, 2H-tetrahydropyrrole), 3.89-3.83 (m, 2H, H-5,1H-cyclopropyl), 3.80 (s, 1H, H-11), 3.78-3.63 (m, 2H, 2H-tetrahydropyrrole), 3.63-3.48 (m, 4H, CH2-O-CH2), 3.49-3.35 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.27 (dd, J=7.3 Hz, 10.1 Hz, 1H, H-2′), 3.21-3.06 (m, 2H, 3-O-CO-NH-CH2, H-10), 2.99 (s, 3H, 6-O-CH3), 2.91-2.81 (m, 1H, H-2), 2.75-2.63 (m, 2H, H-tetrahydropyrrole, H-3′), 2.56-2.46 (m, 1H, H-8), 2.41 (s, 6H, -N(CH3)2), 2.27-2.06 (m, 1H, H-tetrahydropyrrole, H-4), 1.98-1.72 (m, 6H, H-tetrahydropyrrole, CH2, H-14eq, H-4′a, H-7a), 1.69-1.53 (m, 2H, H-14eq, H-7a), 1.47 (s, 3H, 12-CH3), 1.35-1.29 (m, 3H, 2H-cyclopropyl, H-4′b), 1.27 (s, 3H, 6-CH3), 1.21 (d, J=6.1 Hz, 3H, 5′-CH3), 1.18-1.07 (m, 14H, 2-CH3, 10-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.85 (t, J=7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.66,176.90,174.34,167.04,158.43,156.31,149.15,149.08,147.51,14 7.24,145.89,145.76,117.97,117.85,111.60,111.59,108.63,103.20,83.88,81.61,78.25,77.85, 72.21,70.45,69.53,69.49,66.13,58.12,49.82,45.31,43.38,40.35,39.18,39.12,37.28,35.77,34.65,29.88,28.57,22.02,21.21,19.30,18.28,15.05,13.88,13.27,10.26,8.99,7.46,7.44,7.34.
[0385] Synthesis of compound 85l
[0386]
[0387] According to the general synthesis method, compound 61 (0.184 g, 0.204 mmol) was reacted with compound Ar-1 (0.125 g, 0.305 mmol) to obtain about 151.3 mg (0.145 mmol, 71.08%) of compound 851. Melting point: 168.2-169.2°C. HRMS (ESI) (M+H) + m / z 1044.5560, calcd. 53 H 79 F5O 15 1044.5551. 1H NMR (CD3OD, 400 MHz) δ: 8.76 (s, 1H, 2″-quinolyl), 7.88 (d, J = 13.2 Hz, 1H, 5″-quinolyl), 7.58 (s, 1H, 8″-quinolyl), 5.16 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.84 (d, J = 11.1 Hz, 1H, H-3), 4.12 (d, J = 7.3 Hz, 1H, H-1′), 3.84 (s, 1H, 2″-quinolyl), 3.98 (s, 1H, 5″-quinolyl), 4.10 (d, J = 13.2 Hz, 1H, 5″-quinolyl), 4.83 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 3.96 (d, J = 11.1 Hz, 1H, H-3), 3.55 (d, J = 13.8 Hz, 1H, H-1′), 3.5 d, J = 3.2 Hz, 1H, H-5), 3.79 (s, 1H, H-11), 3.78-3.72 (m, 1H, H-cyclopropyl), 3.71-3.54 (m, 4H, 1, O-CH2, H-piperidinyl, CH), 3.52-3.37 (m, 2H, H-5′, 3-O-CO-NH-CH2), 3.31-3.18 (m, 3H, H-2′, 3-O-CO-NH-CH2, H-piperidinyl), 3.1 6-3.04 (m, 2H, H-10, H-piperidinyl), 2.99 (s, 3H, 6-O-CH3), 2.88-2.78 (m, 1H, H-2), 2.77-2.67 (m, 1H, H-3′), 2.57-2.36 (m, 7H, H-8, -N(CH3)2), 2.15-1.96 (m, 3H, H-4, CH2), 1.95-1.54 (m, 9H, 4H-piperidinyl, H-14eq, H- 7a, H-4′a, H-7b, H-14eq), 1.48 (s, 3H, 12-CH3), 1.45-1.28 (m, 3H, 2H-cyclopropyl, H-4′b), 1.26 (s, 3H, 6-CH3), 1.25-0.99 (m, 17H, 2-CH3, 10-CH3, 5′-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.84 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.69,177.07,174.36,167.02,158.44,156.34,154.33,152.91,147.42,146.27,146.2 2,139.18,119.63,119.58,112.48,112.35,108.11,105.06,103.21,83.90,81.59,78.22,77.85,75.78,73.87, 70.45,69.52,66.77,66.10,58.11,54.38,54.35,50.31,49.81,45.31,43.38,40.34,39.34,39.11,37.28,35.77,35.30,30.12,29.52,28.48,22.37,22.02,21.21,19.31,18.28,15.03,13.88,13.28,10.26,8.94,8.28,8.24.
[0388] Synthesis of compound 85o
[0389]
[0390] According to the general synthesis method, compound 61 (0.184 g, 0.204 mmol) was reacted with compound Ar-o (0.125 g, 0.305 mmol) to obtain about 110.8 mg (0.106 mmol, 51.96%) of compound 85o. Melting point: 165.4-166.2°C. HRMS (ESI) (M+H) + m / z 1045.5510, calcd. 52 H 78 F6O 15 1045.5504. 1H NMR (CD3OD, 400 MHz) δ: 8.72 (s, 1H, 2″-quinolyl), 7.96 (d, J = 13.7 Hz, 1H, 5″-quinolyl), 5.18 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.85 (d, J = 11.2 Hz, 1H, H-3), 4.13 (d, J = 7.3 Hz, 1H, H-1′), 4.10-3.87 (m, 3H, 2H-piperidinyl, CH), 3.84 (d, J = 3.4 Hz, 1H, H-5), 3.80 (s, 1H, H-11), 3.78-3.63 (m, 3H, H-cyclopropyl, 2H-piperidinyl), 3.64-3.54 (m, 3H, O-CH2, H-piperidinyl), 3.45-3.36 (m, 1H, H-5′), 3.31-3.14 (m, 2H, H-2′, 3-O-CO-NH-CH2), 3.10 (q, J = 6.5 Hz, 1H, H-10), 3.0 5-2.94(s,4H,6-O-CH3,H-piperidinyl),2.92-2.82(m,1H,H-2),2.81-2.68(m,1H,H-3′),2.56-2.36(m,7H,H-8,-N(CH3)2),2.15-2.07(m,1H,H-4),2.07-1.94(m,2H,CH2),1.92-1.74(m,4H,2H-piperidinyl,H-14eq,H-4′a,), 1.74-1.56 (m, 5H, 2H-piperidinyl, H-7a, H-7b, H-14eq), 1.48 (s, 3H, 12-CH3), 1.37-1.23 (m, 6H, 2H-cyclopropyl, H-4′b, 6-CH3), 1.23-1.02 (m, 17H, 2-CH3, 10-CH3, 5′-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J=7.4 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.68,177.06,174.34,166.82,158.44,156.34,150.57,148.08,146.93,146.60,146.51 ,146.35,119.93,119.80,113.12,108.88,103.24,83.90,81.63,78.33,77.86,75.81,73.86,70.45,69.54,66.60 ,66.13,58.13,53.45,51.34,51.27,49.80,47.69,47.65,45.31,43.37,40.34,40.30,39.12,39.03,37.28,35.79,34.69,30.23,29.92,28.50,28.43,22.15,22.02,21.20,19.31,18.28,15.02,13.88,13.29,10.27,9.00,7.49.
[0391] Synthesis of compound 86l
[0392]
[0393] According to the general synthesis method, compound 62 (0.195 g, 0.216 mmol) was reacted with compound Ar-1 (0.133 g, 0.325 mmol) to obtain about 62.8 mg (0.0601 mmol, 27.84%) of compound 861. Melting point: 172.3-173.0°C. HRMS (ESI) (M+H) + m / z 1044.5550, calcd. 53 H 79 F5O 15 1044.5551. 1H NMR (CD3OD, 400 MHz) δ: 8.77 (s, 1H, 2″-quinolyl), 7.87 (d, J = 13.2 Hz, 1H, 5″-quinolyl), 7.59 (s, 1H, 8″-quinolyl), 5.16 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.82 (d, J = 11.1 Hz, 1H, H-3), 4.11 (d, J = 7.2 Hz, 1H, H-1′), 3.83 (d, J = 3.2 Hz, 1H, H-1′). z, 1H, H-5), 3.77 (s, 1H, H-11), 3.76-3.71 (m, 1H, H-cyclopropyl), 3.70-3.59 (m, 3H, O-CH2, CH), 3.59-3.50 (m, 1H, H-piperidinyl), 3.49-3.36 (m, 3H, H-5′, 3-O-CO-NH-CH2, H-piperidinyl), 3.30-3.21 (m, 3H, H-2′, 3-O-CO-NH-CH2), 3.17 -3.03 (m, 2H, H-10, H-piperidinyl), 2.98 (s, 3H, 6-O-CH3), 2.78-2.66 (m, 2H, H-2, H-3′), 2.54-2.37 (m, 7H, H-8, -N(CH3)2), 2.13-1.95 (m, 3H, H-4, CH2), 1.93-1.68 (m, 7H, 4H-piperidinyl, H-14eq, H-7a, H-4′a), 1.67-1.53 (m, 2H , H-7b, H-14eq), 1.45 (s, 3H, 12-CH3), 1.43-1.27 (m, 3H, 2H-cyclopropyl, H-4′b), 1.26 (s, 3H, 6-CH3), 1.24-1.09 (m, 12H, 2-CH3, 10-CH3, 5′-CH3, 8-CH3), 1.08-0.95 (m, 5H, 4-CH3, 2H-cyclopropyl), 0.84 (t, J=7.3Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.68,177.05,174.31,167.00,158.45,156.27,154.34,152.92,147.39,146.35,139.16,119.65,1 19.60,112.49,112.36,108.12,105.10,103.01,83.90,81.26,78.09,77.82,77.79,75.76,73.61,70.46,69.52,66.77,66. 11,58.08,54.35,54.31,50.08,49.82,45.36,45.31,43.38,40.34,40.31,39.42,39.09,37.27,35.68,35.30,29.89,29.38,28.46,22.33,22.00,21.20,19.30,19.27,18.35,18.28,14.98,13.88,13.84,13.20,10.25,10.19,8.91,8.84,8.28,8.23.
[0394] Synthesis of compound 86o
[0395]
[0396] According to the general synthesis method, compound 62 (0.195 g, 0.216 mmol) was reacted with compound Ar-o (0.133 g, 0.325 mmol) to obtain about 92.3 mg (0.0883 mmol, 40.88%) of compound 86o. Melting point: 163.0-164.2°C. HRMS (ESI) (M+H) + m / z 1045.5504, calculated value C 52 H 78 F6O 15 1045.5504. 1H NMR (CD3OD, 400 MHz) δ: 8.71 (s, 1H, 2v-quinolyl), 7.96 (d, J = 13.4 Hz, 1H, 5″-quinolyl), 5.19 (dd, J = 2.4 Hz, 10.8 Hz, 1H, H-13), 4.85 (d, J = 11.2 Hz, 1H, H-3), 4.20-3.98 (m, 4H, H-1′, 3H-piperidinyl), 3.83 (d, J = 3.2 Hz, 1H, H -5), 3.79 (s, 1H, H-11), 3.77-3.65 (m, 2H, H-cyclopropyl, CH), 3.63-3.51 (m, 3H, O-CH2, H-piperidinyl), 3.39-3.34 (m, 1H, H-5′), 3.31-3.14 (m, 2H, H-2′, 3-O-CO-NH-CH2), 3.10 (q, J=6.5Hz, 1H, H-10), 3.05-2.94 (s, 4H, 6-O-CH3, H-piperidinyl), 2.89-2.82 (m, 1H, H-2), 2.79-2.67 (m, 1H, H-3′), 2.58-2.39 (m, 7H, H-8, -N(CH3)2), 2.17-2.08 (m, 1H, H-4), 2.08-1.93 (m, 2H, CH2), 1.92-1.74 (m, 3H, 2H-piperidinyl, H-14eq), 1.77-1.56 (m, 6 H, H-4′a, 2H-piperidinyl, H-7a, H-7b, H-14eq), 1.48 (s, 3H, 12-CH3), 1.37-1.22 (m, 6H, 2H-cyclopropyl, H-4′b, 6-CH3), 1.22-1.04 (m, 17H, 2-CH3, 10-CH3, 5′-CH3, 4-CH3, 8-CH3, 2H-cyclopropyl), 0.86 (t, J=7.3 Hz, 3H, 15-CH3). 13C NMR(CDCl3,176MHz)δ:217.69,177.05,174.33,166.82,158.45,156.29,150.58,148.08,146.92,146.50,119. 93,119.80,113.13,108.88,103.21,83.91,81.57,78.26,77.85,75.82,73.84,70.45,69.54,66.69,66.15,58 .12,53.44,51.24,51.18,49.81,47.65,45.31,43.37,40.34,39.11,39.03,37.28,35.75,34.68,33.86,30.12,29.92,29.70,28.47,22.13,22.02,21.18,19.30,18.28,15.00,13.88,13.27,10.27,8.96,7.52,7.49,7.46.
[0397] Test Example 1 In vitro antibacterial activity experiment
[0398] According to the standards recommended by the Clinical and Laboratory Standards Institute (CLSI, 2010), the in vitro antibacterial activities of some target compounds against sensitive Streptococcus pneumoniae ATCC49619, mef efflux-resistant Streptococcus pneumoniae PU-09, constitutively erm-resistant Streptococcus pneumoniae 07P390, induced ermB-resistant Streptococcus pyogenes, constitutively ermA-resistant Streptococcus pyogenes 12-206, Staphylococcus aureus ATCC29213, induced ermA-resistant Staphylococcus aureus PU32, constitutively resistant Staphylococcus aureus 19D052, 19B133, 19B130, 19E131, 15B196, Haemophilus influenzae ATCC49247 and Catarrhalis 13L332 were determined by broth dilution method. Each bacterial strain was plate-transfected and purified before the test, and fresh bacteria were used in the test. In each experiment, standard strains were used as quality control bacteria for sensitive experiments; bacterial solution without antimicrobial drugs was used as growth control for test strains. The minimum inhibitory concentration (MIC) was determined by the broth two-fold dilution method. The concentration range of antimicrobial drugs was 256-0.008 μg / mL, and the final concentration of the tested bacterial solution was approximately 5×10 5 CFU / ml. The test results are shown in the following table:
[0399] Table 1. Antibacterial activity data of the compounds
[0400]
[0401] Note: “-” in the above table means not tested.
[0402] Table 2. Antibacterial activity data of compounds and control drugs (MCX-198 is compound 14n in the literature Eur J Med Chem, 125 (2017) 210-224.)
[0403]
[0404]
[0405] Table 3. Antibacterial activity data of compounds
[0406]
[0407] Table 4. Anti-Staphylococcus aureus activity data of compounds and control drugs
[0408]
[0409] cMLSB: constitutive resistance to macrolide-lincosamide-streptogramin B.
[0410] Table 5. Antibacterial activity data of compounds and control drugs
[0411]
[0412] Table 6. Antibacterial activity data of compounds and control drugs
[0413]
[0414] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. The compound represented by formula I, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug: in, W is an oxygen atom O or NOC 1-12 alkyl; V is an oxygen atom O or a secondary amine NH, X is a methylene CH2, a secondary amine NH or an oxygen atom O; Y is a nitrogen atom N or a methine CH; n1 is an integer in the range of 1-10, n2 is an integer in the range of 0-6, m1 is 0, 1 or 2, m2 is 0, 1 or 2; Q is a methine CH, CRa or a nitrogen atom N, Ra is a halogen, C 1-12 Alkyl, haloC 1-12 Alkyl or C 1-12 Alkoxy; R 1 is a hydrogen atom, an amino group, a halogen, or the following groups which are unsubstituted or optionally substituted by one, two or more Rb: 1-12 Alkyl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group, C 6-20 Aryl or 5-20 membered heteroaryl; Rb is selected from halogen, amino, C 1-12 Alkyl, halogenated C 1-12 Alkyl or C 1-12 Alkoxy; R 2 is absent, a hydrogen atom, unsubstituted or optionally substituted by one, two or more Rb: 1-12 Alkyl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group, C 6-20 Aryl or 5-20 membered heteroaryl; Rb is selected from halogen, C 1-12 Alkyl, halogenated C 1-12 Alkyl or C 1-12 Alkoxy; Z is CH, CRc, nitrogen atom N, or Z is C and R 2 The connected N is connected to form a ring, where the connecting part between Z and N is -OCH2-CH(CH3)-, then R 2 does not exist; Rc is halogen, nitrile, amino, C 1-12 Alkyl, haloC 1-12 Alkyl, C 1-12 Alkoxy or halogenated C 1-12 Alkoxy.
2. The compound according to claim 1, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug, characterized in that: W is an oxygen atom O or NOC 1-6 alkyl; V is an oxygen atom O or a secondary amine NH, X is a methylene CH2, a secondary amine NH or an oxygen atom O; Y is a nitrogen atom N or a methine CH; n1 is 1, 2, 3, 4, 5, 6 or 7, n2 is 0, 1, 2, 3, 4, 5 or 6, m1 is 0 or 1, m2 is 1 or 2; Q is a methine CH, CRa or a nitrogen atom N, Ra is a halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or C 1-6 Alkoxy; R 1 is a hydrogen atom, a halogen, or the following groups which are unsubstituted or optionally substituted by one, two or more Rb: 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Rb is selected from halogen, C 1-6 Alkyl or C 1-6 Alkoxy; R 2 is absent, a hydrogen atom, unsubstituted or optionally substituted by one, two or more Rb: 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl; Rb is selected from halogen, C 1-6 Alkyl or C 1-6 Alkoxy; Z is CH, CRc, nitrogen atom N, or Z is C and R 2 The connected N is connected to form a ring, where the connecting part between Z and N is -OCH2-CH(CH3)-, then R 2 does not exist; Rc is a halogen, C 1-6 Alkyl or C 1-6 Alkoxy.
3. The compound according to claim 2, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug, characterized in that: W is an oxygen atom O or NOCH3; V is an oxygen atom O or a secondary amine NH, X is a methylene CH2, a secondary amine NH or an oxygen atom O; Y is a nitrogen atom N or a methine CH; n1 is 2, 3, 4, 5, 6 or 7, n2 is 0, 1 or 2, m1 is 0 or 1, and m2 is 1 or 2; Q is a methine CH, a fluorine-substituted carbon atom CF or a nitrogen atom N; R 1 is a hydrogen atom, a methyl group or an ethyl group; R 2 is absent, a hydrogen atom, a methyl group, an ethyl group, a cyclopropyl group, a fluoroethyl group, a fluorocyclopropyl group; Z is a methine group CH, a carbon atom CF substituted with fluorine, a nitrogen atom N, a carbon atom C-OCH3 substituted with methoxy, or when Z is C, the same as R 2 The connected N is connected to form a ring, where the connecting part between Z and N is -OCH2-CH(CH3)-, then R 2 Does not exist.
4. The compound according to any one of claims 1 to 3, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug, characterized in that: The compound shown in formula I is selected from the following: Ar 1 : Ar 2 : 5. Use of the compound according to any one of claims 1 to 4, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug in the preparation of antibacterial drugs.
6. The use according to claim 5, characterized in that The antibacterial drug is used to inhibit or kill at least one of the following pathogenic microorganisms: Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Mycoplasma or Chlamydia.
7. The use according to claim 5 or 6, characterized in that The antibacterial drug is used to inhibit or kill at least one of the following bacterial species that are sensitive to erythromycin or have different types of resistance: sensitive Streptococcus pneumoniae, constitutively resistant Streptococcus pneumoniae, exudatively resistant Streptococcus pneumoniae, sensitive Staphylococcus aureus, inducibly resistant Staphylococcus aureus, constitutively resistant Staphylococcus aureus, sensitive Streptococcus pyogenes, exudatively resistant Streptococcus pyogenes, inducibly resistant Streptococcus pyogenes, constitutively resistant Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.
8. A pharmaceutical composition, characterized in that The invention comprises the compound according to any one of claims 1 to 4, its tautomer, stereoisomer, pharmaceutically acceptable salt or prodrug, and optionally a pharmaceutically acceptable carrier.
9. The pharmaceutical composition according to claim 8, characterized in that The pharmaceutical composition is used for preparing antibacterial drugs.
10. A method for preparing the compound according to any one of claims 1 to 4, characterized in that: The steps include: Among them, W, V, X, Y, n1, n2, m1, m2, R 1 , R 2 , Z, Q have the definitions in any one of claims 1-4; R is Ac or Bz.
Citation Information
Cited By
Quinolone derivative of macrolide, preparation method therefor, and use thereof
WO2026007903A1
